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ABSTRACT 
 
Background: Breast cancer is the most common female cancer worldwide and in sub-
Saharan Africa (SSA). Breast cancer incidence in SSA is relatively low but, as survival 
from the disease in the region is poor, mortality rates are as high as in high income 
countries. Late stage at diagnosis, and delays in a woman’s journey to a cancer diagnosis, 
are features known to contribute to poor breast cancer survival rates. There has been little 
focus on the factors affecting stage at diagnosis and the determinants of diagnostic delays 
in SSA despite previous studies highlighting the importance of early detection and 
treatment in breast cancer control.  
Aims and Methods: The main objectives of this thesis are: (i) To conduct a systematic 
review and meta-analysis of stage at breast cancer diagnosis in SSA to examine trends 
over time and examine possible sources of variation across the region. Random-effects 
meta-analyses were performed to investigate between-study heterogeneity in percentage 
of late-stage disease (stage III/IV) breast cancer, and meta-regression analyses were 
carried out to identify possible sources of variation. Percentages of Black women with 
late-stage breast cancer in SSA were compared with equivalent estimates for US Black 
and White women using the Surveillance, Epidemiology and End Results Database. (ii) 
To design and conduct a study, the Nigerian Integrative Epidemiology of Breast Cancer 
(NIBBLE) study, (iii) to investigate determinants of late stage at breast cancer diagnosis 
and diagnostic delays at six tertiary and secondary health facilities in Nigeria. Ordinal 
logistic regression was used to examine associations of socio-demographic, breast cancer 
awareness, health care access and clinical factors with the odds of later stage disease. 
Linear regression analyses were performed to examine the association of these factors 
with time from noticing symptoms to diagnosis (total delay), and its two main 
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components: pre-contact delay (i.e. time from symptoms to first contact with any care 
provider including traditional healers) and post-contact delay (i.e. time from first contact 
to diagnosis).  
Results: (i) Systematic review:  83 studies were eligible representing 26,788 women from 
17 SSA countries. There was wide variation in percentage of late stage (median 74.7%, 
range 30.3-100%, I2=93.3% p<0.0001). Late stage at diagnosis was notably higher in 
Black vs non-Black women in SSA and higher for populations from mixed (urban and 
rural) settings than from urban settings. The percentage of women with late stage breast 
cancer decreased over time but it was still higher than in US White and Black women 40 
years previously. (ii) Findings from NIBBLE: 300 breast cancer patients were recruited, 
67.7% with late stage (III/IV) at diagnosis. Multivariate analyses showed lower 
educational level (odds ratio (OR) 2.35; 95% confidence interval (CI) 1.04, 5.29), not 
believing in a cure for breast cancer (OR 1.81; 95% CI 1.09, 3.01), Muslim religion (OR 
0.46; 95% CI 0.22, 0.94) and living in a rural area (OR 2.18; 95% CI 1.05, 4.51) to be 
significantly associated with later stage. No associations were found between later stage 
and age at diagnosis, tumour grade or oestrogen receptor status.  Women diagnosed in 
stages III/IV self-reported, on average, 36% longer total delay times than those in stages 
I/II. Median (IQR) for pre-, post and total delays were 2.6 (0.6, 8.3), 3.1 (0.79, 8.7) and 
7.8 (3.3, 18.7) months, respectively, for all women who presented with suspicious 
symptoms (n=430). In fully-adjusted analyses, post-contact delays in all women with 
symptoms were associated with lack of a personal income (OR 1.49; 1.04, 2.00), no 
previous history of benign breast disease (OR 0.61; 0.42, 0.89) and having 5 or more 
children (OR 1.88; 95% CI 0.96, 3.67) whilst total delay was inversely associated with 
presentation at a secondary facility (OR 0.68; 95% CI 0.51, 0.92) and no previous history 
of benign breast disease (OR 0.64; 0.47, 0.88). Post-contact and total delays were both 
positively associated with the total number of providers visited before a diagnosis (P for 
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trend (Pt)=0.014 and Pt<0.001, respectively). Only 18% of all women with symptoms and 
12.4% of the subset with breast cancer were diagnosed within 3 months of noticing a 
breast symptom. 
Conclusions: Although stage at breast cancer diagnosis improved over time in SSA, it is 
still a common feature. This thesis identified factors amenable to intervention such as 
breast cancer awareness and health care access, rather than intrinsic tumour 
characteristics, as the main drivers of late stage at diagnosis in Nigeria. Strategies for 
early diagnosis of symptomatic breast cancer should be regarded as a major priority in 
cancer control programmes in SSA. 
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PREFACE 
 
The thesis for this PhD uses the “research/review papers” format with some chapters in 
the “book style” format. It therefore includes papers that have been published or 
submitted to peer-reviewed journals. The chapters that have been published or formatted 
for publication are preceded by a cover sheet which includes details of the publication, 
and acknowledges the contributions of other people who are co-authors on the papers. 
The other chapters not formatted for publication which are written in the “book style 
format” are preceded by linking material which helps to make the thesis a coherent body 
of work.  
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CHAPTER 1 
1.1 BACKGROUND 
1.1.1 GLOBAL BURDEN OF BREAST CANCER  
Breast cancer is the most common malignancy among women worldwide and the second 
most common in both sexes after lung cancer (1). There were an estimated 1.67 million 
new cases of breast cancer diagnosed in 2012, representing 25% of all cancers worldwide 
(1). The belief that breast cancer is a disease of the developed world is changing, 
considering that almost 50% of breast cancer cases and 58% of deaths occur in low and 
middle income countries (LMICs) (2). Worldwide, the incidence rates of breast cancer 
vary greatly from low rates of 27 per 100,000 women in Middle Africa to 92 per 100,000 
women in Northern America (1) (Figure 1). However, the incidence is rising rapidly 
throughout LMICs, where it has superseded cervical cancer as the most frequently 
diagnosed type of cancer (2, 3).  
Breast cancer was responsible for 522,000 deaths in 2012, with 62% (324,000) of these 
deaths occurring in less developed regions of the world (1). Breast cancer mortality rates 
range from 6 per 100,000 women in Eastern Asia to 20 per 100,000 women in Western 
Africa(1). There is less regional variation in the breast cancer mortality rates than in the 
case of incidence (Figure 2) due to differences in terms of access to treatment and survival 
worldwide. While breast cancer incidence is affected by a demographic transition with a 
resultant increasing life expectancy and a westernisation of diet and lifestyle, the mortality 
from breast cancer is affected by early diagnosis, an increasing awareness of the disease 
and the advances that have been made in breast cancer therapy in many HICs in recent 
years (4). 
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1.1.2 BURDEN OF BREAST CANCER IN  SUB-SAHARAN AFRICA AND NIGERIA  
There is a scarcity of high-quality data on the incidence and mortality associated with 
breast cancer in sub-Saharan Africa (SSA) due to a limited number of population-based 
cancer registries on the continent (3). However, available estimates indicate that the 
number of new cases of breast cancer and breast cancer deaths in SSA is increasing(1). 
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Figure 1: Age standardised incidence rates of breast cancer worldwide per 100,000 women(1) 
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Nigeria has one of the highest age standardised incidence rates (ASR) of breast cancer in 
SSA, second only to South Africa and lower than in the case of Europe and North America 
(2). Breast cancer incidence in Nigeria, although relatively high compared to other SSA 
countries, is lower than in most developed regions of the world. In 2010, the ASR of 
breast cancer in the country was 54.3 per 100,000 women. Although much lower than the 
rate of 111.9 per 100,000 women in Belgium and 92.9 per 100,000 women in the United 
States (5), it represented a 100% increase in the incidence of breast cancer in the country 
over the last decade (3). In contrast, Nigeria has the 3rd highest breast cancer mortality 
rate worldwide (25.9 per 100,000 women) (6) with half of all women diagnosed with 
breast cancer in the country dying from the disease. 
Figure 2: Breast cancer incidence and mortality rates by world region per 100,000 women (7) 
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1.1.3 FUTURE TRENDS IN BREAST CANCER INCIDENCE IN LMICS 
Future trends in breast cancer incidence in LMICs are being driven by two main factors. 
Firstly, most LMICs are undergoing a demographic transition, which in turn leads to an 
increasing life expectancy. Consequently, a larger proportion of women are living longer 
and thus reaching the ages when the incidence of breast cancer is the highest. For 
example, the female life expectancy in Nigeria was 46 years in 1997, as opposed to 56 
years in 2012(8). Although an increase in life expectancy will not lead to an increase in 
incidence rates, it will nevertheless translate into increases in the absolute number of 
breast cancer cases occurring in less developed regions of the world. The International 
Agency for Research on Cancer (IARC) has estimated that these demographic changes 
alone suggest that the number of breast cancer cases occurring in less developed regions 
of the world will increase from 882,949 in 2012 to 1,428,133 in 2035, when they will 
represent over 60% of all breast cancer cases worldwide(1).  
Secondly, the trends associated with the incidence of breast cancer in LMICs will be 
affected by the changes in incidence rates due to adoption of more “westernised” 
lifestyles. The incidence rates of breast cancer across regions worldwide are essentially a 
consequence of the distribution of established risk factors for the disease (4). These well-
established risk factors affect the risk of disease across all populations regardless of their 
ethnic/racial background and have been well documented in the literature (9-11). Non-
modifiable (intrinsic) and modifiable (extrinsic) risk factors for breast cancer have been 
identified in many populations. The non-modifiable risk factors include gender, 
increasing age, race and ethnicity, and a genetic/family predisposition to breast cancer 
(12, 13). Other risk factors include prolonged exposure to endogenous sex hormones and 
growth factors, which result from early age at menarche and late menopause, and taller 
stature (14). The use of exogenous sex hormones (i.e. replacement therapy, oral 
contraceptives) is also associated with increased risk. Excess weight at post-menopausal 
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ages also increases the risk of breast cancer, despite the fact that the pre-menopausal high 
Body Mass Index (BMI) is protective (15). Alcohol consumption and limited physical 
activity also influence breast cancer risk (15). In contrast, young maternal age at first 
birth, high parity and breastfeeding reduce breast cancer risk. In Nigeria, similar to other 
countries in SSA, the demographic transition has resulted in an increasing life expectancy 
(16), but with changes to increasingly risky reproductive lifestyles characterised by 
advanced maternal age at first birth, a small number of children and shorter durations of 
breastfeeding. The adoption of a western lifestyle has been particularly evident in urban 
areas. According to the 2008 Nigerian Demographic and Health Survey, the general 
fertility rate in Nigeria is 194 births for every 1,000 women(17). This report highlights 
the declining fertility rate over the past 20 years and significant rural vs. urban disparities 
with rural areas and Northern Nigeria recording higher fertility rates(17). The changing 
patterns of child birth, breastfeeding, dietary factors, excess body weight, and use of 
exogenous hormones have been identified by other authors as some of the driving forces 
in the changes noted in the breast cancer incidence rates worldwide (4). 
1.2 BREAST CANCER CONTROL IN HICS AND OPPORTUNITIES FOR LMICS  
Breast cancer control constitutes a public health approach aimed at reducing the burden 
of breast cancer in populations worldwide, particularly in those characterised by high 
incidence and mortality from breast cancer. There are three components to breast cancer 
control. These include the primary, secondary and tertiary prevention of breast cancer 
(18). In many HICs, the governments through national cancer control programmes along 
with non-governmental organisations through breast cancer outreach and early detection 
activities incorporate evidence-based and cost-effective interventions that are spread 
across these three categories of breast cancer prevention.  
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1.2.1 Primary Prevention 
The aim of primary prevention is to reduce the incidence of breast cancer by controlling 
the exposure to established risk factors for breast cancer. However, many of the well-
established risk factors for breast cancer (e.g. reproductive-related factors, such as 
advanced maternal age at first birth, low parity and short duration of breastfeeding) are 
not amenable to change in modern societies.  Thus, primary prevention strategies for 
breast cancer have been restricted to established modifiable risk factors such as post-
menopausal excess weight, lack of physical activity, alcohol intake, use of exogenous 
hormones (i.e. oral contraceptives and hormone therapy) and exposure to ionizing 
radiation. Regular physical activity, maintenance of a healthy body weight and reductions 
in the alcohol intake are important components of the primary prevention strategy against 
a large number of non-communicable diseases including many other types of cancer apart 
from breast cancer, cardio-vascular disorders and diabetes.  
For a small proportion of women who are at high risk of breast cancer (e.g. those with a 
strong family history) chemoprevention is also recommended (19).  
Chemoprevention has been recommended by the United States Preventive Services Task 
Force, whereby it was suggested that asymptomatic women aged 35 years and above 
without a prior diagnosis of cancer should be informed about medications such as 
tamoxifen and raloxifene, which can reduce their risk for the disease (19). 
Primary prevention, whilst important in cancer control, is unlikely to prevent the majority 
of breast cancers, therefore, early detection seeking to improve the outcomes and survival 
from this disease remains the cornerstone of breast cancer control (20). 
1.2.2 Secondary Prevention 
In secondary prevention, the goal is to either detect asymptomatic breast cancer by means 
of mammographic screening or to detect symptomatic breast cancer at an early stage 
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through early detection when treatment is more effective and, hence, more likely to lead 
to reductions in mortality.  
Breast cancer mammographic screening 
The primary aim of a breast cancer screening programme is to reduce disease mortality. 
Globally, mammography is the most common screening method for the detection of 
asymptomatic breast cancer and is an important component of the secondary prevention 
strategy in many HICs. The World Health Organization (WHO), the American Cancer 
Society and a wide range of other public health organisations recommend population-
based mammography screening in the case of HICs. In the United Kingdom and many 
other high-income countries, population-based mammographic screening programmes 
have been implemented. The age groups targeted by such programmes vary from country 
to country but in general they range from the early/mid-40s to the late 60s/early 70s.  
The introduction of a breast cancer screening programme in some populations has led to 
increases in the proportion of cancers diagnosed at an earlier stage (21) , improvements 
in the survival rates from the disease and, ultimately, reductions in breast cancer 
mortality. However, there has been some controversy recently, regarding the relative 
benefits and harms of breast cancer screening in HICs. An Independent UK Panel on 
Breast Cancer Screening concluded that screening reduces breast cancer mortality by 
about 20% but that it was associated with some degree of over-diagnosis, as well as other 
harms (e.g. false-positives, false-negatives, exposure to ionizing radiation) (22).  These 
findings were broadly supported by a subsequent review by the International Agency for 
Research on Cancer (IARC) (23). 
Population-based mammographic screening is not feasible in LMICs (24). Health systems 
in LMICs face a myriad of challenges including a lack of resources and a poor 
infrastructural capacity that is currently unable to support population-based breast cancer 
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screening programmes. Factors such as a younger population with a shorter life 
expectancy and more prevalent competing causes of mortality could reduce the benefits 
of such programmes in LMICs. Furthermore, breast cancer screening programmes in 
LMICs cannot be rigorously evaluated given the current state of the health facilities and 
the limited number of care providers (25). In Nigeria and other SSA countries, the lack 
of proper health infrastructure and the limited access to health care services impedes the 
successful implementation of a population-wide breast cancer screening programme. 
Even where opportunistic breast cancer screening programmes exist in certain SSA 
settings, their effect may be limited because women lack basic knowledge of the disease 
and are therefore unaware of the benefits entailed by these screening programmes (26). 
Over the past two decades, there has been a significant improvement in the stage at 
diagnosis of breast cancer in some African settings despite the lack of population-based 
or opportunistic breast cancer screening programmes in the region (27). However, more 
than 60% of the patients diagnosed with breast cancer still present late in Nigeria. 
Therefore, early detection strategies that have been successfully implemented in several 
LMICs, such as India (28), Malaysia (29), South Africa (30), Tanzania (31) and Sudan 
(32), where the stage at diagnosis has improved over time can be reproduced in other 
settings that lack screening programmes.  
Early detection of symptomatic breast cancer  
Many initial breast cancers are asymptomatic. Therefore, a lack of population-wide 
screening programmes may contribute to the late stage diagnosis in many African 
countries (33). In settings where mammographic screening is widely unavailable, the 
main methods used in the secondary prevention of breast cancer are self-breast 
examination (SBE) and clinical breast examination (CBE). A consequence thereof is that 
most breast lumps are identified only when they become palpable, which in most cases 
measure >2 cm in diameter(34). In a Norwegian study using breast tumour growth 
26 
 
models, it was estimated that on average tumours in women grow 10-20 mm every 1.7 
years, increasing with age (35). The authors also reported larger tumour sizes, prior to the 
onset of screening (35) (Figure 3). The average tumour size recorded among US women 
aged 50-60 years and <40 years is 1.4 cm and 1.9 cm respectively (36). These tumour 
sizes are in sharp contrast with those found in the SSA countries, where the average 
tumour size ranges from 3-13 cm(37, 38). This therefore indicates the need for public 
health interventions to promote awareness and encourage downwards stage migration in 
the absence of mammographic screenings in the region. 
Although some authors have questioned the effectiveness of SBE and CBE in reducing 
the stage at diagnosis (39), a recent review by IARC reports sufficient evidence 
suggesting that CBE shifts the stage distribution of breast cancers towards a lower stage, 
though there is limited evidence indicating that CBE reduces breast cancer mortality (23). 
However, both SBE and CBE contribute to increasing the awareness about breast cancer 
in the population, particularly in LMICs where the general knowledge about breast cancer 
and its symptoms is limited. The Breast Health Global Initiative recommends CBE as a 
diagnostic tool and a necessary resource for both HICs and LMICs (40, 41). Furthermore, 
the findings from a large randomised controlled trial in India suggest that CBE can be 
used as a method to stage migrate breast cancer downwards, and if combined with 
effective treatment, it can improve breast cancer survival (42).  
In the USA, prior to the onset of the breast cancer screening in 1973, improvements in 
the breast cancer survival rates were largely due to breast education programmes and the 
detection of palpable breast cancers by means of SBE or CBE (43). These findings, 
together with the tumour size distributions found in SSA, which are much larger than 
those in the pre-screening era in Norway, thus suggest that the breast cancer outcomes in 
developing countries can be improved in a more rapid manner by means of early detection 
and migration to a lower stage at diagnosis, rather than by screening mammography (44). 
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Figure 3: Distribution of tumour sizes of the cases found on screening and before the onset of the 
mammographic screening programme in Norway (35). 
  
1.2.3  Tertiary Prevention 
Tertiary prevention involves the treatment of women with breast cancer with the purpose 
of improving the quality of life, disease specific outcomes and survival. This often 
includes breast surgery, radiotherapy, systemic therapy and palliative care (41). For breast 
cancer survivors, support groups and rehabilitation programmes are key components of 
the tertiary prevention strategy in HICs. In LMICs, the most common treatment method 
for breast cancer is surgery. However, in cases where women present at late stages, the 
tumour may be inoperable (45). Although radiotherapy is an important component of any 
cancer control programme, the access to radiotherapy machines is often limited or non-
existent in many LMICS. A recent review by Abdel-Wahab and colleagues revealed that 
out of 52 African countries, only 23 provided radiotherapy services (46). Out of the 277 
radiotherapy machines available in the African continent in 2010, 60% of these were 
concentrated in South Africa and Egypt with over 198 million people in the neighbouring 
regions having no access to radiotherapy (46). The access to cancer drugs for systemic 
therapy is often limited in LMICs. Conducting a laboratory assessment for oestrogen, 
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progesterone and the human epidermal growth factor receptor 2 (HER2), though required 
prior to the initiation of the hormonal treatment, is expensive and often unavailable in 
many low-resource settings. Therefore, in LMICs where the resources may be limited to 
effectively incorporate tertiary prevention programmes, the impact of primary and 
secondary prevention would be significantly important in improving outcomes and 
survival. 
1.3 BREAST CANCER SURVIVAL IN SUB-SAHARAN AFRICA  
As mentioned above, the ultimate goal of a breast cancer control programme is to reduce 
mortality from this disease. However, in order to achieve this, such programmes must 
lead to improvements in breast cancer survival. Survival is significantly influenced by the 
stage at diagnosis of breast cancer. In Uganda, the 5-year survival rate for women 
diagnosed in a tertiary hospital in Kampala was 100% for those in the early stages (I/II) 
and 51.8% for those in the late stages (III/IV) (47) (Figure 4) (the staging classification 
is discussed in section 1.6). Previous studies conducted on breast cancer survival in SSA 
report low survival estimates, particularly in women diagnosed at late stages (Table 1). 
The incidence of breast cancer in Uganda is 27.5 per 100,000 women, constituting only 
30% of the overall breast cancer incidence in the USA which is 92.9 per 100,000 
women(1). However, the probability that a Ugandan woman would die from breast cancer 
is much higher than in the case of her counterpart in a western country owing to the 
differences in the available treatment and survival (48).  
An advanced stage at diagnosis has been widely reported to significantly affect breast 
cancer survival worldwide (49) and in SSA (Table 1), and further research into the factors 
that predict the late stage at diagnosis is needed in SSA. Potential determinants of the late 
stage at diagnosis and, hence, breast cancer survival include factors that affect the tumour 
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growth rate – e.g. age at diagnosis and tumour morphology, grade, and hormone receptor 
status – as well as delays in breast cancer diagnosis. 
 
Figure 4: Probability of dying from breast cancer by stage at diagnosis (47) 
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Table 1: Published studies showing breast cancer survival estimates in SSA 
Author, year of 
publication ref no. 
Country Setting Sample 
size (n) 
/Study 
design 
Mean age 
at 
diagnosis 
Year of 
diagnosis 
Late 
stage % 
(III/IV) 
Survival 
time 
(years)  
Survival (%) 
Early Vs Late  
   Population-based studies  
Coleman, 2008 (50) Africa- 
Algeria 
NR  P NR 2008 NR 5 45 
Sankaranarayanan, 
2011 (51) 
Uganda NR  P NR 1993-1997 NR 5 36 
Zimbabwe NR P NR 1993-1997 NR 5 47 
Gambia NR P NR 1993-1997 NR 5 10 
         
   Hospital-based studies 
Anyanwu, 2000 (52) Nnewi, 
Nigeria 
1 tertiary 
and 2 
secondary 
hospitals  
78 (R) 44 NK 56 2.6 50 
Gakwaya, 2008 (53) 
Early/Late 
Uganda Tertiary  297 (R) 45 1996-2000 77 5 74/39 
Kene, 2010 (54) Zaria, 
Nigeria 
Tertiary  99 (R) 44.5 2001-2005 62.1 3 70 
Arowolo, 2010 (55) Ife, Nigeria Tertiary  62 (R) 49.1 NR 100 1, 2, 5 66.7, 42.9, 11.9 
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Author, year of 
publication ref no. 
Country Setting Sample 
size (n) 
/Study 
design 
Mean age 
at 
diagnosis 
Year of 
diagnosis 
Late 
stage % 
(III/IV) 
Survival 
time 
(years)  
Survival (%) 
Early Vs Late  
Popoola, 2012 (56) Lagos, 
Nigeria 
Tertiary  176 (R) 50.5 2005-2011 65.3 5 26 
Kantelhardt, 2012 (57) 
Early/Late 
Ethiopia Tertiary  1303 (P) 43 2005-2010 74.7 5 78/38 
Galukande, 2015 (47) 
Early/Late  
Uganda Tertiary 262 (P) 45 2004-2007 & 
2010-2012 
89.5 5 100/51.8 
SSA: sub-Saharan Africa; NK: not known; P: prospective; R: retrospective; Early: sages I/II; Late stages III/IV 
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1.4 STAGE AT DIAGNOSIS OF BREAST CANCER 
1.4.1 TNM CLASSIFICATION  
Breast cancer has been categorised into four stages (I, II, III and IV) by the American 
Joint Committee on Cancer (AJCC), using the tumour, node, metastasis (TNM) 
system(58). This categorisation takes into account the size of the primary tumour (T), the 
lymph node involvement (N) and the absence or presence of metastases (M), which are 
all important prognostic indicators in breast cancer.  
 
Tumour Size (T)  
Tumour size (T) is an important component of the stage at diagnosis and a strong predictor 
of survival (59). Tumours with a small size are associated with a better prognosis. In stage 
1, T measures less than 2 centimetres (cm) in diameter, in stage II, T = 2-5 cm in size, in 
stage III T >5 cm in diameter, whereas stage IV involves a tumour of any size with 
extension to the skin or chest wall.    
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Table 2: Breast cancer staging by T, N, M grouping (AJCC) 7th Edition (58) 
Anatomic Stage/Prognostic Groups  
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 N1mi M0 
 T1* N1mi M0 
Stage IIA T0 N1** M0 
 T1* N1** M0 
 T2 N0 M0 
Stage IIB T2 N1 M0 
 T3 N0 M0 
Stage IIIA T0 N2 M0 
 T1* N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
Stage IIIB T4 N0 M0 
 T4 N1 M0 
 T4 N2 M0 
Stage IIIC Any T N3 M0 
Stage IV Any T Any N M1 
 
Regional lymph node involvement (N) 
Breast cancer can spread through the lymphatic vessels to the lymph nodes. Therefore, 
the regional lymph node involvement is an important component of the TNM staging. If 
the lymph nodes cannot be assessed, the result is reported as NX; if there is no regional 
lymph node involvement, the result is N0; if there is involvement of the ipsilateral lymph 
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node, it is N1; if the lymph nodes are fixed to each other or to other structures, N2; if 
there is involvement of the ipsilateral internal mammary lymph node(s), it is reported as 
N3 (Table 2).  
Metastases (M)  
The absence (M0) or presence of metastases (M1) to distant body organs forms the (M) 
component of the TNM staging (Table 2). In cases where metastases cannot be assessed, 
the result is reported as (MX).  
The various combinations of T, N and M to give stages I, II, III and IV are shown in Table 
2. Stages I and II are usually referred to as “early stage” breast cancer and stages III and 
IV as “late stage” breast cancer. 
1.4.2 LATE STAGE DIAGNOSIS OF BREAST CANCER IN SSA AND NIGERIA  
The stage at diagnosis is one of the most important prognostic factors associated with 
breast cancer (52, 54). The situation in SSA and Nigeria is similar to that in many other 
developing regions where a late stage diagnosis is usually the more common outcome 
(60-62). In HICs, such as the United States and the United Kingdom, reductions in 
mortality from breast cancer prior to the introduction of a population-wide screening 
programme suggest that an earlier stage at diagnosis, which can be achieved through 
improved breast cancer awareness, is crucial in obtaining favourable outcomes in the 
management of breast cancer patients (4). Breast cancer awareness and knowledge of the 
benefits associated with early stage at diagnosis are poor in most SSA countries (63). 
There is a lack of awareness among the public and health care professionals of the need 
for early detection of breast cancer in SSA (64) and consequently, advanced stage at 
diagnosis remains a common feature in the region (61, 65). Studies from western 
countries have reported ethnic disparities in the stage at diagnosis, with minority groups 
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presenting at later stages (66, 67). However, there is little empirical evidence of the 
drivers of late stage diagnosis in SSA.  
The stage at diagnosis is an important predictor of treatment options and breast cancer 
survival. Studies have reported a survival advantage (disease free and overall survival) in 
early stage (I and II) over late stage (II and III) breast cancer patients (54). Identifying the 
factors that predict late stage diagnosis is crucial to the development of strategies to stage 
migrate breast cancer downwards in SSA settings. Breast cancer stage migration can 
result in improved survival rates among the breast cancer patients in SSA. As many risk 
factors for breast cancer are not amenable to change, as discussed in section 1.4.1, 
reductions in breast cancer mortality can be mainly achieved through early diagnosis and 
treatment. Consequently, many have advocated the need for more research into the factors 
responsible for the late stage at diagnosis in SSA populations (68).  
1.5 DIAGNOSTIC DELAYS IN BREAST CANCER  
Delays in a woman’s journey from her first reported symptom to a diagnosis of breast 
cancer can significantly affect the stage at diagnosis and survival (69). Longer waiting 
periods prior to a breast cancer diagnosis and the initiation of therapy are of prognostic 
concern, as these delays can lead to stage progression and death from breast cancer (69). 
Delays in breast cancer have been described in the context of total delay, patient delay 
and provider delay. Total delay has been defined as the time from the symptom discovery 
to the diagnosis or the start of treatment for breast cancer (70). This time period has been 
further categorised into two main intervals of patient delay and provider or system delay 
(69). Patient delay has been described in the literature as the time from the first reported 
symptoms to the presentation at a care provider, while provider delay is the time from the 
presentation at the care provider to a confirmed diagnosis of breast cancer (69). In HICs, 
the time from when a woman discovers a breast cancer symptom to her presentation and 
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subsequent diagnosis is significantly shorter than in many LMICs. In a London breast 
clinic, the median patient delay was 13 days, whereas the median system delay was 18 
days (71). Poum et al. from Thailand also reported a median patient delay of 12 days and 
a system delay of 21 days (72), similar to the reports from Canada (73), France (74), 
Germany (75) and the United States (76). In Mexico, the self-reported patient delay was 
only 10 days, similar to findings in HICs. However, the system delay was much longer at 
5 months due to patients having to visit multiple care providers before a definitive 
diagnosis was made, in line with findings from other LMICs (70). The short delay 
intervals in HICs are in sharp contrast with the SSA setting. In South Africa, the median 
patient delay reported by Moodley et al.  was 164 days and the median system delay was 
92 days (77). In Rwanda, the median patient and system delays were both 150 days (78). 
Similar long delays have been reported in Nigeria (60) and Uganda (79). In HICs, less 
than 20% of women report a total delay of over 3 months (72), which is comparable to 
the findings in Germany (75). In contrast, 70% of the breast cancer patients in Nigeria 
reported a total delay greater than 3 months (60). 
A relationship between delayed diagnosis of breast cancer and more advanced clinical 
stage has been highlighted in studies conducted in other settings including Mexico (70), 
Thailand (72) and Germany (75), and in a SSA country, namely Rwanda (78). These 
findings suggest that the efforts to promote shorter intervals from the first reported 
symptoms to the presentation and diagnosis in LMICs could have a substantial impact on 
disease stage and survival (78). A delayed diagnosis is also associated with an increasing 
tumour size and longer travel distance to a diagnostic health facility. In Figure 5 below, 
the expected growth curves were generated based on the observed delay to diagnosis and 
the tumour sizes from the review by Weedon-Fekjær et al. (35), and the travel distance 
to a health facility as reported in South Africa by Dickens et al. (80). In the South African 
study, a more advanced stage at diagnosis at the Chris Hani Baragwanath Academic 
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Hospital, Johannesburg (Soweto) South Africa (CHBAH) was reported in patients who 
lived further away from the facility. The authors speculated that the delays to diagnosis 
in women who lived further away from the facility could contribute to the later stage at 
diagnosis reported in this population. 
38 
 
Figure 5: Tumour growth curve model based on the tumour sizes reported in the review by Weedon-Fekjær, 2008 (35) and the travel distance reported by Dickens, 
2014 (80) in South Africa.
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CHBAH- Chris Hani Baragwanath Academic Hospital, South Africa  
Patient and system delays have been described extensively in the literature from high 
income countries, but only a limited number of studies in SSA have been published on 
this topic (60, 78, 81). It is critical that the reasons for the delay are properly investigated 
and that interventions seeking to address these issues are developed in SSA. The 
conceptual framework below (Figure 6) shows the various factors that may contribute to 
the delays in a woman’s journey from her first reported symptom to a diagnosis of breast 
cancer. These factors have been grouped into sociodemographic, breast cancer awareness, 
health care access and clinical factors. 
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Figure 6: Conceptual framework showing the determinants of diagnostic delays in women with breast cancer  
 
BC: Breast Cancer, SBE: Self-Breast Examination  
Delays in 
Breast 
Cancer
Sociodemographic factors: Age, 
Marital Status, Religion, Education, 
Socioeconomic class,  Income, 
Number of children 
Health care access: 
Region or residence, Type 
of health facility visited, 
Time taken to first 
provider
Clinical factors: Previous history 
of benign breast disease, Previous 
cormorbidities, Family history of 
BC, Body Mass index, Waist hip 
ratio. 
Breast cancer 
awareness: Previous 
Knowledge of BC, Knowledge of 
BC symptoms, belief in a cure for 
BC, practice of SBE, Type of first 
symptom noticed 
41 
 
Sociodemographic factors  
Lower educational levels, younger age at diagnosis and single status are some of the 
sociodemographic factors that have been identified as being significantly associated with 
diagnostic delays in women with breast cancer in Nigeria (82). Other authors have 
identified women with older age, lower income and low socioeconomic class more likely 
to present late (75). 
Breast cancer awareness factors  
Previous knowledge of breast cancer and awareness of breast cancer symptoms and the 
treatment thereof might be significant determinants in relation to diagnostic delays in 
women with breast symptoms. Previous studies have identified a lack of breast cancer 
awareness (among women and health care professionals) (60), poor knowledge of breast 
cancer symptoms and poor screening practices as some of the factors associated with 
diagnostic delays (83).  
Health care access factors  
A lack of clear referral channels from primary to secondary or tertiary health facilities 
notably results in prolonging the time from when symptoms are initially noticed to when 
a diagnosis is made and the treatment is offered, which imposes health system related 
barriers on the diagnosis and treatment of breast cancer (41). Some studies have reported 
region of residence and urban vs. rural differences in relation to the diagnostic delays in 
breast cancer. In Mexico, although a short patient delay of 10 days was reported, whereas 
a long system delay of 5 months (150 days) was observed and the authors speculated that 
this delay may be due to patients typically receiving care from different practitioners and 
different facilities, which often prolongs the health care system navigation process (70). 
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Clinical factors  
The role of clinical factors such as a previous history of benign breast disease, the 
presence or absence of co-morbidities, family history of breast cancer, body mass index 
(BMI) and waist hip ratio have not been properly described in the SSA setting. The focus 
of the previous studies investigating the delays in the diagnosis of breast cancer in SSA 
has been on sociodemographic and health care access factors and not on clinical factors. 
The extent to which clinical factors contribute to these delays is therefore unclear. In the 
case of women with a previous history of comorbidities, such as hypertension or diabetes, 
who are in constant contact with the health care system for regular checks and follow-
ups, it is not known whether being in close contact with the health care system renders 
them less likely to delay than others or whether women with a previous history of benign 
breast disease are less likely to delay given their previous contact and ability to navigate 
the health care system.  
1.6 PROBLEM STATEMENT, RESEARCH QUESTIONS AND OBJECTIVES  
The stage at breast cancer diagnosis significantly affects breast cancer survival in SSA. 
Therefore, there is a need to investigate the factors that influence stage and diagnostic 
delays in the region. As presented above, there is evidence suggesting that breast cancer 
in SSA is often characterised by an advanced stage at diagnosis and delays from the first 
reported symptom to diagnosis in majority of women with symptoms (60, 61, 78). There 
also appears to be a consensus suggesting that interventions in the region should target 
factors that have been reportedly associated with a later stage at diagnosis. However, there 
is a dearth of literature on the determinants of later stage at diagnosis and diagnostic 
delays in SSA, particularly in West Africa and Nigeria. As such, the new knowledge 
provided in this study will serve as a first step towards developing interventions aimed at 
achieving a downward stage migration in the region. 
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The main focus of this PhD thesis was to investigate the determinants of stage at diagnosis 
and the delays to diagnosis in women with breast cancer in SSA and to identify the factors 
that may be amenable to intervention in order to reduce late stage diagnosis of breast 
cancer, and to improve survival and reduce mortality from BC in SSA.  
The main objectives of this PhD thesis were: 
1. To carry out a systematic review of stage at diagnosis of breast cancer in sub-
Saharan Africa to: (i) identify possible sources of variation across SSA and (ii) 
compare the percentage of late stage of breast cancer diagnosis in SSA with black 
and white populations in the United States (US) using Surveillance, 
Epidemiology, and End Results (SEER) data. 
2. To design and implement a multicentre case-control study referred to as the 
Nigerian Integrative Epidemiology of Breast Cancer Study (NIBBLE), at six 
government hospitals in Nigeria. 
3. To conduct a case-only analysis within the framework of NIBBLE, to identify the 
sociodemographic, breast cancer awareness, health care access and clinical 
determinants of (i) stage at diagnosis of breast cancer; and (ii) a woman’s journey 
from the first reported symptom to the diagnosis of breast cancer, and of any 
delays, in Nigerian women with breast cancer. 
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1.7 OUTLINE OF THE THESIS 
This thesis incorporates published and recently submitted journal papers and other 
chapters linked by supporting material. There are six chapters in this thesis. Following 
the introduction, and five other chapters which are described in detail below, the 
references and appendices are presented. 
Chapter 2: In this chapter, the published literature on stage at diagnosis of breast cancer 
in SSA is systematically reviewed in order to provide the overall context for the thesis 
(objective 1). The factors associated with late stage diagnosis in SSA are investigated and 
the results are subsequently presented. A comparison of stage at diagnosis is made 
between the studies conducted in SSA and those in white and black populations in the 
United States. This chapter follows the conventions that govern research paper writing 
and is titled, “Stage at Diagnosis of Breast Cancer in Sub-Saharan Africa: A Systematic 
Review and Meta-Analysis”. 
Chapter 3: This chapter provides an overview of the methods used to design and 
implement a multi-centre study in Nigeria (objective 2). The study setting, study 
population, data collection process and field work are described. The parent study - The 
Nigerian Integrative Epidemiology of Breast Cancer Study (NIBBLE), within the 
framework of which this PhD study was conducted, and the six study sites in Nigeria are 
described in detail.  
Chapter 4: The fourth chapter follows the conventions that govern research paper 
writing, is written in research paper style and is titled: “Determinants of the Stage at 
Diagnosis of Breast Cancer in Nigerian Women: Sociodemographic, Breast Cancer 
Awareness, Health Care Access and Clinical Factors” This chapter addresses objective 
3(i).  
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Chapter 5: The fifth chapter addresses objective 3(ii) and describes the determinants of 
delays to diagnosis in Nigerian women and a woman’s journey from her first reported 
symptom to a diagnosis of breast cancer. In this chapter, the factors contributing to 
diagnostic delays in Nigerian women are identified and presented. 
Chapter 6: This chapter collates the major findings of the thesis to provide a critical 
assessment of the factors that affect the stage at diagnosis of breast cancer and the 
diagnostic delays in SSA women. In chapter six, the previously known findings on these 
topics will be discussed and how this thesis contributes to the existing body of knowledge. 
The strengths and limitations of this thesis are highlighted, the implications for future 
research and policy are discussed and further recommendations are made for future 
research. 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT 
www.lshtm.ac.uk 
 
Registry 
T: +44(0)20 7299 4646 
F: +44(0) 7299 4656 
E: registry@lshtm.ac.uk  
 
46 
 
 
RESEARCH PAPER COVER SHEET 
PLEASE NOTE THAT A COVER SHEET MUST BE COMPLETED FOR EACH RESEARCH 
PAPER INCLUDED IN A THESIS. 
 
SECTION A- Student Details 
Student Elima Jedy-Agba 
Principal Supervisor Prof. Isabel dos-Santos Silva 
Thesis Title Breast Cancer in sub-Saharan Africa: 
Determinants of Stage at Diagnosis and 
Diagnostic Delays in Women with 
Symptomatic Breast Cancer 
 
If the Research Paper has previously been published, please complete Section B, if not 
please move to Section C 
 
SECTION B- Paper already published 
Where was the work published? The Lancet Global Health 
When was the work published? December 2016 
If the work was published prior to 
registration for your research degree, give a 
brief rationale for its inclusion 
Not applicable 
Have you retained the copyright for the 
work?* 
Yes Was the 
work subject 
to academic 
peer review? 
Yes 
*If yes, please attach evidence of retention. If no, or if the work is being included in its published 
format, please attach evidence of permission from the copyright holder (publisher or other 
author) to include this work. 
The work was published under the CC BY 4.0 copyright license which allows the redistribution 
of the material in any medium or format. 
 
SECTION C- Prepared for publication, but not yet published 
Where is the work intended to be 
published? 
 
Please list the paper’s authors in the 
intended authorship order: 
 
Stage of publication Choose an item. 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT 
www.lshtm.ac.uk 
 
Registry 
T: +44(0)20 7299 4646 
F: +44(0) 7299 4656 
E: registry@lshtm.ac.uk  
 
47 
 
 
SECTION D- Multi-authored work 
For multi-authored work, give full details of 
your role in the research included in the 
paper and in the preparation of the paper. 
(Attach a further sheet if necessary) 
I extracted data from all eligible studies in 
the review, analysed data, drafted the 
manuscript, and made subsequent revisions 
to the manuscript 
 
 
 
 
Student Signature:           Date: 30/12/2016 
 
 
 
Supervisor Signature:        Date: 21/12/2016 
 
 
 
 
 
 
 
  
 
48 
 
 
CHAPTER 2 
 
2.1 RESEARCH PAPER 1: STAGE AT DIAGNOSIS OF BREAST CANCER IN SUB-SAHARAN 
AFRICA: A SYSTEMATIC REVIEW AND META-ANALYSIS 
 
Elima Jedy-Agba MD1,2, Valerie McCormack PhD3, Clement Adebamowo MD4, Isabel 
dos-Santos-Silva PhD1 
 
1 Department of Non-Communicable Disease Epidemiology, London School of Hygiene 
and Tropical Medicine, UK 
2 Institute of Human Virology, Abuja, Nigeria 
3 Section of Environment and Radiation, International Agency for Research on Cancer, 
Lyon, France 
4 Department of Epidemiology and Public Health; Greenebaum Cancer Centre and the 
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, 
USA 
 
 
 
Corresponding author: 
Professor Isabel dos-Santos-Silva 
Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology and 
Population Health, London School of Hygiene and Tropical Medicine, UK 
Email: isabel.silva@lshtm.ac.uk 
Tel: +44 (0)20 7927 2113 
 
  
  
 
49 
 
ABSTRACT  
Background: Breast cancer incidence rates in sub-Saharan Africa (SSA) are relatively 
low but, as survival from the disease in the region is poor, mortality rates are as high as 
in high-incidence countries. Stage at diagnosis is a major contributing factor to poor 
survival from breast cancer. We conducted the first systematic review and meta-analysis 
on stage at diagnosis of breast cancer in SSA to examine trends over time, and investigate 
sources of variations across the region.  
Methods: A search was conducted in MEDLINE, EMBASE, Africa-Wide Information 
and Web of Knowledge to identify studies on breast cancer stage at diagnosis in SSA 
women published before 1st January 2014. Random-effects meta-analyses were 
performed to investigate between-study heterogeneity in percentage of late stage breast 
cancer (stage III/IV), and meta-regression analyses to identify potential sources of 
variation.  Percentages of late stage breast cancer in SSA were compared with similar 
estimates for US Blacks and Whites derived from the Surveillance, Epidemiology, and 
End Results database.  
Findings: Eighty-three studies, representing 26788 women from 17 SSA countries, were 
included. There was wide between-study heterogeneity in the percentage of late stage 
(median 74∙7%, range: 30∙3%, 100%; I2=98∙3%, P<0∙001). Percentage of late stage was 
lower for Southern African non-Blacks (absolute difference (AD) relative to Western 
African Blacks=-18∙1%; 95% CI: -28∙2%, -8∙0%), but higher for populations from mixed 
(urban and rural) rather than urban settings (AD=13∙2%, 95% CI: 5∙7%, 20∙7% in analysis 
restricted to Blacks). Percentage of late stage in Blacks decreased over time (AD for years 
≥2000 vs. <1980: -10∙5%, 95% CI: -19∙3%, -1∙6%) but, around 2010, it was still higher 
than it was in US Whites and Blacks four decades previously.  
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Interpretation: Strategies for early diagnosis of breast cancer should be regarded as a 
major priority by cancer control programmes in SSA.  
RESEARCH IN CONTEXT 
Evidence before this study 
The number of new diagnoses of breast cancer in sub-Saharan Africa (SSA) is expected 
to rise rapidly due to population aging and changes in the prevalence of risk factors. As 
survival from breast cancer in the region is poor, despite relatively low incidence rates, 
mortality rates from this disease are as high as those in western countries. Stage at 
diagnosis is a main determinant of survival from breast cancer. Previous studies have 
reported a wide variation in stage at diagnosis of breast cancer across SSA, but none has 
examined trends in stage at diagnosis over time or investigated potential sources of 
variations across the region. We searched four databases – MEDLINE, EMBASE, Web 
of Knowledge and Africa-Wide Information – using a combination of keywords and 
MESH terms (detailed in Appendix 3) to identify all studies published in any language 
before the 1st January 2014 which reported on stage at diagnosis of primary invasive 
breast cancer in women in SSA. Studies which focused only on a particular stage (e.g. 
metastatic breast cancer only), reviews and conference proceedings were excluded. A 
total of 83 eligible papers were identified (as detailed in Figure 1), comprising a total of 
24213 staged patients. Random effects models revealed wide between-study 
heterogeneity in the percentage of late stage (stages III/IV): median 74∙7%, range: 30∙3 
to 100%; I2=98∙3%, P<0∙001. Meta-regression analyses showed that percentage of late 
stage was lower for Southern African non-Black women and, among Black women, 
higher for women residing in areas that included rural settings than in urban only settings. 
Percentage of late stage in SSA Black women decreased over time. Nevertheless, a 
comparison with data from the US Surveillance, Epidemiology, and End Results database 
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showed that the percentage of late stage in SAA Black women around 2010 was still 
higher than it was in US White and Black women in the 1970s. 
 
Added value of this study  
This systematic review provides the most comprehensive synthesis to date of the available 
evidence on stage at diagnosis of breast cancer in SSA. The review showed that the large 
majority of patients in SSA were diagnosed at a late stage (stages III/IV). There was, 
however, a wide range of estimates across the region; the reasons for this were unclear. 
Percentage late stage was, as expected, higher in Black than non-Black women; however, 
among Black women there were no clear differences by region or type of health facility, 
except that it was lower in urban settings. The review also highlighted the paucity of 
published data on breast cancer stage from certain parts of the region, e.g. from Middle 
Africa.  
Implications of all the available evidence  
Although some improvements in stage at diagnosis of breast cancer in sub-Saharan Africa 
have occurred over the last few decades, in many settings, very advanced disease is still 
prevalent at diagnosis. Nevertheless, within the region, public-sector settings exist with a 
much improved stage profile, indicating that stage migration is achievable in such 
settings, i.e. in the absence of organised screening. To prevent avoidable deaths from this 
potentially good prognosis cancer, breast cancer control measures require a strong 
emphasis on early diagnosis and treatment. Earlier diagnosis primarily concerns a time 
window with symptomatic disease; thus efforts to promote early presentation and faster 
referrals, diagnosis and treatment need strengthening.   
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INTRODUCTION 
Breast cancer incidence is highest in high-income countries (HICs) but it has been rising 
in low and middle income countries (LMICs).(84, 85) Survival from breast cancer is 
poorer in LMICs, and because of their large populations, most deaths from this cancer 
now occur in less developed parts of the world. In 2012, about 53% of all newly diagnosed 
cases of breast cancer, and about 58% of deaths from this disease, occurred in LMICs.(1) 
Breast cancer incidence in LMICs is likely to increase further in forthcoming decades as 
a result of population ageing and increased adoption of Western lifestyles.(84, 85)  
Breast cancer incidence in Sub-Saharan Africa (SSA) is among the lowest in the world 
(estimated age-standardized rates (ASR) ranging from 27/100000 in Middle Africa to 
39/100000 in South Africa regions). However, mortality from this cancer is as high as in 
high-incidence countries (estimated ASR range from 15/100000 in Middle Africa to 
20/100000 in Western Africa)(86), higher than in North America (ASR=14.8/100000) 
which has a much higher breast cancer incidence (ASR=91.6/100000).(86)  
Stage at diagnosis is a major determinant of survival from breast cancer, with early stage 
disease being associated with a better prognosis compared to late stage disease(49), a 
pattern present in SSA settings.(57, 87-89) Earlier stage at diagnosis, combined with 
therapeutic advances, was a major contributor to the sharp reductions in breast cancer 
mortality over recent decades in most HICs.(49) In contrast, the majority of breast cancer 
patients in SSA present with late stage disease, thought to be due to low levels of 
awareness, lack of early detection programme and poor facilities for accurate and timely 
diagnosis and treatment.(87, 90-98) Variations in stage of breast cancer at diagnosis 
across SSA, and over time in some of its settings(30), have been previously reported in 
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individual settings(47, 87, 89, 90, 94) but, to our knowledge, have not been examined 
systematically across SSA.  
In this study, we systematically review the published literature on stage at diagnosis of 
breast cancer in SSA, examine trends over time, and investigate possible sources of 
between-study heterogeneity which may help to identify appropriate approaches for 
down-staging this disease in the region.   
METHODS 
Literature search and study inclusion 
A study protocol (Appendix 1), based on the PRISMA guidelines (Appendix 2), was 
developed. Four databases – MEDLINE, EMBASE, Web of Knowledge and Africa-Wide 
Information (AWI) (https://www.ebscohost.com/academic/africa-wide-information) – 
were searched to identify all studies published before 1st January 2014 which reported on 
stage at diagnosis of primary invasive breast cancer in women in SSA. The United 
Nations classification (99) was used to define SSA countries and to group them according 
to region (i.e. Southern, Eastern, Western and Middle Africa). An initial keyword search, 
and subsequent searches based on Medical Subject Headings (MeSH), were performed 
using various combinations of “breast cancer*” or “breast neoplasm*” or “breast 
carcinoma*” or “breast sarcoma*” or “breast tumour*” or “breast tumour*” or “breast 
malignanc*” AND “Stage” or “presentation” or “grade” or “clinical features” or “clinical 
findings” AND “Africa” (Appendix 3). No restrictions were imposed on the ethnicity/race 
of women, whether conducted in public/private settings, age at diagnosis, or language of 
the publication. 
We identified 675 articles and reviewed in a two-step process (Figure 1). The first step 
consisted of a title and abstract review to identify those that were deemed potentially 
eligible for inclusion. This review was done by one of three authors (EJA, IdSS or VM) 
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to exclude: duplicate publications; articles from North Africa (i.e. Algeria, Egypt, Libya, 
Morocco, Sudan, Tunisia, and Western Sahara)(99); those which did not focus on breast 
cancer (e.g. studies of ‘all cancers’), did not include women with breast cancer (e.g. 
surveys on awareness), did not provide information on stage (e.g. pathology series, papers 
on screening), or focused exclusively on male breast cancer. Articles that restricted 
inclusion to a particular stage (e.g. metastatic breast cancer) were also excluded. Reviews 
and conference proceedings were not included, but their references were cross-checked 
for completeness. Studies that included both female and male breast cancer patients were 
included, even if they did not provide enough information to allow the exclusion of male 
patients because men typically represented <2% of all study subjects. A random sample 
of 50% of the total abstracts was independently reviewed by one of the other two 
reviewers; this showed no disagreements on which papers to select for full text review. A 
total of 170 articles were considered as potentially relevant, and the full text retrieved for 
all of these except six which could not be traced through institutional libraries or direct 
contact with the authors (the latter attempts proved futile). The sample sizes of 
two(100),(101) of the untraceable six studies were 47 and 120 according to Edmund et 
al.(102)  
Data Extraction and quality appraisal 
In the second step, all 164 full-text articles were reviewed to confirm eligibility and, if 
eligible, data extraction was performed. EJA assessed all articles for eligibility and 
abstracted the data, using an adapted version of a pretested data entry e-form.(103) All 
articles were independently reviewed by one of the other two reviewers (IdSS or VM). 
For each eligible paper, data were extracted on the numbers of patients who presented in 
stages I, II, III and IV at diagnosis, or at early (I/II) and late (III/IV) stages if only this 
combined information was provided, country, study design, study population and type of 
clinical setting (e.g. primary, secondary, or tertiary clinical facility; population-based 
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cancer registry; public/private/mixed patients), years when breast cancer patients were 
diagnosed, race, average age at time of diagnosis (mean or median; if only age categories 
were reported the mean age was estimated from the mid-point and the reported numbers 
in each category), and methods and classification used to ascertain stage.  
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Figure 1. Flow diagram describing study identification, screening and eligibility 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Footnote: Many studies could fit into more than one exclusion category; these were allocated to the first eligible 
category in the order listed in the Figure. 
 
AWI 
n=332 
Eligible and Included 
n=83  
Web of Science 
n=456 
Medline 
n=183 
Embase  
n=284 
Total abstracts screened 
after removing duplicates 
n=675 
Full text articles assessed 
for eligibility 
n=170 
Exclusion n=101 
Reasons for exclusion: 
Meeting abstracts/PhD Thesis (n=8) 
No information on Stage (n=76) 
Study population overlaps with another 
study (n= 7) 
Study distribution assumed/not original 
(n=9)  
Attempts to retrieve paper/abstracts 
unsuccessful (n=1) 
 
 
Exclusion n=505 
Reasons for exclusion: 
Non-human studies (n=7) 
Not Sub-Saharan Africa (n=111) 
Not breast cancer studies (n=152) 
Not female (n=21) 
Conference abstracts (n=46) 
No information on stage/Stage not 
mentioned in abstract (n=133) 
No stage distribution/only a particular 
stage given (n=35) 
Excluded n=9 
Reasons for exclusion: 
Overlapping study population= 1 
Stage distribution excluded stage 
4 patients (operable breast cancer 
only )=1 
Stage distribution could not be 
ascertained=1 
Attempts to retrieve 
paper/abstracts unsuccessful= 6 
 
Additional papers identified by 
hand searches of bibliographic 
references 
n=23 
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Time at diagnosis in the original papers was either the time at clinical or pathological 
diagnosis. If a study provided numbers for each specific American Joint Committee 
Cancer Tumour Node Metastases (TNM) category (e.g. T2, N0, M0; Chapter 1, Table 2) 
we used these to derive numbers in each one of the four stages. For three studies(104-
106) we obtained estimates that differed from those published because T3N1M0 tumours 
in the original publications were classified as stage II, but they should be stage III 
according to the 7th edition of the American Joint Committee on Cancer Breast Cancer 
Staging Manual.(107) Four studies(108-111) provided information on the tumour (T1-
T4) only and, for these, T3/T4 was taken as a proxy for stages III/IV. Whenever available, 
we extracted data on menopausal status, tumour’s characteristics (e.g. histology, size, 
grade, receptor status) and time from first symptoms to diagnosis. Disagreements between 
extractors were discussed and a consensus reached. Most of the papers with missing 
information were from studies conducted several decades ago, hence no attempt was 
made to contact their authors as it is unlikely that the required information could still be 
retrieved. If there were multiple papers for the same study period, setting and author, the 
paper with the most information on tumour stage was selected for inclusion.  
The quality of the papers included in the review was assessed by two independent 
reviewers. An adapted version of the standardized quality assessment criteria developed 
by Eng et al.(103) was used to assess the potential for selection and information bias as 
well as the availability of data on key variables (e.g. age and year at diagnosis, tumour 
grade) (Appendix 4).  A quality score ranging from 0 (low) to 28 (high quality) was given 
to each paper. 
Data analysis 
The primary outcome was percentage (p34) of breast cancer diagnosed at late stages 
(stages III/IV), defined as p34=n34/n, where n34 is the number of women who presented at 
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stages 3 or 4 and n is the number of women with known stage information. The suite of 
metan and metaprop commands from Stata version 13 (StataCorp, Texas) were used to 
graphically display population-specific late stage percentages and to estimate pooled 
percentages using random effect models. The metaprop command was specifically 
designed to model binary data, thereby allowing for proportions near boundaries (i.e. in 
this instance near 100% late stage). Between-population heterogeneity was assessed using 
I2-statistic and the P-value for heterogeneity (Cochrane’s Q statistic). To examine 
potential sources of heterogeneity population-specific estimates were stratified by 
relevant clinico-epidemiological variables, and meta-regression analyses were conducted 
to identify independent correlates of percentage late stage disease. Study-level 
determinants of late stage are expressed as absolute differences (AD) in the percentage 
of patients with late stage (p34). Analyses were conducted among all study populations 
(Black and non-Black) and among Black populations only (non-Black populations, which 
were all from South Africa, were excluded from the latter analysis owing to their known 
privileged access to health care). The potential for small study bias was assessed using 
Funnel plots and the Egger test.(112)   
To compare late stage breast cancer in SSA with corresponding figures for Whites and 
Blacks in the US, relevant data were extracted from the Surveillance, Epidemiology, and 
End Results (SEER) database, which includes information on all incident female cases of 
invasive primary breast cancer from nine US population-based cancer registries for two 
time periods: 1973-2002 and 1998-2011.(113) The SEER database provided numbers of 
incident in situ, localised, regional and distant (metastatic) breast cancer cases as well as 
numbers with unknown or missing stage. No age restrictions were imposed on the data.  
The SEER summary staging classification was used to estimate the percentage of patients 
with regional or distant disease, as a proxy for stages III/IV, out of those with known 
stage.  
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RESULTS  
Characteristics of eligible studies 
The full-text review identified 83 eligible papers (Figure 1) from 17 sub-Saharan African 
countries comprising late-stage estimates for 91 distinct study populations as five studies 
provided separate estimates for different subsets of participants (i.e. for pregnant/lactating 
(PL) and non-pregnant/lactating (NPL) women(114) or different racial groups(93, 
115),(116),(117)). The characteristics of the included studies are summarised in Table 1; 
study-specific details and references are given in Table 2. They comprised 26788 breast 
cancer patients, with sample sizes ranging from 12 to 2346 (median: 141; -Table 1). Stage 
information was available for 24213 (90·4%) patients. Thirty-six studies (43.4%), 
comprising 8407 staged patients, were from Nigeria and 16 studies (19.3%), comprising 
10182 staged patients, were from South Africa. Thirty-five (42·2%) were consecutive 
case series; the remaining were convenience case series, i.e. patients seen in pathology or 
radiotherapy departments only or studies where not all eligible patients that reported at 
the surgery/oncology clinics were included (Table 1). The average age at diagnosis was 
<45 years in 33.7% of studies, between 45-49 years in 43.4% and >49 years in 19.2%. 
Age was not reported in only 3 (3.6%) studies as shown in Table 1. The mean year of 
diagnosis ranged from 1960 to 2011, being 2000 or later for 39·8% of the studies.   
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Table 1. Summary characteristics of 83 studies included in the systematic review.  
 
 
Variable 
No.  of 
studies 
No. study 
population
s a 
No.  of 
breast 
cancer 
patients 
Breast cancer patients 
with known stage 
 
N % 
TOTAL  83 91 26788 24213 90·4  
       
Race       
   Black b 75 76 18805 16669 88.6  
   Non-Black c 8 15 7983 7544 94·5  
Region/Country       
Western Africa  48 49     
    Nigeria 36 37 8623 8407 97·5  
    Benin  2 2 204 204 100  
     Ghana 5 5 1969 1191 60·5  
     Mali 2 2 324 324 100  
     Other d 3 3 797 719 90·2  
Eastern/Middle Africa  19 19     
    Tanzania 5 5 1 310 1151 87·7  
     Kenya 2 2 287 157 54·7  
     Ethiopia 3 3 1267 841 66·4  
     Madagascar                                                           2 2 289 233 80·6  
     Uganda                        3 3 562 502 89·3  
     Other e 4 4 445 302 67·9  
  Southern Africa  16 23     
     South Africa  16 23 10711 10182  95·1  
Study design       
 Convenience case series 48 55 10780 9788 90·8  
 Consecutive case series         35 36 16008 14425 90·1  
Study population       
 Urban 27 34 15571 14208 91·2  
 Mixed (rural/urban)  56 57 11217 10005 89·2  
Type of health facility       
  
 
61 
 
 
Variable 
No.  of 
studies 
No. study 
population
s a 
No.  of 
breast 
cancer 
patients 
Breast cancer patients 
with known stage 
 
N % 
  
Tertiary/Secondary/Primary 
f 
9           12 1639 1503 91·7  
  Tertiary 72 77 24742 22399 90·5  
  NR 2 2 407 311 76·4  
Age at diagnosis (years) g       
    < 45  28 29 5475 4840 88·4  
    ≥ 45 to <50 36 37 7882 7218 91·6  
    ≥ 50 
   NR 
16 
3 
22 
3 
11056 
2375 
9841 
2314 
89·0 
97·4 
 
Year of diagnosis h       
     < 1980 11 16 3971 3782 95·2  
    1980-1999 32 34 11125 10737 96·5  
    ≥2000 33 33 8648 6733 77·8  
    NR 7 8 3044 2961 97·3  
Staging methods       
    Clinical and imaging 25 26 10416 9516 91·4  
    Clinical only 10 10 975 967 99·2  
    NR 48           55 15397 13730 89·2  
Staging classification       
TNM  
Manchester 
NR 
50 
11 
22 
57 
11 
23 
20388 
1436 
4964 
18048 
1426 
4739 
88·5 
99·3 
95·5 
 
Study quality scores i       
≥23 (higher quality ) 12 12 4067 3569 87·8  
22-20 26 27 6181 5721 92·6  
19-17 31 38 14541 13327 91·7  
<17 (lower quality)      14 14 1999 1596 79·8  
 
NR: Information not reported in the original paper; TNM: Tumour, lymph Node and Metastasis staging system 
a Five studies provided separate estimates for different subsets of participants (i.e. for pregnant/lactating (PL) and non-
pregnant/lactating (NPL) women(114) or different ethnic groups.(93, 115-117) 
b Includes seven Southern African studies which reported estimates for Black women only(93, 115-120); one Southern African 
study(30) which presented only an overall (all ethnic groups combined) estimate but reported that >80% of their study population was 
Black; nine studies from Western and Eastern Africa which were conducted exclusively among Black women (87, 110, 111, 121-126) 
as well as the remaining 58 studies from these two regions which did not report on race but were assumed to have been conducted in 
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predominantly Black women (i.e. >80% Black; see webappendix-Table 1), corresponding to 76 study population groups as one 
Nigerian study(114) presented separate estimates for pregnant/lactating (PL) and non-pregnant/non-lactating (NPL) women (see 
webappendix-Table 1). 
c Includes 15 Southern African study population groups: four studies(127, 128) (95, 129) which did not report on race but were 
assumed to be predominantly non-Black, four studies(109, 130-132) which present only overall estimates but reported an ethnically 
mixed population with ≤80% being Black, and four multi-ethnic studies(93, 115-117) which together reported separate estimates for 
seven non-Black population groups (see Table 2). 
d Includes one study from Guinea (total no. of cases/total no. cases with known stage: 178/124), one from Niger (146/146) and one 
from Senegal (473/449). 
e Includes one study from Rwanda (total no. of cases/total no. cases with known stage: 145/7), one from Zimbabwe (84/79), one from 
Eritrea (82/82) and one from Zaire (now Democratic Republic of Congo, 134/134).  
f All studies which recruited participants from secondary and primary health centers also included a tertiary center. 
g Mean or median age at breast cancer diagnosis. If only age categories were reported mean or median age was estimated from the 
mid-point and the reported number in each age category. The three studies in the NR category did not provide sufficient information 
to allow their allocation into one of the three age categories: Ajekigbe 199171 reported that 50.8% of the participants were aged <50 
years; Amir 199772 reported that 90% of the participants were aged <50 years; and Pegoraro 1980(109) reported that 50% were 
between ages 45-64 years (Table 2). 
h Middle year of the time interval during which patient recruitment took place.  
i Categories represent fourths of the overall score distribution (Appendix). 
 
 
Stage at diagnosis and sources of between-study heterogeneity  
There was wide variation in the distribution of stage at diagnosis in SSA. For instance, 
among studies that provided stage IV specific estimates, the percentage of women 
diagnosed with stage IV breast cancer ranged from 4%(65) to 70%(114) (Figure 2a). 
Consequently, there was wide between-population heterogeneity (I2=98·3%; P<0·0001) 
in the percentage of late stage (III/IV) (median 74·7%; range: 30·3%-100%), with 64·8% 
study populations yielding an estimate >70% (Figure 2b).     
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Figure 2a: Breast cancer stage at diagnosis: (a) study-specific distribution of stages I, II, III and 
IV (133) 
 
Footnote: B: Blacks; C: Coloured: I: Indian; NPL: Non-pregnant/non-lactating women; PL: Pregnant/lactating women SP: study 
population; W: Whites. Study-specific references given in webappendix-Table 1. In four studies (Ly 2012(108) Muguti 1993(111), 
Pegoraro 1980(109) and Rafaramino 2001(110), percentage of T3/T4 was used as a proxy for percentage stage III/IV. In Ly 2012(108), 
Muguti 1993(111) and Rafaramino 2001(110), the percentage with metastases (M1) was given and this was taken to be the percentage 
of stage IV in figure 1a. Race as defined in Table 1 and Table 2.  
 
Region and race 
Nine studies from Western and Eastern Africa were conducted exclusively among Black 
women(87, 110, 111, 121-126); the remaining 58 did not report on race but their 
populations were assumed to have the racial composition of their countries’ population 
and, hence, to comprise predominantly (≥80%) Black women. Studies from South Africa 
included exclusively(118-120) or predominantly (≥80%) Black(30); or predominantly 
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(≥80%)(95, 109, 127-132) non-Black women (i.e. White, Indian or Coloured women); or 
provided separate estimates for Black and non-Black women(93, 115-117) (Table 2).  
South African Black women presented much later than their non-Black counterparts, but 
with marked between-population heterogeneity within each racial stratum (I2>97% for 
both; Figure 3). Four South African studies examined racial differences (Figure 4), 
consistently showing higher percentage of late stage for Blacks (range: 74%-91%) than 
Whites (30-44%), with Indian and Coloured women having intermediate values, even 
when all the participants were diagnosed at the same facility. However, these were not 
adjusted for socio-economic status owing to lack of information from the original 
publications.  
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Figure 2b: Study-specific percentage of late stage disease (III/IV) ranked by increasing 
magnitude(133) 
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Figure 3: Study-specific percentage of late stage disease (III/IV) ranked by region of SSA(133) 
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Figure 4: Study-specific percentage late stage breast cancer at diagnosis in multi-racial South 
African studies 
 
Fully-adjusted meta-regression analysis (adjusting for region/race, study design, setting, 
facility type, age and year of diagnosis) confirmed the racial differential with percentage 
of late stage being 18.1% lower (95% CI: -28·2%, -8·0%) for South African non-Blacks 
than for Blacks in Western Africa. In contrast, analysis restricted to Blacks revealed no 
difference in late stage between the three SSA regions (Table 3).  
Study design and setting 
After adjustment for region/race there were no differences in late stage disease between 
consecutive or convenience case series, or by type of health facility (Table 3). Studies 
conducted in mixed urban/rural populations had an excess percentage of late stage disease 
than those conducted in urban populations, and this finding remained significant in the 
fully adjusted model (AD=12·9%; 95% CI: 5·5%, 20·3%) and in analysis restricted to 
Blacks (AD=13·2%; 5·7%, 20·7%) (Table 3). 
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Age and year of diagnosis 
Women aged ≥50 years had a lower percentage of late stage disease than those aged <45 
years (AD=-13·2%; 95% CI -21·2%, -5·3%), but most studies of older women comprise 
predominantly South African non-Blacks. Consequently, the age difference attenuated 
markedly upon adjustment for region and race, and disappeared in analysis restricted to 
Blacks (Table 2). There was a slight improvement in stage at diagnosis over time (Figure 
5). In the fully-adjusted meta-regression model, percentage of late stage disease was 
lower in Blacks diagnosed since 2000 compared to those diagnosed prior to 1980 (AD=-
10·5%; 95% CI: -19·3%, -1·6%; Table 2). In analysis restricted to Blacks, percentage late 
stage was lower in studies that did not report on year of diagnosis than studies published 
prior to 1980, but this finding was not statistically significant (Table 2); as the years of 
publication of these studies ranged from 2002 to 2011, it is likely that patients recruited 
into these studies would have been diagnosed in recent years. 
Staging approach 
The TNM or the Manchester staging classification (Table 2) were used in the majority of 
studies, but this information was missing in 21 studies (Table 1). There were no clear 
differences in percentage of late stage disease between studies that reported the staging 
classification used and those which did not, or between those conducted in facilities where 
there was access to imaging methods (e.g. x-rays) – either routinely or in clinically 
suspicious cases – and those performed without access to imaging (Table 2).  
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Figure 5: Study-specific percentage of late stage (III/IV) breast cancer at diagnosis by calendar 
year at diagnosis(133) 
 
Footnote: B: Blacks; C: Coloured: I: Indian; NPL: Non-pregnant/non-lactating women; PL: Pregnant/lactating women SP: study 
population; W: Whites. Study-specific references given in webappendix-Table 1. 
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Correlation of stage with tumour characteristics 
Few studies reported on tumour characteristics or duration of symptoms (Table 4) Among 
studies of Black populations that reported on these characteristics, late stage at diagnosis 
was positively associated with mean tumour size (Pearson correlation coefficient 
(r)=0.63, P=0.004, based on data from 19 studies), but not with self-reported mean 
duration of symptoms (r=-0.14, P=0.42, 35 studies) or with percentages of tumours 
classified as being invasive ductal carcinomas (r=0.09; P=0.50, 53 studies), oestrogen 
receptor (ER)-positive (r=-0.03, P=0.91, 15 studies) or grade 3 (r=0.21, P=0.26, 32 
studies).  
Study Quality and Study Small Bias 
The median study quality score was 19·5 (inter-quartile range: 17·5-21·5), with no 
evidence of regional or racial differences. There was also no variation in the percentage 
of late stage breast cancer by study quality (Table 2). The funnel plot (Figure 6) and the 
value of the Egger’s test for small study bias (P=0.01) were difficult to interpret due to 
the marked between-population heterogeneity.  
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Figure 6: Funnel plot assessing small study bias 
 
 
Comparison with US SEER data 
The proportion of late stage breast cancer at diagnosis declined markedly in the US 
between 1973 and 2011: from 50% to 27% among Whites, and from 60% to 32% among 
Blacks (Figure 7). In contrast, the large majority of study-specific estimates of late stage 
disease among SSA Blacks remained well above 60% from the 1970s to 2012, albeit with 
some indication of a slight downward trend in some settings in more recent years (Figure 
7). Notably, the proportion of late stage disease in SSA Blacks in the most recent study 
years (around 2010) was still higher than in US Black women 40 years previously. Among 
Southern African women, the proportion of late stage disease remained unchanged for 
non-Blacks but appeared to have declined somewhat among Blacks. Remarkably, only 
two studies were conducted after 2000 in the whole Southern African region, both in 
South Africa: one in non-Blacks(95) and one in Blacks.(30) In contrast, the number of 
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studies from Eastern and Western Africa published after 2000 was higher than in previous 
decades, although the majority had relatively small sample sizes. 
Figure 7: Trends in stage of breast cancer at diagnosis in Black and non-Black populations in 
SSA, 1960-2011, and in Black and White women in the US for two time periods, 1973-2002 and 
1988-2011.(133)  
 
Footnote: * The SSA estimates correspond to percentage of stage III/IV breast cancer patients at diagnosis, with the size of the point 
estimate symbols being proportional to the size of the study. The US estimates represent percentage of breast cancer patients with 
regional or distant disease (as a proxy for stages III/IV) out of all patients with known stage in the Surveillance Epidemiology End 
Results (SEER) database (see Data Analysis section); the SEER summary staging classification was used for both time periods 1973-
2002 (based on 365,695 and 31,781 breast cancer cases in US Whites and US Blacks, respectively) and 1998-2011 (based on 780,137 
and 96,526 breast cancer cases in US Whites and US Blacks, respectively). The discontinuity between the two time series was due to 
a change in staging classification as detailed in http://seer.cancer.gov/seerstat/variables/seer/yr1973_2009/lrd_stage/index.html.   
 
DISCUSSION 
This is the first systematic review of stage at diagnosis of breast cancer in SSA. It 
compiled data from 83 studies comprising 24213 staged patients. The findings highlight 
two main issues. First, they demonstrate the paucity of data on one of the most important 
clinical prognostic markers of breast cancer in this region. Specifically, no published data 
from Middle Africa were identified, and those from Southern Africa were restricted to 
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one country (South Africa), with only two studies (one among Blacks and another among 
non-Blacks) having been conducted after 2000. Furthermore, no study presented data 
from population-based cancer registries. Secondly, the findings demonstrate that the large 
majority of patients in SSA (77% across all Black study populations) were diagnosed at 
stages III/IV. Whilst this overall situation may seem grave, the presence of public-sector 
SSA settings with a better stage profile needs to be highlighted as those settings reveal 
that progress in down-staging breast cancer can be made within the public sector setting 
where mammography is often unavailable. However, the reasons for the marked between-
population heterogeneity, present even in analyses restricted to Blacks, are not entirely 
clear – with no distinct patterns defining the better settings. Late stage was, as expected, 
more frequent in Blacks than non-Blacks; however, among Blacks there were no clear 
differences in the percentage of late stage by region or type of health facility, except that 
it was lower in urban settings. There was evidence of down-staging of breast cancer over 
time among Blacks diagnosed after 2000, consistent with the within-study downward 
trend in late stage at diagnosis described by one of the studies in this review –  
McCormack et al. reported a decrease in the frequency of stage III/IV in South Africa 
from 66% in 2006-7 to 46% in 2010-2012.(30)  
We did not find a strong association between age at diagnosis and late stage in Blacks. 
Most patients were aged 35-49 years at diagnosis, i.e. approximately 10 to 15 years earlier 
than in developed countries.(134) This likely reflects the much younger age structure of 
the SSA population, consequent to higher fertility and shorter life expectancy, and the 
lower prevalence of risk factors in older generations rather than any inherent biological 
differences in disease aggressiveness between Blacks and Whites. Consistent with this 
interpretation is the fact that, at a study level, late stage was not correlated with tumour 
grade perhaps indicating that the former is not entirely a consequence of Blacks 
experiencing a biologically more aggressive form of disease – indeed a recent review 
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suggests that ER-positive disease constitutes two-thirds of tumours in SSA Blacks.(103)  
Late stage disease was, however, positively correlated with mean tumour size, as expected 
given that tumour size is used to derive stage, consistent with delays in access to health 
care.  
Increased breast cancer awareness and improvements in healthcare over time have been 
paralleled by decreases in tumour size and down-staging of breast cancer in other 
LMICs.(135, 136) However, studies have reported a low level of breast cancer awareness 
among the general population and health care professionals in SSA.(77, 137)  This 
significantly contributes to the late stage at diagnosis seen in SSA.(138, 139)  Other 
barriers to access, such as distance to health care facility, also play a role in this 
region.(80)  
Most studies used the TNM or the Manchester staging classifications, but only a quarter 
reported on the staging methods used. Of these, the majority relied on both clinical and 
imaging methods but a few relied on clinical-only methods. Although the latter approach 
leads to under-staging,(140) most women in settings where imaging procedures are 
unavailable or unaffordable(141) are likely to have presented at advanced stages when 
clinical methods may suffice. This is consistent with our finding of no differences in late 
stage disease according to whether staging methods were reported and, if reported, by 
type used.  
There was no correlation, at a study level, between percentage of late stage and average 
self-reported duration of symptoms (i.e. time between onset of symptoms and diagnosis).  
It is unclear the extent to which this ecological-level association reflects a similar lack of 
association at an individual level. Women may not recognise symptoms due to poor breast 
cancer awareness(142, 143), or they may not accurately remember the dates they first 
noticed symptoms. Nevertheless, average duration with symptoms were between 8 and 
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12 months in most studies (Table 4), indicating that for the most part advanced stage at 
diagnosis may be a result of delayed diagnosis. Hence, a large window exists in which 
delays to diagnosis can be shortened. 
The frequency of late stage at diagnosis among SSA Black women remained higher than 
among US Whites and Blacks from over the 1970-2010 period, including during the pre-
mammography screening era (in the US, screening began in 1976(144)). This illustrates 
that, through the more rapid diagnosis of palpable clinical disease, considerable 
improvements can still be made before expensive systems for the detection of pre-clinical 
disease are warranted. In SSA, where mammography is often unavailable or unaffordable, 
down-staging through breast cancer awareness and improved access to diagnostic 
facilities, not mammographic screening, is urgently required. 
Strengths and limitations 
Major strengths of this review include the detailed and inclusive search strategy (e.g. 
including non-English publications); the large sample size (>24000) of women with 
breast cancer in the region; and the use of standard methodology for study identification, 
and data extraction and synthesis. There were also limitations. The representativeness of 
the review might have been compromised by several factors. Firstly, it comprised studies 
from only 17 out of 49 SSA countries, albeit together they represent 71% of the total 
population in the region, with the majority of the studies being based on convenience 
samples of patients. Secondly, by definition, the large numbers of breast cancer patients 
in the region who never reach a health care facility could not be included. Dickens et 
al.(80) showed that distance to a tertiary care facility was a major determinant of access 
to diagnosis even within a relatively small geographical area (i.e. Soweto in 
Johannesburg, South Africa). As the patients in the review are, by definition, those who 
reach a health facility, predominantly a tertiary centre, they may not be a representative 
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sample of the generality of breast cancer patients in SSA. Thirdly, some participants 
might have contributed to more than one study; to minimize this, whenever papers from 
the same institution and recruitment period were identified we included the paper that had 
the more comprehensive information on stage at diagnosis. Fourthly, six potentially 
eligible papers could not be retrieved; the sample sizes for two of these papers are known 
to be small, and therefore it is unlikely that their exclusion would have significantly 
affected our findings. Finally, the lack of information on staging methods and procedures 
in many studies as well as the lack of standardisation in staging procedures between 
studies, and possibly even within studies, might have obscured some of the findings. 
Staging is affected by neo-adjuvant chemotherapy but this treatment is not available in 
most SSA settings(145); it was mentioned in only two papers in this review(95, 146) 
being unclear whether staging was ascertained before or after its administration. 
Implications 
This review demonstrates that the percentage of late stage breast cancer at diagnosis in 
SSA Black populations around 2010 was higher than it was in US White and US Black 
populations four decades previously. Cancer control strategies in the region should target 
early detection and diagnosis as one essential component of the strategy to improve 
survival from breast cancer. In most settings, 8-12 months symptoms duration shows that 
there is a considerable delay and thus a considerable time window in which to realistically 
achieve this. Population-level interventions for down-staging of breast cancer have been 
shown to be successful in Tanzania(31), similarly to what has been observed in other 
LMICs, e.g. Malaysia(29). Indeed, several SSA studies have shown improved survival 
rates in women diagnosed at earlier stages(47, 88), demonstrating that early-diagnosis 
coupled with timely and appropriate treatment can prevent deaths from this disease.  
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Table 2. Characteristics of the study populations included in the systematic review, by SSA region  
 
First author,  
year of 
publication 
[ref no.] 
 
 
Country 
 
Race 
 
Hospital/clinic, location 
 
Study 
design 
 
Sample 
size 
females 
(males) 
 
No. of 
patients 
with 
known 
stage 
 
Staging 
classification / 
edition (yr) 
Joint TNM 
distribution 
given (Y/N) 
Criteria used to 
define late stage 
 
Staging 
methods 
 
Percent 
stage 
III/IV 
 
Year of 
diagnosis 
 
Mean/
Median 
age at 
diagnos
is  
(males 
where 
given) 
 
Study  
quality 
 score  
As reported 
in the 
original 
publication 
As assigned 
in the 
present 
review a 
   
                
West Africa                
Abudu, 
2007(147) 
Nigeria NR Black Olabisi Onabajo 
University Teaching 
Hospital, Shagamu 
OCS 50 50 Manchester 
(NK) 
N   Manchester Stage 
III and IV 
NR 72 2003-2004 47·5 18·5 
Adebamowo, 
1999(121) 
Nigeria Black Black University College 
Hospital, Ibadan 
CCS 250 250 Manchester 
(NK)  
N  Manchester Stage 
III and IV 
NR 72·8 1992-1995 43 16·5 
Adebamowo, 
2008(148) 
Nigeria NR Black University College 
Hospital, Ibadan 
CCS 192 89 TNM (NK) Y Stage IIIA 
T0 N2 M0 
T1 N2 M0 
T2 N2 M0 
T3 N1 M0 
T3 N2 M0  
Stage IIIB 
T4 N0 M0 
T4 N1 M0 
T4 N2 M0 
Stage IIIC 
Any T N3M0 
Stage IV 
Any T Any N M1 
NR 86·5 2004-2005 48·8 19·5 
Adesunkanmi, 
2006(149) 
Nigeria NR 
 
Black Obafemi Awolowo 
University Teaching 
Hospital, Ife 
CCS 211 (+1) 212 Manchester 
(NK) 
N  Stage III & IV NR 80·6 1996-2003 48 22·5 
Adisa, 
2008(150) 
Nigeria NR Black Obafemi Awolowo 
University Teaching 
Hospital, Ife 
OCS 219 (+6) 225  TNM (NK) N Stages III & IV NR 82·2 1993-2002 48 15·5 
Adisa, 
2012(151) 
Nigeria NR Black Abia State University 
Teaching Hospital, Abia 
CCS 22 22 NR  - Stages III & IV  NR 90·9 2008-2009 47 20·5 
Ajekigbe, 
1991(152) 
Nigeria NR Black Lagos University 
Teaching Hospital, Lagos 
CCS 2154 2154 TNM (NK) N Stages III & IV NR 87·3 1984-1989 50·8%  
<50 yrs 
17·5 
Alatise, 
2010(104) 
Nigeria NR Black Surgery Clinic Obafemi 
Awolowo University 
Teaching Hospital, Ife 
OCS 12 12 TNM (NK) Y Stages III & IV NR 75 NR 50 17·5 
Anyanwu, 
2000(153) 
Nigeria NR Black University of Nigeria 
Teaching Hospital, 
Enugu; Iyi-Enu Hospital, 
Onitsha; Nnamdi Azikiwe 
University Teaching 
CCS 134 (+2) 136 Manchester 
(2008) 
N Stages III & IV  C & I 
(occasiona
l Imaging, 
likely 
64 1987-1997 44·3 25·5 
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First author,  
year of 
publication 
[ref no.] 
 
 
Country 
 
Race 
 
Hospital/clinic, location 
 
Study 
design 
 
Sample 
size 
females 
(males) 
 
No. of 
patients 
with 
known 
stage 
 
Staging 
classification / 
edition (yr) 
Joint TNM 
distribution 
given (Y/N) 
Criteria used to 
define late stage 
 
Staging 
methods 
 
Percent 
stage 
III/IV 
 
Year of 
diagnosis 
 
Mean/
Median 
age at 
diagnos
is  
(males 
where 
given) 
 
Study  
quality 
 score  
As reported 
in the 
original 
publication 
As assigned 
in the 
present 
review a 
   
                
Hospital, Nnewi; Ace 
Specialist Hospital, 
Onitsha  
under-
staged) 
Anyanwu,  
2008(65) 
Nigeria NR Black Nnamdi Azikiwe 
University Teaching 
Hospital, Nnewi; Ace 
Specialist Hospital, 
Onitsha  
CCS 179 179 NR - NR C & I 
(Occasional 
imaging, 
likely 
understaged) 
72 1998-2005 46·9 22·5 
Anyanwu,  
2011(154) 
Nigeria NR Black Nnamdi Azikiwe 
University Teaching 
Hospital, Nnewi; & Ace 
Specialist Hospital, 
Onitsha  
CCS 273 (+2) 196 NR - Stages III & IV  C & I 72 2004-2008 45·2 21·5 
Atoyebi, 
1997(155) 
Nigeria NR Black Lagos University 
Teaching Hospital, Lagos 
CCS 99 (+1) 100 Manchester 
(NK) 
N Stages III & IV NR 77 1992-1995 45·8 19·5 
Ayoade, 
2012(156) 
Nigeria NR Black Olabisi Onabanjo 
University Teaching 
Hospital, Shagamu 
CCS 44 40 TNM Y Stage III & IV 
T3N1M0,T4N1M
x & T4N2M1 
NR 77·5 2005-2006 47 18·5 
Bagnan, 
2013(157) 
Benin NR Black Hopital de la Mere et de 
l'enfant-Lagune Cotonou 
& Clinique Universitaire 
de gynécologie et 
d’obstétrique, Cotonou 
CCS 93 93 NR - Stages III and IV NR 69·9 2000-2008 34·2 15·5 
Chiedozi, 
1985(122) 
Nigeria Black Black University of Benin 
Teaching Hospital, Benin 
CCS 116 116 TNM (1985) N Stages III & IV C 85·3 1974-1979 42·4 20·5 
Chiedozi, 
1987(158) 
Nigeria NR Black University of Benin 
Teaching Hospital, Benin 
CCS 120 120 TNM (1973) N Stages III & IV NR 85 1978-1983 44·8 22·5 
Chiedozi (PLb), 
1988(159) 
Nigeria NR Black University of Benin 
Teaching Hospital, Benin 
CCS 36 36 TNM (1988) N Stages III & IV  C 83·4 1977-1984 28·3 22·5 
Clegg-
Lamptey, 
2007(160) 
Ghana NR Black Korle Bu Teaching 
Hospital, Kumasi 
CCS 156 (+2) 158 TNM (2002) N Stages III & IV C & I 57·6 NR 48·1 21·5 
Clegg-
Lamptey, 
2009(146) 
Ghana NR Black Korle bu Teaching 
Hospital, Accra 
OCS 64 64 NR - Stages III & IV NR 66 2001-2005 51 14·5 
Edmund, 
2013(102) 
Ghana NR Black Dept. Of Pathology, 
University of Ghana 
Medical School, Accra 
CCS 1342 564 TNM (2013) Y Stages III & IV NR  50·9 2005-2009 50·3 16·5 
Etuk, 
2009(161) 
Nigeria NR Black Lagos University 
Teaching Hospital & 
OCS 29 29 NR - Stages III & IV NR 68·9 NR 47·2 16·5 
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First author,  
year of 
publication 
[ref no.] 
 
 
Country 
 
Race 
 
Hospital/clinic, location 
 
Study 
design 
 
Sample 
size 
females 
(males) 
 
No. of 
patients 
with 
known 
stage 
 
Staging 
classification / 
edition (yr) 
Joint TNM 
distribution 
given (Y/N) 
Criteria used to 
define late stage 
 
Staging 
methods 
 
Percent 
stage 
III/IV 
 
Year of 
diagnosis 
 
Mean/
Median 
age at 
diagnos
is  
(males 
where 
given) 
 
Study  
quality 
 score  
As reported 
in the 
original 
publication 
As assigned 
in the 
present 
review a 
   
                
Lagos State University 
Teaching Hospital 
(LASUTH).Lagos 
Ezeome, 
2010(98) 
Nigeria NR Black University of Nigeria 
Teaching Hospital, Enugu 
CCS 162 (+2) 152 NR - Stages III & IV NR 78·3 1999-2005 45·7 20·5 
Fente, 
2011(162) 
Nigeria NR Black Niger Delta University 
Teaching Hospital, 
Okolobiri 
OCS 42 42 TNM & 
Manchester 
(UICC 1960) 
N Stage IV 
(Manchester) 
NR 90·5 2007-2009 40 16·5 
Gukas, 
2008(163) 
Nigeria NR Black Jos University Teaching 
Hospital, Jos 
OCS 34 34 TNM (2008) Y Stages III & IV C 61·8 1999-2001 45 21·5 
Harouna, 
2002(164) 
Niger NR Black General Surgery Unit,  
Issaka Gazoby's Maternity 
Hospital, Niamey 
CCS 146 146 TNM (2002) Y Stages III & IV C & I 74·7 NR 41·1 22·5 
Hassan,  
1992(165) 
Nigeria NR Black Ahmadu Bello University 
Teaching Hospital, Zaria 
CCS 129 129 TNM (1979) Y Stages III & IV C 88 1977-1989 38 21·5 
Hassan (PL), 
1995(114) 
Nigeria NR Black Ahmadu Bello Univeristy 
Teaching Hospital, Shika 
OCS 25 22 TNM (1979) N Stages III & IV NR 100 1977-1989 34 19·5 
Hassan (NPL), 
1995(114) 
Nigeria NR Black Ahmadu Bello University 
Teaching Hospital, Shika 
OCS 70 68 TNM (1979) N Stages III & IV NR 95·5 1977-1989 37 19·5 
Ibrahim, 
2011(166) 
Nigeria NR Black Lagos State University 
Teaching Hospital, Lagos 
CCS 344 (+6) 350 TNM (2002) Y Stages III & IV C & I 82 2006-2009 48·9 25·5 
Ibrahim, 
2012(167) 
Nigeria NR Black Lagos State University 
Teaching Hospital, Lagos 
CCS 201 201 NR - Stages III & IV C 79·1 2009-2010 49·8 22·5 
Ihekwaba, 
1992(123) 
Nigeria Black Black University College 
Hospital, Ibadan 
CCS 1842 1842 TNM (1992) Y Stage III (T2/T3 
N2M0) and Stage 
IV (T2-4N2M1) 
C & I 82·8 1971-1990 48 18·5 
Ikpatt, 
2002(168) 
Nigeria NR Black University of Calabar 
Teaching Hospital, 
Calabar 
OCS 300 300 TNM ( 1997) N Stages III & IV  C & I 53·3 1983-1999 42·7 25·5 
Kene, 2010(87) Nigeria Black Black Ahmadu Bello University 
Teaching Hospital, Shika 
(near Zaria) 
OCS 99 (+4) 103 Manchester N  Stages III & IV NR 62·1 2001-2005 44·5 18·5 
Ketiku, 
1986(169) 
Nigeria NR 
 
Black Lagos State University 
Teaching Hospital, Lagos 
OCS 214 188 NR - Stages III & IV C & I 66·3 1971-1981 45·1 19·5 
Khwaja, 
1980(170) 
Nigeria NR Black Ahmadu Bello University 
Teaching Hospital, Shika 
CCS 73 (+7) 80 NR - Stages III & IV C 82·5 1972-1977 42 19·5 
Lawani, 
1973(171) 
Nigeria NR Black University College 
Hospital, Ibadan 
CCS 169 137 Manchester N Stages III & IV C 74·5 1961-1968 43·5 24·5 
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First author,  
year of 
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Ly, 2012(108) Mali NR Black Hopital du Point G, 
Bamako University 
Hospital, Bamako 
CCS 114 114 TNM (NK)  N T3 & T4 C & I 90 2008-2011 46 23·5 
Mehinto, 
2007(105) 
Benin NR Black Centre National 
Hospitalier et Universite 
Hubert K. Maka  de 
Cotonou, Cotonou 
OCS 111 111 TNM (UICC 
1987) 
Y Stage III 
T3N1M0 
T4N1M1 
T4N2M1 
Stage IV 
T4N1M2 
NR (but 
metastatic 
sites listed) 
70·3 1994-2005 48·5 18·5 
Ntekim, 
2009(96) 
Nigeria NR Black University College 
Hospital, Ibadan 
OCS 221 221 NR - NR NR 85 2003-2006 35·0 c 17·5 
Ohene-
Yeboah, 
2012(140) 
Ghana NR Black Komfo Anokye Teaching 
Hospital, Kumasi 
CCS 325 (+5) 330 TNM (AJCC 
2002) 
Y Stage IIIA 
T2N2M0 
T3N1M0 
T3N2M0 
Total 
Stage IIIB 
T4N1M0 
T4N2M0 
Total 
Stage IIIC 
Any TN3Mx 
Stage VI 
M1 
C  & I (no 
bone scans 
done; 
likely most 
patients 
were 
under-
staged) 
85·2 2004-2009 49·1 24·5 
Oluwole, 
1987(172) 
Nigeria NR Black University of Ife, Ile-Ife CCS 138 (+1) 138 NR - Stages III & IV NR 81·2 1977-1986 42 15·5 
Okobia, 
2001(91) 
Nigeria NR Black University of Benin 
Teaching Hospital, Benin 
OCS 75 (+2) 77 Manchester N Stages III & IV C (mostly 
late stage) 
67·5 1987-1996 43·8 19·5 
Pearson, 
1963(92) 
Nigeria NR Black University College 
Hospital, Ibadan 
CCS 99 (+1) 100 Manchester N Stages III & IV NR 95 1957-1963 44·9 19·5 
Popoola, 
2011(56) 
Nigeria NR Black Lagos State University 
Teaching Hospital, Lagos 
CCS 129 124 TNM (NK) N Stages III & IV NR 65·3 NR 50·5 19·5 
Sarre, 
2006(173) 
Senegal NR 
 
Black Hospital Principal de 
Dakar, Dakar 
OCS 473 449 TNM (NK) Y T4N1M & 
T3N1M0 
NR 73·1 1986-2001 42·5 18·5 
Stark, 2010(37) Ghana NR Black Komfe Anokye Teaching 
Hospital, Kumasi 
OCS 75 75 NR - Stages III & IV C 76 2007-2008 48 17·5 
Togo, 
2010(174) 
Mali NR Black Teaching Hospital of 
Gabriel Toure & Mother 
and Children Hospital 
Luxembourg,  Bamako 
OCS 205 (+5) 210 TNM (NK) Y NR NR (but 
metastatic 
sites listed) 
72·9 1999-2008 47·4 19·5 
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Traore, 
2012(175) 
Guinea NR Black Surgical Oncology Unit, 
Donka University 
Hospital, Conakry 
CCS 178 (+6)  124 NR - Loco-regional 
involvement & 
Metastatic  
C & I 
(skeletal x-
ray, chest 
x-ray, US 
scans) 
93·5 2007-2009 48 16·5 
Ukwenya, 
2008(176) 
Nigeria NR Black Ahmadu Bello University 
Teaching Hospital, 
Kaduna 
CCS 111 111 Manchester 
(NK) 
N Stages III & IV NR 74·7 2003-2005 43·8 20·5 
East Africa 
Amir, 1997(62) Tanzania NR Black Muhimbili Medical 
Centre, Dar Es Salaam  
CCS 50 50 TNM (NK) Y Stage IIIA 
T3N0M0,T1N2M
0, T3N2M0  
Stage IIIB 
T3N3M0 
T4N1MO, 
T4N2MO 
Stage IV 
M1 
C & I 
(rays, 
abdominal 
US, bone 
scans) 
98 
 
1996-1996 90% < 
50years 
25·5 
Bird, 2008(177) Kenya NR Black Africa Inland Church 
Kijabe Hospital, Kijabe 
CCS 125 (+4) 115 NR - NR C & I (No 
bone scans 
performed 
so patients 
might have 
been 
under-
staged) 
62·6 2001-2007 48 21·5 
Burson, 
2010(178) 
Tanzania NR Black Muhimbili National 
Hospital and Ocean Road 
Cancer Institute, Dar es 
Salaam 
OCS 474 (+14) 356 TNM (2002) N Stages III & IV NR 90·7 2007-2009 43·4 16·5 
Ersumo, 
2006(124) 
Ethiopia Black Black Tikur Anbessa Hospital 
Addis Ababa 
OCS 112 (+13) 125 TNM (1992) N Stages III & IV C & I 60·2 1995-1999 42·4 18·5 
Gakwaya, 
2008(89) 
Uganda NR Black Mulago Hospital, 
Kampala 
CCS 285 (+12) 243 TNM (AJCC, 
2002) 
N Stages IIIA, IIIIB, 
IIIC & IV 
NR 77·4 1996-2000 47 18·5 
Galukande, 
2013(179) 
Uganda NR Black Mulago Hospital, 
Kampala;  Makarere 
University Teaching 
Hospital; & Ugandan 
Cancer Institute, Kampala 
CCS 113 109 NR - Stages III & IV  NR 79·8 2011-2012 46·7 20·5 
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Gebremedhin, 
1998(94) 
Ethiopia NR Black Tikur Anbessa Hospital, 
Addis Ababa 
CCS 62 (+10) 72  NR - Stages III & IV NR 76·4 1992-1997 41·8 
(52·1) 
21·5 
Kantelhardt, 
2014(88) 
Ethiopia NR Black Addis Ababa University 
Radiotherapy Center, 
Addis Ababa 
OCS 1070 644 TNM (AJCC 7th 
Edition 2010) 
N Stage III & IV d C & I 
(Chest x-
ray and 
abdominal 
US) 
 
74·7 2005-2010 43 26 
Kenda, 
1988(180) 
Zaire 
(Democratic 
Republic of 
Congo) 
NR Black Kinshasa University 
Hospital, Kinshasa 
CCS 134 134 TNM (NK) N Stages III & IV NR 95·6 1974-1983 47 17·5 
Mabula, 
2012(90) 
Tanzania NR Black Bugando Medical centre, 
Mwanza 
CCS 376 (+8) 384 TNM (AJCC 
2012) 
N Stages III & IV C & I 84·4 2002-2011 45 18·5 
Mbonde, 
2000(181) 
Tanzania NR Black Muhimbili Medical 
Center, Dar Es Salaam 
 
OCS 60 60 TNM (NK) N Stages III & IV NR 93·3 1995-1997 52 22·5 
Mody, 
2013(182) 
Rwanda NR Black Butare University 
Teaching Hospital; Kigali 
University Teaching 
Hospital; Kigali & King 
Faisal Hospital, Kigali 
CCS 141 (+4) 7 TNM (2013) N NR NR 57 2007-2011 48·5 13·5 
Muguti, 
1993(111) 
Zimbabwe Black (B) 
100% 
Black Mpilo Central Hospital, 
Bulawayo  
CCS 82 (+2) 79 TNM (NK) N T3 and T4 tumours  C & I 83·5 1987-1990 50 24·5 
Nyagol, 
2006(183) 
Kenya NR Black Pathology Department 
Nairobi Hospital, Nairobi 
CCS 158 42 TNM (2006) N Stages IIIA, IIIB 
& IV 
NR 69·1 2002-2004 47 20·5 
Ojara, 
1978(125) 
Uganda Black Black Mulago Hospital, 
Kampala 
CCS 152 150 M (1978) N Stage III & IV NR 78 1970-1975 35 21·5 
Pignon, 
1988(126) 
Madagascar Black Black The island's only cancer 
hospital, Antananarivo 
CCS 30 29 TNM (1988) N NR NR 44·8 1977-1986 30·7 e 20·5 
Rafaramino, 
2001(110) 
Madagascar Black Black The island's only cancer 
hospital, Antananarivo 
CCS 259 204 TNM (1998) N T3 & T4 tumours C & I 77·9 1996-1998 48·5 22·5 
Rambau, 
2011(184) 
Tanzania NR Black Bugando Medical centre, 
Mwanza 
OCS 328 328 TNM (AJCC 
2011) 
N Stages III & IV NR 74·7 2002-2010 47·8 18·5 
Tesfamariam, 
2013(185) 
Eritrea NR Black Orotta Medical Surgical 
National Referral 
Hospital, Asmara; Halibet 
Hospital, Asmara & 
Sembel Hospital, Asmara  
OCS 77 (+5) 82 TNM (WHO 
classification of 
tumours 2003) 
N Stages III & IV C & I 
(Imaging 
in 29% of 
patients) 
64 2007-2008 48·4 22·5 
Southern Africa  
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Ariad, 
1991(186) 
South 
Africa 
NR  Non-Black  Johannesburg  Hospital, 
Johannesburg 
OCS 58 58 NR - Stages III & IV  C & I 70·7 NR 45·5 20·5 
Basro, 
2010(95) 
South 
Africa 
NR Non-Black  Tertiary Hospital and 
private breast health 
center in South Africa 
OCS 141 139 TNM (AJCC 
2002) 
N Stage III (locally 
advanced) & Stage 
IV (metastatic 
disease) 
NR 55·3 2000-2008 31 
f 19·5 
Dansey, 
1988(115) 
South 
Africa 
White: 60.5% Non-Black Johannesburg and 
Hilbrow Hospitals, 
Johannesburg 
CCS 1351 1267 TNM (AJCC 
1983) 
N Stage 3: T3 and 
T4 & any N; any T 
& N3;  
Stage 4: any T & 
any N & M1 
C & I 43·6 1976-1985 60 22·5 
Black: 39.5% Black  Johannesburg and 
Hilbrow Hospitals, 
Johannesburg 
CCS 882 863 TNM (AJCC 
1983) 
N Stage 3: 
T3 and T4 & N, 
any T & N3;  
Stage 4: 
any T any N  & MI 
C & I 83·3 1976-1985 50 22·5 
DuToit, 
1988(132) 
South 
Africa 
White: 45% 
Black: 55% 
 
Non-Black   
 
Bloemfontein Academic 
Hospital, Bloemfontein 
CCS 20 20 TNM (AJCC 
1988) 
N Stages III & IV  NR 40 1971-1982 53·6 17·5 
Hacking, 
1984(116) 
South 
Africa 
White: 49%  Non-Black  Groote Schuur Hospital, 
Cape Town 
OCS 1085 1078 g TNM (1978) & 
Manchester  
Y T3-4, N0-3,M0 & 
T1-4,N0-3, M1 
NR 40·2 1971-1981 60 17·5 
Coloured: 
48% 
 Non-Black  Groote Schuur Hospital, 
Cape Town 
OCS 1063 1063 g TNM (1978) & 
Manchester  
Y T3-4, N0-3,M0 & 
T1-4,N0-3, M1 
NR 59·9 1971-1981 53 17·5 
Black: 3%  Black  Groote Schuur Hospital, 
Cape Town 
OCS 66 66 g TNM (1978) & 
Manchester  
Y T3-4, N0-3,M0 & 
T1-4,N0-3, M1 
NR 74·2 1971-1981 49 17·5 
Hoffman, 
2000(130) 
South 
Africa 
Black: 15%; 
Coloured: 
85% 
Non-Black 
 
2 Tertiary Hospitals in 
Cape Town 
PB 485 478 TNM (1992) N Stages III & IV 
(advanced breast 
cancer) 
NR 42·2 1994-1997 59% < 
45 years 
19·5 
McCormack, 
2013(30) 
South 
Africa 
Black: 
90.3%;  
White: 4.1%, 
Coloured: 
3.8% & 
Asian: 1.8% 
Black  
 
Chris Hani Baragwanath 
Academic 
Hospital (CHBAH) h 
CCS 1216 1192 TNM & 
Manchester 
N Stages III & IV C & I 54 2006-2012 55·3 25·5 
Odendaal, 
2003(187) 
South 
Africa 
NR Non-Black  NR OCS 236 201 TNM (1988) Y Stage III & T4b 
N0-1 lesions only  
C & I 53·2 i 1990-1996 79 
j 25·5 
Ostyn, 
1987(131) 
South 
Africa 
Mostly 
Coloured or 
Indian 
Non-Black  Coronation Hospital, 
Johannesburg 
OCS 156 120 TNM (1979) N Stages III & IV NR 51·7 1974-1984 52·1 16·5 
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Pegoraro, 
1980(109) 
South 
Africa 
Whites: 23%, 
Indians: 35% 
Blacks:  42% 
Non-Black NR OCS 167 (+4) 110 TNM (1980) N T3 & T4  NR 77·2 NR 50% were 
between 
45-64 
years 
14·5 
Pegoraro, 
1985(117) 
South 
Africa 
White: 31% Non-Black University of Natal 
Teaching Hospital & all 
major hospitals, Durban 
OCS 197 91 TNM (AJCC 
1983) 
N Stages III & IV NR 41 1975-1983 60 19·5 
Indian:  26% Non-Black University of Natal 
Teaching Hospital & all 
major hospitals, Durban 
OCS 168 151 TNM (AJCC 
1983) 
N Stages III & IV NR 54 1975-1983 46·6 19·5 
Coloured: 4% Non-Black  University of Natal 
Teaching Hospital & all 
major hospitals, Durban 
OCS 23 22 TNM (AJCC 
1983) 
N Stages III & IV NR 77 1975-1983 52·8 19·5 
  Black: 39% Black  University of Natal 
Teaching Hospital & all 
major hospitals, Durban 
OCS 252 240 TNM (AJCC 
1983) 
N Stages III & IV NR 90 1975-1983 49·8 19·5 
Walker, 
1984(118) 
South 
Africa 
Black: 100% Black  Baragwanath Hospital, 
Johannesburg 
CCS 96 84 NR - NR NR 77·5 1980-1982 51·7 17·5 
Walker, 
1989(120) 
South 
Africa 
Black 100% Black Baragwanath Hospital, 
Johannesburg 
CCS 65 59 NR - Stages III & IV NR 67 1986-1987 52·5  
Walker, 
2004(119) 
South 
Africa 
Black: 100% Black King Edward the VIII 
Hospital, Durban 
CCS 57 57 NR - Stages III & IV NR 84·2 1999-1999 54·1 12·5 
Wasserman, 
2007(127) 
South 
Africa 
NR Non-Black Tygerberg Hospital, 
Tygerberg 
OCS 483 421 j TNM (6th 
edition) 
Y Stages III & IV NR (14) 
54·8 k 
1990-2004 77·3 l 20·5 
 
 
 
 
 
 
Winters, 
1988(93) 
 
 
 
South 
Africa 
 
White: 96% 
 
Non-Black 
 
NR m 
 
OCS 
 
2346 
 
2324 
 
NR 
 
- 
 
NR 
 
NR 
 
30 
 
NR 
 
58 
 
19·5 
Black: 4% Black  Baragwanath Hospital, 
Johannesburg  
OCS 94 77 NR - NR NR 90 1980-1986 51 20·5 
                
C: Clinical methods; CCS: Consecutive case series; I: Imaging methods; M: Manchester staging classification; NPL: Non-pregnant/non-lactating women; NR: Not reported in the original publication; OCS: Opportunistic 
(convenience) case series; PBS: Population-based study; PL: Pregnant/lactating women; TNM: Tumour Node Metastases. 
a As defined in Table 1. 
b This study included a group of PL and a group of NPL, but the latter was not included in the review because NPL women were matched the PL women on stage at diagnosis.   
c This study included women aged ≤40 years only.    
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d Information in supplementary material used to calculate number in Stage IV. 
e This study included women aged ≤35 years only. 
f This study included women aged ≤35 years only. 
g Numbers of women by stage and race were not given; hence, approximate numbers were inferred from the data shown in table 1 and  figure 1 of the original publication.  
h Chris Hani Baragwanath Academic Hospital Johannesburg was previously the Baragwanath Hospital Johannesburg. 
i The authors included stages I to III and early stage IV cancers in their study but provided stage information on the patients excluded and we included these in the calculation of % late stage in our review. 
j This was a study of elderly breast cancer patients aged ≥70 years with T1-T3 and small localised T4N0-1 tumours. 
k The authors gave stage distribution for the included patients (n=188) with % stage III as 14% in table 5 of the paper, however, the stage of distribution of excluded patients (n=233) was also given in the text, so a total of 421 
patients were used to derive % III/IV (54.8%). 
l This study included women aged ≥70 years only.  
m The authors stated that their series of Black patients was compared with a similar unpublished study of White women but did not provide details on how the latter were recruited. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
87 
 
 
 
Table 3. Sources of between-population heterogeneity in the percentage of late stage breast cancer (stages III/IV) of breast cancer from meta-regression analyses 
 No. 
BC 
cases 
All study populations (Black & non-Black)  Black populations only 
 
 Unadjusted analysis Region & race adjusted 
analysis 
Fully-adjusted analysis a Unadjusted Analysis Fully-adjusted analysis b 
Variable   Absolute 
difference 
(%) 
 
95% CI 
Absolute 
difference 
(%) 
 
95% CI 
Absolute 
difference 
(%) 
 
95% CI 
Absolute 
difference 
(%) 
 
95% CI 
Absolute 
difference 
(%) 
 
95% CI 
Region/Race c 
West Africa/Black  
East Africa/Black 
Southern Africa / Black  
Southern Africa / Non-
Black  
 
10845 
3186 
2638 
7544 
 
0 (ref) 
-0·2 
0·1 
-25·5 
 
 
(-6·8, 6·4) 
(-9·0, 9·3) 
(-32·6, -18·3) 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
0 (ref) 
-3·0 
8·6 
-18·1 
 
 
 
(-9·2, 3·2) 
(-2·0, 19·1) 
(-28·2, -8·0) 
 
0 (ref) 
-0·2 
0·1 
- 
 
- 
(-6·6, 6·3) 
(-8·9, 9·1) 
- 
 
0 (ref) 
-3·3 
5·8 
- 
 
 
(-9·5, 2·9) 
(-5·9, 17·5) 
- 
Study Design 
Consecutive case series 
Convenience case series 
 
 
14425 
9788 
 
0 (ref) 
-6·5 
 
 
- 
( -12·9, -0·4) 
 
 
0 (ref) 
-0·6 
 
 
- 
(-6·1, 4·9) 
 
 
0 (ref) 
-2·0 
 
- 
(-7·1,  3·1) 
 
 
0 (ref) 
-2·2 
 
- 
(-7·9, 3·6) 
 
0 (ref) 
-2·6 
 
- 
(-8·0, 2·8) 
Study Setting 
Urban 
Mixed (urban/rural) 
 
14208 
10005 
 
0 (ref) 
16·3 
 
- 
(10·6,  22·0) 
 
0 (ref) 
10·7 
 
- 
(3·4, 17·9) 
 
0 (ref) 
12·9 
 
- 
(5·5, 20·3) 
 
0 (ref) 
7·7 
 
- 
(1·7, 13·7) 
 
0 (ref) 
13·2 
 
- 
(5·7, 20·7) 
 
Facility Type  
Tertiary 
Tertiary/Secondary/Prima
ry 
NR 
 
 
22399 
1503 
311 
 
 
0 (ref) 
-3·7 
-8·8 
 
- 
(-13·2,  5·8) 
(-30·5, 12·9) 
 
0 (ref) 
-1·2 
14·8 
 
- 
(-8·8, 6·4) 
(-3·4, 32·9) 
 
0 (ref) 
-1·9 
10·1 
 
- 
(-9·1, 5·4) 
(-0·8, 28·3) 
 
 
0 (ref) 
-3·2 
- 
 
- 
(-11·5, 5·1) 
- 
 
0 (ref) 
-1·4 
- 
 
- 
(-9·5, 6·6) 
- 
Age at Diagnosis (yrs) d 
    <45 
    ≥ 45 to <50 
    ≥ 50 
 NR 
 
4840 
7218 
9841 
2314 
 
0 (ref) 
0·8 
-13·2 
12·0 
 
- 
(-6·0, 7·8) 
(-21·2, -5·3) 
(-4·4, 28·5) 
 
 
0 (ref) 
0·3 
-6·2 
17·4 
 
- 
(-5·5, 6·0) 
(-14·4, 2·0) 
(3·8, 31·1) 
 
0 (ref) 
3·9 
-1·7 
20·6 
 
- 
(-2·0, 9·9) 
(-9·9, 6·4) 
(6·4, 34·8) 
 
0 (ref) 
-0·3 
-3·9 
14·6 
 
- 
(-6·2, 5·6) 
(-12·0, 4·1) 
(-1·3, 30·6) 
 
0 (ref) 
3·9 
1·8 
20·4 
 
- 
(-2·3, 10·1) 
(-8·9, 12·4) 
(4·8, 36·1) 
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Year of Diagnosis e 
<1980 
1980-1999 
≥2000  
NR 
 
3782 
10737 
6733 
2961 
 
0 (ref) 
4·8 
4·3 
-6·5 
 
- 
(-4·3, 13·9) 
(-5·0, 13·5) 
(-19·9, 6·9) 
 
0 (ref) 
-3·0 
-6·2 
-7·3 
 
 
(-10·6, 4·6) 
(-14·2, 1·8) 
(-18·2, 3·6) 
 
0 (ref) 
-5·2 
-8·5 
-8·5 
 
 
(-12·6, 2·2) 
(-16·1, -1·0) 
(-19·0, 2·1) 
 
0 (ref) 
-4.7 
-8.4 
-16.5 
 
 
(-13·1, 3·7) 
(-16·8, -0·1) 
(-29·7, -3·3) 
 
0 (ref) 
-6·8 
-10·5 
-12·5 
 
 
(-15·5, 1·9) 
(-19·3, -1·6) 
(-26·9, 1·8) 
Staging Methods  
Clinical & Imaging 
Clinical only 
NR 
 
9516 
967 
13730 
 
0 (ref) 
5·0 
0·2 
 
- 
(-6·4, 16·4) 
(-7·1, 7·4) 
 
0 (ref) 
2·3 
3·0 
 
 
(-7·0, 11·6) 
(-2·7, 8·8) 
 
0 (ref) 
-1·4 
3·2 
 
 
(-10·4, 7·6) 
(-2·3, 8·7) 
 
0 (ref) 
3·0 
4·0 
 
 
(-5·9, 11·9) 
(-1·9, 10·0) 
 
0 (ref) 
-1·3 
4·1 
 
 
(-10·3, 7·8) 
(-1·7, 9·8) 
Staging classification 
TNM  
Manchester 
NR 
 
18048 
1426 
4739 
 
0 (ref) 
2·4 
3·1 
 
- 
(-7·6, 12·5) 
(-4·5, 10·7) 
 
0 (ref) 
-3·7 
-0·8 
 
- 
(-12·1, 4·6) 
(-7·0, 5·5) 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
 
- 
- 
- 
 
 
- 
 
Study quality scores f 
≥23 (highest quality) 
22-20 
19-17 
<17 (lowest quality) 
 
3569 
5721 
13327 
1596 
 
 
0 (ref) 
-2·1 
-1·1 
0·7 
 
- 
(-12·7, 8·5) 
(-11·2, 9·0) 
(-11·5, 12·9) 
 
0 (ref) 
-0·1 
2·1 
2·9 
 
- 
(-8·5, 8·3) 
(-5·9, 10·1) 
(-6·9, 12·6) 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
 
 
- 
- 
- 
BC: breast cancer; CI: confidence interval; NR: not reported in the original publication; ref: reference category; TNM: Tumour, lymph Node and Metastasis staging system 
a Adjusted for all other variables in the Table except for staging classification and study quality because of concerns of over-adjustment. 
b Adjusted for all other variables in the Table except region/race, staging classification and study quality 
c The study population was classified as Black if  >80% of the participants were Black (see webappendix-Table 1 and Figure 3b). 
d Mean or median age at breast cancer diagnosis (see footnote g of Table 1 for details). 
e Taken as the middle year of the period during which patient recruitment took place. 
f Categories defined using fourths of the overall score distribution. Analyses were not further adjusted for the other variables in the table because most of them were integrated into the study quality scores (see webappendix-
Text 4).   
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Table 4: Late stage (III/IV) breast cancer at diagnosis, self-reported duration of symptoms, and 
tumour characteristics (size, grade, ER positivity and histology), by study population in SSA a, b 
 
 
First author, year 
(race) c 
 
% Late 
stage  
(III/IV) at 
diagnosis 
 
Mean/median 
duration of 
symptoms 
(months)  
 
Mean/median 
tumour size 
(cm) 
 
%  
ER-
positive 
tumours  
 
%  
grade 3 
tumours 
 
Histology 
(% 
ductal 
NST) 
 
West Africa 
      
Abudu, 2007 (B) 72 - - - 62 92 
Adebamowo, 2008 
(B) 
86·5 - - 65·1 15·6 82·3 
Adesunkanmi, 2006 
(B) 
80·6 11·2 - - - 90 
Adisa, 2012 (B) 90·9 - - 24 100 53 d 
Alatise, 2010 (B) 75·0 - 8·5 - 91·7 100 
Anyanwu, 2000 (B) 64·0 4·5 - - - 73 
Anyanwu, 2008 (B) 72·0 3·5 - - - 80 
Anyanwu, 2011 (B) 72·0 52% >6 months - - - 85·5 
Atoyebi, 1997 (B) 77·0 13·3 - - - 94 
Ayoade, 2012 (B) 77·5 6·7 - - - - 
Bagnan, 2013 (B) 69·9 - - - - 33·3 e 
Chiedozi, 1985 (B) 85·3 - - - 50 19 f 
Chiedozi, 1987 (B) 85.0 - - - 50 - 
Chiedozi, 1988 (B, 
PL) 
83·4 6 - - 55·6 - 
Clegg-Lamptey, 
2007 (B) 
57·6 10 7 - - 85·8 
Edmund, 2013 (B) 50·9 7·5 4·5 - 28·9 91·6 
Ezeome, 2010 (B) 78·3 2 - - - - 
Fente, 2011 (B) 90·5 - - - - 54·7 g 
Gukas, 2008 (B) 61·8 - - 26·5 70·6 97 
Harouna, 2002 (B) 74·7 8·8 - - - - 
Hassan, 1992 (B) 88·0 9·3 10 - - 85 
Hassan, 1995 (B, 
PL) 
100 10 8 - - 72 
Hassan, 1995 (B, 
NPL)  
95·5 9 8 - - 70·5 
Ibrahim, 2011 (B) 82·0 10·8 - - - 93 
Ibrahim, 2012 (B) 79·1 12·1 - - - - 
Ihekwaba, 1992 (B) 82·8 10·9 6·5 - - 49·2 h 
Ikpatt, 2002 (B) 53·3 - 4·8 - 45·7  84 
Kene, 2010 (B) 62·1 -    82·5 
Ketiku, 1986 (B) 66·3 - - - - 33·6 i 
Khwaja, 1980 (B) 92·5 11 - - 90·9 82·5 
Lawani, 1973 (B) 74·5 9 - - 31 53·8 j 
Ly, 2012 (B) 90·0 - 90% >5 39 78 94 
Mehinto, 2007 (B) 70·3 k - - - 38·9 86·4 
Ntekim, 2009 (B) 85 - - - - 95 
Ohene-Yeboah, 
2012 (B) 
85·2 13·8  - 47·1 53·7 82·1 
Okobia, 2001 (B) 67·5 9 - - - 66·8 
Oluwole, 1987 (B) 81·2 - - - - 30·2 l 
Pearson, 1963 (B) 95·0 6 9·7 - 80 - 
Sarre, 2006 (B) 73·1 9 - - 45·6 89·9 
Stark, 2010 (B) 76·0 - 3·2 24 76 66·7 
Togo, 2010 (B) 72·9 17·8 - 58·1 - 57·4 m 
Traore, 2012 (B) 93·5 - - 30·7 - 73·8 
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- Information not provided in the original publication; B: Black women; I: Indian women; NST: invasive intra-ductal carcinoma; NB: 
Non-Black women; NPL: Non-pregnant and non-lactating women; PL: Non-pregnant and non-lactating women; SSA: sub-Saharan 
Africa; W: White women 
a Some studies have more than one study population (i.e. PL and NPL women; multiple racial groups) – see Table 1 (footnote a). 
b Restricted to study populations with information on stage at presentation and at least one of the other variables shown in this Table.  
c Reference numbers as in webappendix-Table 1. Race as defined in Table 1 (footnote b) and webappendix-Table 1. 
d The authors reported that 53% of the tumours were invasive ductal carcinoma, not otherwise specified (NST), 18% invasive lobular 
carcinoma (ILC), 18% a mix of NST and ILC, and 12% other subtypes.   
e Other histological subtypes not reported.  
f Other histological subtypes included anaplastic carcinoma (50%), scirrhous carcinoma (28.4%), Paget’s disease (1.7%), and mucoid 
carcinoma (0.9%). 
Ukwenya, 2008 (B) 74·7 9 - - - - 
 
East Africa  
      
Amir, 1997 (B) 98 - - - - 100 
Bird, 2008 (B) 62·6 12 6·8 24 50 90 
Burson, 2010 (B) 90·7 17·2 69·1% >5 50·8 - 85·5 
Ersumo, 2006 (B) 60·2 11·5 60% >5 - - 77·6 
Gakwaya, 2008 (B) 77·4 - - - 58 76 
Galukande, 2013 
(B) 
79·8 - - 47 65·2 93·8 
Gebremedhin, 1998 
(B) 
76·4 12 6·5 - - 85·2 
Kantelhardt, 2014 
(B) 
71 - 5 - 24·8 79·2 
Kenda, 1988 (B) 95·6 - - -      26·5 68·9 
Mabula, 2012 (B) 84·4 11·4 6 - 63·8 91·7 
Mbonde, 2000 (B) 93·3 11 8 33·3 46·6 78·3 
Mody, 2013 (B) 57 11·2 - - - - 
Muguti, 1993 (B) 83·5 7 8 - - - 
Nyagol, 2006 (B) 69·1 - 4·5 37·3 66 92·4 
Pignon, 1988 (B) 44·8 14·1 - - 60 0 n 
Rafaramino, 2001 
(B) 
77·9 9·4 - - 56·5 55·6 o 
Rambau 2011 (B) 74·7 - 5·5 - 56·4 91·5 
Tesfamariam, 2013 
(B) 
64 34·8 - - - 82 
 
South Africa  
 
Ariad, 1991 (NB) 70·7 - - 40·7 - 84·5 
Basro, 2010 (NB) 55·3 - 79%  >2 67·8 46·7 92·9 
Du Toit, 1988 (NB) 40 - - - -  85 p 
McCormack, 2013 
(B) 
54 - - 64·9 42·3 80 
Odendaal, 2003 
(NB) 
53·2 - 4 - 11·2 73 
Ostyn, 1987 (NB) 51·7 - - - - 67 
Pegoraro, 1980 
(NB) 
77·2 - 7·5 52·7 - - 
Pegoraro, 1985 (B) 90 - 7·5 - 71 - 
Pegoraro, 1985 
(NB, I) 
54 - 5 - 72 - 
Pegoraro, 1985 
(NB, W) 
41 - 3·5 - 47 - 
Winters, 1988 (B) 90 - - 55 27 90 
Winters, 1988 (NB, 
W) 
30 - - 65 - - 
 
No. of study populations with available information a 
All (Black & non-
Black) 
73 b 36 27 19 36 58 
Black only 64 36 22 15 32 53 
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g Other histological subtypes comprised undifferentiated (19.1%), lobular carcinoma (12%), papillary (7.4%), others (6.9%). 
h Other histological types included infiltrating anaplastic carcinoma (33.3%), medullary carcinoma (5.9%), lobular carcinoma (2.8%), 
papillary carcinoma (2.3%),  mucinous carcinoma (1.5%), others (5%). 
i Other histological subtypes comprised anaplastic carcinoma (22.9%), scirrhous carcinoma (8.9%), adenocarcinoma (7.5%), 
medullary carcinoma (4.2%), mixed carcinoma (3.7%),  colloid carcinoma (2.8%), comedo carcinoma (2.8%) and other subtypes 
(13.6%). 
j The most common subtypes reported were adenocarcinoma 33.7%, and other subtypes 12.5% 
k The authors used the UICC 1987 TNM classification (33rd Edition). Stage reclassified using the AJCC TNM classification 7th Edition  
l Other histological subtypes were poorly differentiated adenocarcinoma (33.8%), anaplastic carcinoma (9.4%), inflammatory 
carcinoma (7.9%), and others (18.7%). 
m Other histological subtypes comprised infiltrating lobular carcinoma (21.4%), medullary carcinoma (3.3%), and others (17.9%) 
n Most common subtypes were adenocarcinoma not otherwise specified (31.3%), intraductal carcinoma (6.3%), atypical carcinoma 
(28.1%), and others (34.4%). 
o Other histological subtypes included adenocarcinoma (31.7%), mucinous carcinoma (3.5%), infiltrating lobular carcinoma 
(2.3%),and  others (6.9%). 
p All patients in this study had Paget’s disease of the breast; histologically, they were all ductal carcinomas but three were intra-ductal. 
  
  
 
92 
  
CHAPTER 3 
 
Study protocol and data collection methods  
This chapter describes the study designed and implemented in order to investigate 
objectives 3 (i) and (ii) of this PhD thesis, which were to identify the sociodemographic, 
breast cancer awareness, health care access and clinical determinants of (i) stage at 
diagnosis of breast cancer; and (ii) a woman’s journey from the first reported symptom 
to the diagnosis of breast cancer, and of any delays, in Nigerian women with breast 
cancer. The study protocol will be described (study design, setting, sample size 
determination, case definition and study sites for the Nigerian Integrative Epidemiology 
of Breast Cancer Study, i.e. the parent study within the framework of which my PhD 
study was conducted) and subsequently the study coordination, recruitment process and 
challenges will be discussed, including methods used in data collection, entry and 
analysis. An overview of the methods is later provided in subsequent chapters 4 and 5. 
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3.1. STUDY PROTOCOL 
3.1.1. Study Design 
This PhD research study was conducted within a larger multi-centre case-control study 
exploring the breast cancer associations with dietary, genetic and epigenetic factors – The 
Nigerian Integrative Epidemiology of Breast Cancer Study referred to as the ‘NIBBLE 
study.’ Its case-control design is supported by the fact that breast cancer is a relatively 
rare disease among Nigerian women with an ASR of 54.3 per 100,000 women (3), for 
which a case-control study is considered efficient. All eligible women (see section 3.1.3, 
box 1) who presented breast symptoms suggestive of breast cancer during the study period 
(January 2014-July 2016) were approached and invited to participate.  
This design was chosen in order to achieve the aim of identifying the determinants of 
stage at diagnosis of breast cancer and diagnostic delays in Nigerian women with breast 
cancer. 
3.1.2. Study Setting 
The NIBBLE study was conducted in six government hospitals in Nigeria (five hospitals 
in the capital, Abuja, and one hospital in Enugu, located about 400 km from Abuja). 
Nigeria is Africa’s most populous country, with a population of approximately 182.2 
million people in 2015(188). The country is home to 50% of the West African population 
and represents 20% of the entire population on the African continent. It is Africa’s most 
diverse economy with a Gross Domestic Product of $481.1 billion(188) a total health 
expenditure of 3.7%(8).  It is located in the Gulf of Guinea and shares boundaries with 
the Republics of Cameroun, Benin, Chad and Niger. The average life expectancy at birth 
in females is 56 years, having increased by five years over the last decade(8). The country 
is divided into six geopolitical zones for ease of administration. However, an easier 
identification is provided by the country’s North and South distinction with large 
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variations in the socio-economic indicators across Northern and Southern Nigeria (189, 
190). The majority of the study sites were located in Abuja, the capital city of Nigeria, 
which has a predominantly younger and working-class population compared with 
Enugu(191). In Abuja, only 10.7% of the female population is aged > 40 years compared 
to 20.5% in Enugu (Table 1). 
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Figure 1: (a) Map of Nigeria showing the study locations (b) Map of Abuja showing 5 study sites in Abuja 
 
FIVE ABUJA 
SITES (North-
Central Nigeria) 
 NHA 
 UATH 
 ADH 
 GH 
 WGH 
 
ONE ENUGU SITE 
(South-Eastern Nigeria) 
 UNTH 
Four sites 
located in 
Abuja AMAC 
Phase 1. 
NHA 
ADH 
GH 
WGH 
 
UATH 
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Table 1: Differences between the city profiles of Abuja and Enugu State (191) 
 
Description  Abuja  Enugu  
Location North-central  South-eastern 
Predominant Religion Mixed: Islam and 
Christianity 
Christianity 
Type of City  Urban  Predominantly rural 
Predominant Ethnic 
Groups  
Indigenous inhabitants are 
Gwari, but due to the large 
influx of people from all 
over the country, a wide 
range of ethnic groups can be 
found in Abuja. 
Igbos 
Predominant Occupation  Government employees in 
public ministries, working 
class population 
Trading, farming  
Total Population  1,406,239 3,257,298 
Total Female Population    673,067 1,671,795 
Total Female Population > 
40 years  
   72,081   343,322 
 
3.1.3. Case Definition 
All newly diagnosed cases of breast cancer during the study period (January 2014-June 
2016) in each of the six participating hospitals, and with no previous history of cancer, 
were considered eligible to be recruited into the study. All participating hospitals 
routinely perform breast tissue biopsies for all new cases. However, in advanced cases 
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where a histological confirmation was not possible, these women were also included in 
the study. 
Inclusion Criteria: 
1. All newly diagnosed cases of breast cancer seen at any of the participating 
hospitals during the period of study (i.e. January 2014- June 2016) 
2. No previous diagnosis of any cancer 
3. Women aged 18 years and above 
4. Must provide written informed consent  
 
  Box 1. Eligibility criteria for study participants 
Pregnant women were not excluded as this study did not interfere with the standard care 
provided by these hospitals. 
3.1.4. Study Sites 
This was a multi-centre study conducted at 6 government hospitals in Nigeria that offer 
diagnostic services, care, and treatment for breast cancer patients. These six centres were 
selected partly due to logistic reasons (e.g. five in the capital city of Abuja) and partly to 
represent different types of hospitals, including tertiary and secondary centres with 
differences in the availability of diagnostic and treatment facilities, and catchment 
populations: one centre in Southern Nigeria, four within the capital city and one on the 
outskirts of Abuja catering to a less urbanised population (e.g. with varying levels of 
urbanisation). A description of each of the study sites and the services offered is provided 
below:  
University of Nigeria Teaching Hospital Enugu (UNTH) 
The UNTH is a large tertiary hospital located in south-eastern Nigeria and a major referral 
centre for breast cancer patients from south-eastern Nigeria. The hospital was founded in 
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1966 and has a capacity of 500 beds and 29 specialist surgeons. The UNTH provides 
chemotherapy and surgery services and has a dedicated oncology department. The 
hospital has a radiotherapy machine which is currently non-functional. The UNTH 
predominantly caters to the urban city of Enugu and the poorer surrounding cities with 
predominantly rural populations, but receives breast cancer patients who are referred from 
smaller institutions across the southern part of Nigeria (Figure 2).  
 
Figure 2: The University of Nigeria, Nsukka (UNTH, Enugu) the only study site outside Abuja 
located 400 km from Abuja, Nigeria  
 
 
National Hospital Abuja (NHA) 
The NHA is a renowned tertiary hospital and referral centre located in Abuja, the capital 
city of Nigeria. This 200-bedded hospital was founded in 1999, initially as a hospital for 
women and children only, but extended its services to the entire population in 2003. The 
hospital has recently undergone expansion to a current capacity size of 407 beds. The 
NHA is one of the best equipped tertiary health care centres in Nigeria, with facilities for 
diagnostic and therapeutic services for breast cancer including magnetic resonance 
imaging (MRI), computerised tomography scans, and radiotherapy/oncology and nuclear 
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medicine departments. Its radiotherapy department is equipped with a linear accelerator, 
SLI Philips simulator and brachytherapy machines. The hospital provides surgery, 
chemo-therapy and radiotherapy services to patients referred from various facilities all 
over the country (Figure 3).  
Figure 3: The National Hospital Abuja, a tertiary hospital located in Abuja, Nigeria 
 
 
University of Abuja Teaching Hospital Gwagwalada (UATH) 
The UATH is a teaching hospital currently affiliated with the University of Abuja, located 
in Gwagwalada, approximately 60 km from the Abuja city centre (Figure 4). This tertiary 
health care facility has a training programme for medical students and resident doctors 
and is equipped with 350 beds. It primarily caters to the rural populations on the outskirts 
of the capital city and provides chemotherapy, surgery, and palliative care services for 
breast cancer patients. For radiotherapy, patients are referred to the National Hospital 
Abuja.  
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Figure 4: The University of Abuja Teaching Hospital, Gwagwalada located on the outskirts of 
Abuja city. 
 
 
Asokoro District Hospital (ADH) 
This is a general hospital located in the capital city of Abuja. This secondary level facility 
has 149 beds and is located within close proximity of the National Hospital Abuja. The 
hospital caters to both urban and rural populations from the surrounding suburbs near the 
city of Abuja. The hospital provides surgery services only and patients are often referred 
to the National Hospital Abuja for chemotherapy and radiotherapy (Figure 5). 
 
 
 
 
 
 
  
 
101 
  
Figure 5: Asokoro District Hospital, one of the secondary centres located in Abuja, Nigeria 
 
 
Garki Hospital (GH) 
This secondary level facility is located in Abuja, and caters mainly to the people of Abuja 
and its surrounding suburbs. The GH also receives referrals from general hospitals located 
in the poorer surrounding states such as the states of Niger, Nassarawa and Kaduna. The 
GH became a public–private partnership (PPP) between the Federal Government and a 
private hospital, the Nisa Premier Hospital in 2007 in a bid to upgrade the facility and the 
types of medical services provided. The hospital has 127 beds and is only equipped with 
surgery facilities (Figure 6). Patients are referred to the oncology unit of the National 
Hospital Abuja or to private centres in the state of Lagos for post-surgical treatment and 
management. 
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Figure 6: Garki Hospital, a secondary level facility located in Abuja, Nigeria 
 
 
Wuse General Hospital (WGH) 
This is a secondary level health facility located in the Phase 1 district of Abuja and the 
smallest of all the sites included in this study. The hospital is equipped with 110 beds and 
has a surgery department that manages breast cancer patients. Patients consulted at the 
WGH following surgery are subsequently referred to the National Hospital Abuja for 
further management. 
3.2. COORDINATION OF THE STUDY 
I took part in each phase of this study from conception to the planning and subsequent 
field execution in Nigeria (Figure 7). This work included the request for ethical approval 
from all study sites, the design of study materials including two questionnaires, a clinical 
report form and a laboratory form for breast tissue sample monitoring. This study was 
overseen by my supervisor, co-supervisor and a member of my Advisory Committee to 
whom I provided regular progress reports on the recruitment and operational challenges 
encountered in the field. I worked with 8 field staff members, including one research 
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interviewer at each of the six participating sites, a data manager for the parent study and 
one laboratory assistant who received samples in the laboratory, recorded all the samples 
received and stored them for analysis purposes. Initial fortnightly meetings, which later 
became monthly meetings after six months when the field staff members had become 
conversant with the project, were held with the field staff to monitor recruitment rates and 
address logistic challenges. Prior to the commencement of the study, a 2-day training 
exercise was held with the field staff where they were introduced to the study aims and 
objectives, use of study materials including nexus tablets for data collection and data entry 
into the database specifically developed for the study (Figures 8 & 9). Other aspects of 
the training addressed the topics of research methodology, research ethics and 
confidentiality. Following the training of the field staff, an initial meeting was held with 
the site collaborators (surgeons) by the principal investigator of the parent study and 
myself to discuss the aims of the study, the recruitment expectations and the publication 
authorship. After this initial meeting, two weekly visits were made to the study sites for 
the first six months to assess the interview process undertaken by the field staff with the 
purpose of addressing individual site logistic peculiarities and challenges (Figures 10, 11, 
12 & 13). Weekly recruitment updates were provided to my supervisors, any existing 
challenges were discussed and the methods seeking to address them were formulated and 
implemented. As per the LSHTM requirements applicable in the case of PhD research 
conducted overseas, my PhD supervisors, Prof. Isabel dos Santos Silva and Dr. Valerie 
McCormack also visited Nigeria in October 2014 in order to monitor the progress being 
made during the fieldwork in Nigeria and to offer advice in relation to the challenges 
encountered and how these could be overcome (Figure 11). 
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Figure 7: Study planning and implementation 
 
 
Figure 8: NIBBLE study initiation training workshop for research assistants (October 2013, 
Abuja, Nigeria) 
 
 
Project 
Planning
•Literature Review 
•Questionnaire development 
•Questionnaire piloting and testing
•Training of field staff
•Meeting with site collaborators/surgeons and visits to study sites to assess 
suitability 
Ethical 
considerations 
•Ethical approval  applications to the LSHTM Ethics Committee, Nigerian 
National Health Research Ethics Committee (NHREC), Health Research Ethics 
Committees (HRECS) of six participating hospitals  and the Institute of Human 
Virology, University of Maryland Baltimore (principal investigator of parent 
study's host institution) 
Study 
Implementation
•Study initiation at the participating hospitals
•Fortnightly team meetings with field staff
•Weekly and monthly progress reports to supervisors and principal investigator of 
the parent study, respectively
•Fortnightly Skype meetings with supervisors to discuss operational challenges 
•Data collection, entry and analysis
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Figure 9: NIBBLE study initiation training workshop on how to take anthropometric 
measurements (October 2013, Abuja, Nigeria) 
 
 
 
 
Figure 10: During a site visit to the UNTH Enugu site, observing Mr. Kenneth Oruka (research 
assistant), recruit a participant with breast symptoms into the study at the UNTH Enugu study site 
in June 2014 
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Figure 11: Visit to the Surgical Outpatients Department (SOPD) of the Asokoro District Hospital 
with Prof. Isabel dos Santos Silva and Dr. Valerie McCormack 
 
 
 
Figure 12: Participant with advanced stage (IV) breast cancer recruited into the study during a 
site visit to Garki Hospital, Abuja, Nigeria 
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Figure 13: A 38-year old participant diagnosed with stage IV breast cancer. Patient had a breast 
lump for a period of 8 months, measuring 8 cm in the widest diameter with matted lymph nodes 
in the axilla, overlying skin changes and metastases to the liver. In the picture above, the patient 
was being examined during enrolment by Elima Jedy-Agba during a site visit to UNTH, Enugu 
in June 2014 
 
 
 
 
3.3. DATA COLLECTION 
Study Questionnaires and Data Collection Forms 
Participants with symptoms consistent with a possible diagnosis of breast cancer were 
interviewed during their first visit at any of the six participating hospitals to ensure that 
all eligible patients would be recruited even if they never returned to the hospital for a 
diagnostic confirmation or treatment. Data were collected for many women prior to the 
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diagnostic confirmation using interviewer-administered structured questionnaires 
specifically developed and piloted for this study. The clarity and appropriateness of the 
questions were assessed during the pilot study. I developed, pretested and piloted all the 
questionnaires and clinical data forms used in the NIBBLE study. (excluding the food 
frequency questionnaire, because it was not relevant to my PhD study). A detailed 
description of each of these forms is provided below: 
Upon enrolment, a questionnaire that focused on patient navigation and diagnosis delays 
(Appendix 6) was administered. This questionnaire was divided into 6 sections which 
focused on (a) the patient’s knowledge, attitudes, and practices towards breast cancer (14 
questions), (b) breast symptoms (8 questions), (c) the patient navigation pathway (66 
questions, including contact details of the first 6 care providers), (d) local health services 
(5 questions), (e) the patient’s perception of family/community support; (8 questions) and 
(f) the hurdles encountered when seeking help for a breast condition (2 questions). 
Detailed information on the patient’s navigation from when the symptoms were first 
noticed to when the patient sought help from any care provider (orthodox or traditional) 
to a subsequent diagnosis and treatment was collected in the 3rd section of the 
questionnaire. Information was collected on the first 6 providers visited and information 
on additional providers, where applicable, was collected on additional forms. During the 
development of the questionnaire, it had been reported that breast cancer patients in SSA 
contacted on average 4-6 care providers before a diagnosis was made (78).  
A second questionnaire developed for the parent NIBBLE study, which focused on the 
risk factors for breast cancer (Appendix 6), was also administered. The questionnaire was 
divided into 7 sections: (a) background information, (b) determination of household 
wealth, (c) reproductive history, (d) medical history, (e) lifestyle factors, (f) family history 
and (g) anthropometric and blood pressure measurements. In this 61-item questionnaire, 
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information was collected on sociodemographic variables such as age, religion, marital 
status, educational level, occupation, and on items used to depict the socioeconomic status 
such as house ownership, ownership of goods, toilet and cooking facilities. The 
questionnaire also included questions on reproductive and other risk factors for breast 
cancer including the age at menarche and, if applicable, menopause, use of hormonal 
contraceptives, total number of pregnancies and live births, family history of cancer, 
smoking and alcohol intake.  
A clinical data form (Appendix 6) was completed by the research assistants when the 
results of the breast tissue biopsies were received. The information collected on this form 
included the patients histology result, stage at diagnosis, tumour grade, morphology, and 
the treatment(s) received.  
As part of the parent study, a food-frequency questionnaire was also administered to 
participants during recruitment, but the information collected using this questionnaire was 
not used in the analyses for my thesis and is therefore not described in detail herein.  
Anonymised information on non-responders, including age and socioeconomic status, 
was collected using a non-responder’s form. Descriptive analyses were performed to 
compare this group of women with those who participated in the study. The reasons 
associated with their refusal to participate were also documented. In the case of the 
participants who dropped out of the study before the interview was completed, the reasons 
for dropping out of the study were documented. 
3.3.1. Pre-testing Questionnaires  
After developing the questionnaires and the forms used in the study, I pre-tested the 
questionnaires on 7 women who sought care at the surgical out-patients department 
(SOPD) at the National Hospital Abuja and who were 18 years of age or above. This 
pretesting was undertaken to check that the questions would work as intended, to identify 
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any issues in terms of clarity, and to question the sequence and the response choices 
offered. In addition to pre-testing the questionnaire on women who sought care at the 
SOPD, the questionnaire was pre-tested with colleagues at the research department of the 
Institute of Human Virology Nigeria who previously served as research coordinators on 
several studies in order to receive feedback on potential difficulties that might not have 
been revealed in a pre-test conducted with the respondents. Based on the feedback 
collected during pre-testing, I identified that the questionnaires took on average 90 
minutes to complete, which some respondents considered too long, and received some 
comments on how to re-word some questions before piloting the questionnaire. 
3.3.2. Questionnaire Piloting 
The pilot study was conducted in order to ensure that the questionnaire developed could 
effectively collect the information required, and to ensure that the range of responses used 
were adequate and could generate accurate information. Following the pre-testing stage, 
a revised instrument was then piloted on the women who presented with breast symptoms 
at the Asokoro District Hospital and the University of Abuja Teaching Hospital, 
Gwagwalada. The pilot study was conducted over a period of 2 months from November 
- December 2013. The trained research assistants interviewed 14 women in total, with 7 
consecutively attending patients who sought care at the SOPD of each hospital. The two 
hospitals were selected in order to ensure that the pilot was conducted at a secondary 
(ADH) and tertiary (UATH) hospital. Following the pilot study, I explored the 
participants’ views in terms of the wording, content, and format of the questionnaire. The 
pilot study revealed that the questionnaire was easy to understand, the questions followed 
in a logical sequence and the responses offered were sufficient in order to elicit responses 
from the participants. Respondents on average visited 3 providers before a diagnosis was 
made and no women visited more than 6 care providers in total. Secondly, some 
respondents had a difficult time remembering the exact date when a first symptom was 
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noticed or when they visited a previous care provider and as a result, these questions had 
to be modified in order to allow for a more open-ended response. The feedback received 
during the pilot study was used in an iterative process in order to develop a modified and 
final version of the questionnaire.  
The study questionnaires were administered in English, the common language spoken in 
Nigeria. All research assistants were fluent in English language and the predominant local 
language(s). For participants who could not speak English or the predominant local 
language, a staff member at the clinic who could speak the participants’ language was 
commissioned to translate on the spot with the research assistant recording the interview. 
A note was made on the questionnaire on whether a translator was used. 
3.3.3. Tumour Staging  
Breast cancer staging formed a significant component of my PhD study. Therefore, in 
order to accurately stage the women, a physical breast examination was performed at the 
time of enrolment by the surgeons. The size of the tumour was measured and the lymph 
nodes were assessed during the clinical examination. Mammography, chest x-rays, 
abdominal ultrasound scans and a bone scan were performed in order to check for 
metastases. The staging of the breast tumours was classified into stages I, II, III, IV based 
on the tumour, node, and the metastases (TNM) staging classification of the American 
Joint Committee on Cancer 7th Edition(58). The TNM staging is described extensively in 
Chapter 1, Table 2. 
3.4. SAMPLE SIZE DETERMINATION 
In order to calculate the sample size, information was obtained from each of the 
collaborating hospitals on the number of the newly diagnosed cases of breast cancer per 
year. This information is presented below: 
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Table 2: Expected number of the newly-diagnosed breast cancer cases per year by study site 
S/No Study Site Expected Number 
of Cases per year 
1 University of Nigeria Teaching Hospital, Enugu (UNTH) 100 
2 National Hospital Abuja 100 
3 University of Abuja Teaching Hospital, Gwagwalada (UATH) 75 
4 Garki Hospital Abuja (GH) 50 
5 Asokoro District Hospital (ADH) 75 
6 Wuse General Hospital (WGH) 25 
 Total Expected  425 
 
The expected number of new cases reportedly seen at these hospitals over the course of 
one year was estimated to be 425. Assuming a 10% (n=43) exclusion (i.e. ineligible, 
refusal to participate, or too ill to partake), 382 women were expected to be recruited in 
1 year, and 764 over a 2-year period. 
At the planning stage, the sample size calculations for the proposed study were made for 
2-year survival estimates, as this was supposed to be the main outcome of interest of my 
PhD studies. Survival from breast cancer is poor in Nigeria with over half of the patients 
dying in the first two years after diagnosis. The anticipated sample size would be large 
enough to provide precise estimates of the survival rates (+/10%) for up to two years 
following breast cancer diagnosis and will have a power rate greater than 80% in terms 
of identifying the major determinants of survival (HR≥2). For example, focusing on the 
differences in survival dictated by the stage at presentation and comparing the 2-year 
fatality rate between the cases with an early stage (I and II) vs. a late stage (stages III and 
IV) at presentation - a study of 700 breast cancer cases will have 80% power to detect a 
hazard ratio (HR) as high as or higher than 2.0, assuming a 5% significance level, with 
35% of the cases being diagnosed at stages I-II (unexposed group) and a 2-year fatality 
rate of 10% among early stage women.  
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The anticipated sample size would also be large enough to ensure that the study would be 
well powered to examine the determinants of late stage at diagnosis and diagnostic delays. 
For instance, the study will have 80% power to detect, at a 5% significance level, an odds 
ratio as low as or lower than 0.70 in the percentage of the late stage diagnosis between 
women with a high vs. low educational level assuming that the proportion of women with 
a low educational level (unexposed group) was 65%.  
3.5. RECRUITMENT PERIOD AND TARGETS 
The recruitment targets were determined based on the required sample size and the total 
number of breast cancer cases reportedly seen at each of the participating hospitals on an 
annual basis. Prior to the commencement of the study the site collaborators assessed the 
clinic registers at their hospitals and provided an approximate number of patients 
expected to be recruited monthly (Table 2). Based on this, I anticipated that the 
recruitment of breast cancer patients in this study would be influenced by the number of 
eligible breast cancer patients seen at the surgical and oncology clinics (where available) 
at each of the individual sites accounting for a refusal rate of 10%. I set a monthly 
recruitment target of 32 cases/month for the six participating sites and assigned numbers 
that were proportionate to the total number reported by the collaborators as the expected 
number of breast cancer patients per year (8 cases from the UNTH and NHA, 6 cases 
from the UATH and ADH and, 2 cases from GH and 2 cases from the WGH). The total 
recruitment by study site is shown in Figure 14. The numbers recruited were lower than 
expected and more details in relation thereto are provided in section 3.6 below. 
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Figure 14: Total recruitment by study site of all women who presented with breast cancer and 
benign breast disease symptoms from January 2014 to July 2016 
 
3.6 . RECRUITMENT CHALLENGES  
I encountered several challenges with the recruitment and implementation of this study 
in Nigeria. There were long periods of strike action by health professionals in Nigeria, 
which adversely affected recruitment. The Nigerian Medical Association went on strike 
in July 2014 until the end of September of the same year. During this period, the 
recruitment was at a standstill and most patients who were admitted in the hospitals were 
discharged and asked to seek care at private facilities. A few months after the strike by 
the Nigerian Medical Association was called off, the Joint Health Sector Unions 
(JOHESU) which are constituted by nurses and other support staff went on strike between 
November 2014 and February 2015. Following these events, there have been several other 
periods of intermittent strike actions throughout the duration of the study that adversely 
affected recruitment. Secondly, as part of the parent study, the research assistants had to 
complete a food frequency questionnaire in addition to the two questionnaires 
administered on the patients. This increased the participants’ waiting time and some 
participants withdrew halfway through the interviews expressing anxiety about time and 
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other commitments. Thirdly, the study required the collection of breast tissue samples 
which constitutes standard practice as part of the management of the breast cancer patients 
at all the participating hospitals. However, for the parent study, additional blood and stool 
samples were required, which in turn increased the time required to recruit the 
participants. There were also some additional logistic challenges associated with the 
transportation of samples from the UNTH Enugu site to the laboratory of the Institute of 
Human Virology in Abuja, in terms of processing and ensuring that the breast tissue 
samples were received in Abuja within 72 hours of collection as per the study protocol. 
Another important challenge was the high turn-over of research assistants working on this 
study. Considering that most of the research assistants working on this study were 
employed on a contract basis, a few resigned from their jobs during the study in favour 
of permanent or better-paying jobs elsewhere. As a result, new research assistants had to 
be employed and trained, often with intermittent periods during which no research 
assistants were present at some of the sites. Finally, the recruitment outcomes from Garki 
Hospital and the Wuse General Hospital were much lower than expected and both sites 
had to be discontinued one year into recruitment. This may have been due to the proximity 
of both hospitals to the National Hospital Abuja (NHA), a tertiary centre that is better 
equipped to manage cancer patients. Although, this study initially included a survival 
component which was the basis of the initial sample size calculation used in this study, it 
was no longer feasible to conduct a survival study within the framework of my PhD study 
owing to the challenges discussed above. Nevertheless, the target sample size was not 
attained. However, despite this drawback, the study was well powered to find the 
determinants of stage at diagnosis and diagnostic delays in Nigerian women with breast 
cancer. A high response rate of 94.3% was recorded and with no differences being 
identified between respondents and non-respondents, as discussed in section 3.10 below. 
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The survival analysis was initially meant to be a component of my PhD study, hence the 
use of the 2-year survival as the outcome in the original sample size calculations 
performed at the planning stage. However, considering that the final sample size was 
smaller than originally anticipated and that delays were experienced with patient 
recruitment due to reasons outside my control, a 2-year patient follow-up became 
unfeasible due to the time constraints of my PhD study.  
3.7. HISTOLOGY, TUMOUR GRADE AND IMMUNOHISTOCHEMISTRY ANALYSES 
All breast tumour samples were transported to the laboratory of the Institute of Human 
Virology Nigeria (IHVN) and to the bio-repository in Abuja where specially qualified 
immunohistochemistry (IHC) staff members analysed the tissue samples. A common 
protocol for the collection, storage, processing, and transport of tumour specimens was 
used in this study (Appendix 7). IHC staining was used in order to assess the prevalence 
of different molecular subtypes of breast cancer. All participants underwent a core needle 
biopsy at presentation using a Bard Magnum core needle and biopsy gun. This method 
was preferred to excisional or incisional biopsies in order to ensure adequate fixation. 
Three cores were taken: one for routine Haematoxylin and Eosin (H & E) to confirm the 
diagnosis of invasive breast cancer, a second core for IHC subtyping, and a third to be 
archived (frozen) for use in instances where the first or second slides were not properly 
stained.  
As soon as the samples were collected they were stored on ice and immediately 
transported to the laboratory. Once the samples were received in the laboratory, the 
laboratory assistant immediately fixed the tissue in a 10% neutral buffered formalin 
solution with a fixation period averaging 18 hours. A sample custody form was 
implemented which detailed the time allocated to each step from collection to fixation. 
This was particularly useful in order to identify any deviations from the study protocol. 
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The H and E slides were prepared in order to confirm the diagnosis of invasive cancer. 
The IHC staining was done using the 1D5 clone for anti-ER, PR-2C5 for anti-PR and 
Z4881 for anti-HER2. The staining results were evaluated for the presence of a positive 
reaction, pattern of staining and intensity of reaction. All slides were graded in a standard 
fashion into 0, 1+, 2+, 3+, and <1% positivity values, as recently recommended by the 
American Society of Clinical Oncology/College of American Pathologist guideline 
recommendations, which constituted the cut-off point for negative staining characteristics 
(192). For the determination of the HER2/neu status, fluorescent in situ hybridization 
(FISH), which has been described as the gold standard for detecting the HER2/neu status 
was used (193).  
The IHC analysis was performed in batches and a standard operating manual was 
followed by the laboratory personnel in order to ensure that the processing of the samples 
in different batches was done in a similar manner in order to reduce the inter-batch 
variability. The batches included a random sample of 5% duplicate specimens with 
laboratory staff and the consultant pathologist (slide reviewer) being unaware of the 
duplicates in order to assess the within- and between-batch variability. To minimise the 
between-observer variability, slides from all six participating hospitals were read by the 
same pathologist who was blinded to the clinical history of the participants. 
3.7.1. Tumour grade 
The pathologist graded tumours as well-differentiated (grade 1), moderately 
differentiated (grade 2) and poorly differentiated (grade 3) using the Scarff-Bloom-
Richardson grading system (194). 
3.8. DATA ENTRY 
The research assistants entered the data into a database using the REDCap online 
platform, designed by an experienced data manager working on the parent study (Figure 
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15). REDCap is a secure, web-based application used for data entry in clinical and 
translational research studies (195). The major advantages of using REDCap are that it is 
easy to use, enables data protection, improves efficiency by making it possible to 
undertake double data entry and has in-built validation checks which enhance the 
accuracy of the data. Data was initially collected on the field using paper questionnaires 
and was subsequently entered into the database using Google Nexus tablets. Data entry 
was performed online and all the research assistants were trained on data entry techniques 
using REDCap (Figure 16), and provided with internet modems (dongles) with monthly 
subscription to the internet. Once the data was entered by the research assistants into the 
database, it immediately became available online and I could remotely access the data, 
monitor recruitment, and perform quality checks on the data. 
Figure 15: REDCap database designed for data entry into the NIBBLE study 
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Figure 16: Training session for the research team on data entry and management using REDCap 
in Abuja, Nigeria 
                                                                                                                                                                     
3.9 . DATA ANALYSES 
The methods used in data analyses are described in detail in the relevant analytical 
chapters (4 and 5) of this thesis. 
3.10. CONSIDERATION OF BIAS IN MY PHD CASE-ONLY STUDIES  
 Selection bias is a major potential bias of my case-only studies. However, clear case 
definitions and strict inclusion and exclusion criteria for the selection of cases were 
defined in this study, rendering the selection bias less likely. To further reduce the 
selection bias, which could have arisen from missed cases of patients who will only come 
to the clinic for their first visit and never return, the patients involved in all suspicious 
cases of breast cancer, including those which were later proved to be benign cases, were 
interviewed upon first contact and a biopsy sample was subsequently received and 
analysed. In cases where they turned out to be benign lesions, we analysed them 
separately whenever appropriate (see Chapter 5). The participation rate for the breast 
cancer cases was high (94.3%). Patients who were eligible, but declined to participate did 
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not differ from those who participated in the study by age, nor were they more critically 
ill than the respondents. Nevertheless, many women with breast cancer in Nigeria, as in 
many other SSA settings, may never be known to the health system (e.g. if they only seek 
traditional or spiritual healers) or may be known but never referred to a secondary or a 
tertiary health hospital for diagnosis and treatment. Despite these caveats, the present case 
series should be representative of the breast cancer cases diagnosed in Abuja and Enugu. 
Furthermore, although a lack of representativeness may affect the external validity of the 
study findings and the generalisability thereof, it should not compromise its internal 
validity. 
Information bias in the study was reduced by minimising observer variability by training 
the field staff/research assistants (mostly nurses) on interviewing the patients and taking 
measurements. A detailed and structured pre-tested and piloted questionnaire was 
administered prior to the confirmation of the breast cancer diagnosis, and quality 
assurance checks were conducted fortnightly on the completed questionnaires. During the 
interviews, in cases where participants forgot important dates, the field staff asked 
questions about significant personal events to help the participants remember the dates. 
Secondly, in order to reduce the number of errors associated with data entry, an online 
data management tool was used (195), which incorporated in-built logical checks and 
data entry into the REDCap database. This was further reviewed by the data manager as 
an additional level of quality control. 
In order to minimise confounding, we attempted to collect high-quality data on a large 
number of variables, which had been formerly identified in previous studies as being 
independent determinants of late stage and/or delays in the breast cancer diagnosis. 
Nevertheless, as this is an observational study, one can never exclude the possibility that 
the reported exposure-outcome associations might have been distorted because of residual 
confounding or confounding by unmeasured variables. 
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3:11. ETHICAL CONSIDERATIONS 
Prior to the commencement of the study, the study protocol and questionnaires were 
submitted to the LSHTM ethics committee, the University of Maryland Baltimore 
Institutional Biosafety Committee (institution of the principal investigator of the parent 
study), the National Health Research Ethics Committee of Nigeria (NHREC) and the 
health research ethics committees of the six participating institutions to obtain ethical 
approvals. After several institutions inquired about the administrative management and 
the funding methods of the study, the approval was granted. 
Patients were adequately informed about the study and provided with the opportunity to 
ask questions about various aspects of the study. All participants were required to give 
written informed consent and were asked for consent prior to having their biological 
samples stored and used for future studies as part of the parent study. The informed 
consent form is included in Appendix 8. Each participant was given a unique study 
identification number which was used across all questionnaires, blood and stool samples, 
and breast tissue biopsies and to link clinical data with the laboratory data. Paper 
questionnaires were stored in accordance with the standard operating practices at the 
Institute of Human Virology, Nigeria. 
All the information collected was treated as confidential. All Google Nexus tablets used 
for data entry were password protected. Participant names were excluded from all 
analyses and electronic information was not sent via email but through a secure password 
protected shared drive.  
3.12. RESEARCH COSTS AND FUNDING 
This study was funded as part of a training grant by the Fogarty International Centre of 
the National Institutes of Health (FIC/NIH D43TW009106), referred to as the ‘Training 
Programme in Nigeria for Non-Communicable Disease Research’ (TRAPING). The grant 
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covered monthly stipends for the research assistants and laboratory assistants and further 
research costs including the purchase of reagents for IHC and histology, Bard Magnum 
biopsy guns and needles, nexus tablets for data entry and payment for the pathologist 
review of the histology slides.
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ABSTRACT 
Purpose: Late stage at diagnosis is a common feature of breast cancer in Sub-Saharan 
Africa (SSA), contributing to poor survival rates. Understanding its determinants is key 
to preventing deaths from this cancer in SSA.  
Methods: Within the Nigerian Integrative Epidemiology of Breast Cancer Study 
(NIBBLE) multicentre case-control study on breast cancer, we studied factors affecting 
stage at diagnosis of cases, i.e. women diagnosed with histologically confirmed invasive 
breast cancer between January 2014 and July 2016 at six secondary and tertiary hospitals 
in Nigeria. Stage was assessed using clinical and imaging methods. Ordinal logistic 
regression was used to examine associations of socio-demographic, breast cancer 
awareness, health access and clinical factors with odds of later stage (I, II, III or IV) at 
diagnosis. 
Results: A total of 316 women were included, with a mean age (SD) of 45.4 (11.4) years. 
Of these, 94.9% had stage information: 5 (1.7%), 92 (30.7%), 157 (52.4%), and 46 
(15.3%) were diagnosed at stages I, II, III and IV respectively. In multivariate analyses, 
lower educational level (odds ratio (OR) 2.35, 95% confidence interval (CI): 1.04, 5.29), 
not believing in a cure for breast cancer (1.81: 1.09, 3.01), and living in a rural area (2.18: 
1.05, 4.51) were strongly associated with later stage, whilst age at diagnosis, tumour grade 
and oestrogen receptor status were not. Being Muslim (Vs Christian) was associated with 
lower odds of later stage disease (0.46: 0.22, 0.94). 
Conclusion: Our findings suggest that factors that are amenable to intervention 
concerning breast cancer awareness and health care access, rather than intrinsic tumour 
characteristics, are the strongest determinants of stage at diagnosis in Nigerian women.  
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INTRODUCTION  
Breast cancer is the most common cancer in women worldwide and in Nigeria. Breast 
cancer incidence in Nigeria (estimated age-standardised incidence rate (ASR)=50.5 per 
100,000) in 2012 was only half that in the United States (US) (ASR=92.9 per 100,000), 
but estimates of mortality rates from this cancer were higher in this West African country 
than in the US (25.9 vs 14.9 per 100,000, respectively)(18), reflecting poorer survival.(5) 
One of the most important prognostic factors for breast cancer is stage at diagnosis, and 
has been shown to be relevant in the African setting.(54, 88, 196) However, in contrast 
with breast cancer diagnosed in developed countries, stage at diagnosis of breast cancer 
in Nigeria, as in the rest of sub-Saharan Africa (SSA), has been widely reported to be 
late.(54, 60, 133) Women are typically symptomatic at presentation as there are no 
organised, and little opportunistic, pre-clinical early detection. Moreover, presentation in 
majority of women is not in the early symptomatic stages, rather at advanced stage when 
regional spread and metastases are not uncommon. Although breast cancer survival data 
in Nigeria are limited, available data support poor survival from this disease in women 
who present late.(52, 54)  
Recognizing the importance of early detection and treatment in breast cancer control, an 
increasing body of research is examining factors associated with late stage at diagnosis, 
particularly in settings where stage has persistently remained late over decades and 
tumour size at presentation (mean 5-8 cm) is far beyond that of a palpable tumour (2 
cm).(133) In SSA, later stage at diagnosis of breast cancer has been linked to various 
factors such as low educational level(139), rural region of residence,(197) lack of medical 
aid/insurance(197) and poor health care access,(60) e.g. long distance to health 
provider(80). These factors would translate into delays in the time to diagnosis. On the 
other hand, clinical factors(198), e.g. young age, poorly differentiated tumour grade(199), 
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and negative hormone receptor status(199), may contribute to advanced stage as a result 
of a more rapid tumour growth rate. A significant number of papers that have investigated 
factors associated with stage at diagnosis have been reported from studies in western 
countries and a few other SSA countries, but has been less well studied in Nigeria. Of 
particular relevance to the African setting, the extent to which the younger age at 
diagnosis distribution and the small excess of more aggressive tumour subtypes(103) 
contribute to later stage diagnosis remains unknown.  
In our study, we examined the role of socio-demographic, breast cancer awareness, access 
to health care and clinical factors on stage at diagnosis of breast cancer among women 
seeking care at tertiary and secondary health institutions in Nigeria as a first step to 
identify which of these factors may be amenable to intervention in the Nigerian setting.  
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METHODS  
Study Design and Setting 
This study was conducted within the Nigerian Integrative Epidemiology of Breast Cancer 
Study (NIBBLE), an on-going multicentre case-control study which began recruitment in 
January 2014 at six government hospitals in Nigeria: five located in the capital city of 
Abuja (population 1.4 million) (191) comprising two tertiary hospitals (National Hospital 
and University of Abuja Teaching Hospital Gwagwalada) and three secondary hospitals 
(Asokoro District Hospital, Garki Hospital and Wuse General Hospital) - and one further 
tertiary hospital site (University of Nigeria Teaching Hospital) located 400 km south in 
Enugu, South-Eastern Nigeria, with a population size of 3.3 million(191). The three large 
tertiary hospitals serve as major referral centres for cancer patients across Nigeria and all 
have facilities for chemotherapy, with one - the National Hospital Abuja - being one of 
four government hospitals in the country that currently also offer radiotherapy. The 
present analysis was restricted to NIBBLE cases, i.e. women newly-diagnosed with 
primary invasive breast cancer at the six participating hospitals between January 2014 
and July 2016. 
Ethical approval was obtained for NIBBLE from the National Health Research Ethics 
Committee of Nigeria, health research ethics committees in each participating hospital, 
and institutional ethics committees at the University of Maryland Baltimore (US) and the 
London School of Hygiene and Tropical Medicine (UK). The study was carried out in 
compliance with the Nigerian National Code for Health Research Ethics and the 
Declaration of Helsinki. Written informed consent was obtained from all participants in 
the study. 
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Subject recruitment and interviewing 
Participants were recruited at the surgical outpatient departments (SOPD) and the 
oncology departments in two of the participating hospitals (i.e. the National Hospital 
Abuja and the University of Nigeria Teaching Hospital, Enugu) and only at the SOPDs 
at the remaining four. All newly-diagnosed patients with a primary invasive breast cancer 
aged 18 years and over were eligible regardless of their ethnicity or language. Potentially 
eligible patients were identified at their first visit by the surgeon, oncologist, or research 
nurse, informed about the study, and invited to participate prior to histological 
confirmation. Overall, 94.3% consented for whom a confidential structured face-to-face 
interview was conducted by a trained research nurse in English (70.6%), a predominant 
Nigerian language (20.6%) or other local language (8.8%) as per the patient’s preference. 
Information was collected on socio-demographic variables, lifestyle, comorbidities, 
awareness of breast cancer causes and symptoms and health care access (Tables 1 and 2). 
The research nurse also performed measurements, using a standard protocol, of the 
patient’s height, weight, and waist and hip circumferences, from which body mass index 
(BMI, weight (kg)/height2 (m2)) and waist-hip ratio (WHR) measures were calculated. 
For these anthropometric measurements, participants were asked to remove shoes, heavy 
outer garments, hair ornaments and head scarves.  
We adapted the scoring method previously used by Mena et al.(200) to generate scores 
for knowledge of breast cancer causes (based on 8 items; Table 1) and symptoms (based 
on 7 items; Table 1). For both domains, a woman was given a score of 2 for a correct 
answer, 1 if not sure/did not know and 0 for the wrong answer to each of its items. The 
total score for each domain was calculated as the sum of its item-specific scores and then 
categorised as poor, fair and good knowledge as described in Table 1 (footnotes a and b).  
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Tumour staging and pathology 
Physical breast examination was performed at the time of enrolment by surgeons. 
Participants were asked to undergo mammography, chest-x-rays, abdominal ultrasound, 
and a bone scan to check for metastases. These tests are routinely recommended and 
majority of patients undergo them. Lymph node involvement was assessed on clinical 
examination at the time of presentation; no information was recorded on possible re-
assessment during surgery. Thereafter, the study assigned tumour stage according to the 
tumour, node, metastasis (TNM) classification (American Joint Committee of Cancer 7th 
Edition TNM classification) into stages I, II, III and IV.  
Most patients underwent a core needle biopsy for histological confirmation, the results of 
which were retrieved from pathologists’ reports within two weeks of a biopsy. Data were 
extracted on tumour characteristics (e.g. laterality, size, morphology, grade, receptor 
status). Tumours were graded as 1, 2 and 3 using the Scarf-Bloom-Richardson 
system.(194) Immunohistochemistry staining was used to assess oestrogen receptor (ER) 
status. A <1% positivity was the cut-off point for negative staining characteristics.(192)  
Statistical analyses 
Ordinal logistic regression models were used to identify correlates of later stage at 
diagnosis, i.e. assuming a common odds ratio (OR) for the binary outcomes: stage IV v 
I/II/III, IV/III vs I/II and IV/III/II vs I). Age at diagnosis was regarded as a priori 
confounder and thus examined alone and included in all models. Age-adjusted models 
were initially fit separately to each group of variables: socio-demographic, breast cancer 
awareness, health care access and clinical. Subsequent models assessed the extent to 
which: (i) associations between socio-demographic variables and later stage at breast 
cancer diagnosis were mediated by breast cancer awareness or health care access factors; 
and (ii) associations between breast cancer awareness and health care access variables 
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with later stage at breast cancer diagnosis were confounded by socio-demographic 
variables. Finally, a fully-adjusted model was fitted to identify independent correlates of 
later stage at breast cancer diagnosis. This model included age at diagnosis, and the two 
most strongly found to be associated with later stage at breast cancer diagnosis within 
each group in the age-adjusted models. Variables found to be associated with others 
already included in the model were excluded (e.g. hospital type was excluded because it 
was defined by region of residence in Enugu). Data analyses were performed using 
Stata14.1 (Stata Corporation, College Station, Texas, USA). 
Principal Component Analyses (PCA) was applied, as previously described by Filmer 
and Pritchett(201), to generate a single summary index of a woman’s socio-economic 
status on the basis of her household assets. The variables included in the PCA were all 
binary variables (Y/N), e.g. for owning your home, living in an apartment, house or 
duplex, drinking water from outside, well, borehole, piped or bottled, various types of 
cooking fuel, having a separate room for cooking, type of toilet used and ownership of 
certain household goods including a car, refrigerator, bicycle, electric fan, television, and 
motorcycle. The first component in the PCA was used, as it explained most of the 
variation, to generate wealth scores and categories of low (lowest 40% of the score 
distribution), middle (middle 40%) and high (highest 20%) socio-economic class. 
Participants with WHR >1.2 or <0.6 and those with a BMI<10 kg/m2 or >50 kg/m2 were 
regarded as outliers and therefore excluded from analyses involving these variables.  
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RESULTS 
Participants’ characteristics 
In all, 316 eligible participants were recruited into the study, but sufficient information to 
derive stage at diagnosis was available for only 300 (94.9%) women. Of these, five (1.7%) 
were diagnosed at stage I, 92 (30.7%) in stage II, 157 (52.4%) in stage III and 46 (15.3%) 
in stage IV. The characteristics of the study participants are summarized in Tables 1 and 
2. The mean (SD) age at breast cancer diagnosis was 45.4 (11.4) years in all women. The 
majority (81%) were recruited in a tertiary hospital, 67.2% of these in Abuja. The 
commonest first breast cancer symptom noticed by the women was a breast lump (Table 
1). Median (interquartile range) self-reported time from symptom to diagnosis was 8.25 
(4.24-18.5) months. In all, 46 (14.6%) breast cancer patients were found to have 
metastases at the time of diagnosis, including to the lung (n=17, 36.9%), liver (n=9, 
19.6%), bone (n=5, 10.9%), brain (n=2, 4.3%) and site unknown (n=13, 28.3%).  
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Table 1: Socio-demographic characteristics of women with breast cancer, by stage at diagnosis 
Characteristics  Early BC 
(Stages I & II) 
N (%) a 
Late BC 
(Stages III & IV) 
N (%) a 
Socio-demographic Total no. of women 97 (32.3) 203 (67.7) 
Age at BC diagnosis (years) Mean age (SD) 42.6 (11.5) 46.4 (11.7) 
Marital status Married  71 (33.6) 140 (66.4) 
Educational level  None 5 (12.2) 36 (87.8)  
 Primary/Secondary  33 (29.2) 80 (70.8) 
 Tertiary/Post graduate 
(PG) 
59 (41.3) 84 (58.7) 
 Not reported  0 (0) 3 (100) 
Religion  Christianity  80 (30.7)  181 (69.3) 
 Islam  17 (47.2) 19 (52.8) 
 Not reported  0 (0)  3 (100) 
Do you have a personal 
income?  
Yes 23 (25.6) 67 (74.4) 
 No  74 (35.2) 136 (64.8) 
Socioeconomic class Low 37 (27.2) 99 (72.8)  
(using household data) Middle 38 (36.5) 66 (63.5)  
 High 22 (36.7) 38 (63.3)  
Lifestyle  No. of ever smokers (%) 1 (50.0) 1 (50.0)  
 No. drinkers (%)  
(1 measure/day) 
10 (21.7) 36 (78.3) 
 (2-5 measures/day) 1 (6.7) 14 (93.3) 
Breast Cancer Awareness    
Ever heard of BC No 8 (16.3) 41 (83.7) 
 Yes 88 (36.1) 156 (63.9) 
 Don’t Know/Not 
reported 
1 (33.3) 2 (66.7) 
Knowledge of BC causes b Poor 57 (28.5) 143 (71.5) 
 Fair  25 (40.9) 36 (59.1)  
 Good 15 (38.5) 24 (61.5) 
Knowledge of BC symptoms 
c 
Poor 48 (28.4) 121 (71.6) 
 Fair 30 (33.3) 60 (66.7) 
 Good 19 (46.3)  22 (53.7) 
Belief in cure for BC No  26 (22.2) 91 (77.8) 
 Yes 71 (39.9) 107 (60.1) 
 Don’t know  0 (0)  5 (100.0) 
Practice of BSE No  37 (25.0) 111 (75.0) 
 Yes 53 (41.1) 76 (58.9) 
 Never heard of / 
Unknown 
7 (30.4) 16 (69.6) 
First BC symptom Breast Lump 86 (33.0) 175 (67.0) 
 Other Symptom d 11 (28.2) 28 (71.8) 
Health Care Access    
Region of residence North-Central (Abuja) 85 (37.6) 141 (62.4)  
 South-Eastern (Enugu) 12 (16.2) 62 (83.8) 
Diagnostic hospital type e Tertiary  68 (28.1) 174 (71.9) 
 Secondary  29 (50.0) 29 (50.0) 
Travel time taken to 
diagnostic hospital  
< 1 hour 66 (36.1) 117 (63.9) 
 1 - < 2  15 (33.3)  30 (66.7) 
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Characteristics  Early BC 
(Stages I & II) 
N (%) a 
Late BC 
(Stages III & IV) 
N (%) a 
 >=2 5 (22.7) 17 (77.3) 
 Not reported  11 (22.0) 39 (78.0) 
BC: breast cancer; BSE: breast self-examination; HCP: health care provider including traditional and spiritual healers; SD: standard 
deviation;  
a Unless otherwise specified 
b A score was assigned to each one of 8 items on BC causes: 2 to the correct answer, 1 to not sure/certain and 0 to the wrong answer. 
The 8 items included (i) lifestyle, (ii) not breastfeeding, (iii) getting older, (iv) family history of BC, (v) if cancer is caused by a curse, 
(vi) an insect bite, (vii) injury to the breast or if (viii) it is contagious. The sum of the 8 item-specific scores was then grouped into 3 
categories of poor (score 0-8), fair (9-11) and good knowledge (12-16).  
c Scores 0, 1 and 2 were assigned as above to 7 common BC symptoms: (i) breast lumps, (ii) breast pain, (iii) change in the size or 
shape of the breast, (iv) dimpling of the skin or a wound to the breast, (v) fluid coming from the nipple in a woman not breastfeeding, 
(vi) swelling in the armpit and (vii) change in the shape of the nipple. The sum of the 7 item-specific scores was then grouped into 
poor (0-7), fair (8-11) and good knowledge of symptoms (12-14).d Other symptoms included swelling underarm, nipple discharge and 
change in shape or size of breast. 
e Recruitment numbers for tertiary hospitals were: National Hospital Abuja- 70, University of Abuja Teaching Hospital Gwagwalada 
- 98, University of Nigeria Teaching Hospital, Enugu - 74; for secondary hospitals: Asokoro District Hospital - 44, Garki Hospital -
11 and Wuse General Hospital - 3) 
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Table 2: Clinical characteristics of women with breast cancer by stage at diagnosis 
Clinical characteristics Categories Early BC (Stages 
I/II) (row %) 
Late BC (Stages III/ 
IV) (row %) 
Total   97 (32.3) 203 (67.7) 
Co-morbidities a    
 Previous HTN or diabetes Yes 29 (36.7) 50 (63.3)  
Previous history of BBD Yes 18 (43.9) 23 (56.1) 
Family history of BC Yes 7 (26.9) 19 (73.1) 
Other Clinical 
characteristics 
   
BMI (kg/m2) < 25 (Normal weight) 22 (24.4) 68 (75.6) 
 25-29 (Overweight) 38 (38.4) 61 (61.6) 
 >30 (Obese) 36 (35.6) 65 (64.4) 
 Unknown 1 (10.0) 9 (90.0) 
WHR <0.80 (low) 15 (48.4) 16 (51.6) 
 0.8-0.85 (moderate) 15 (27.8) 39 (72.2) 
 >0.85 (high) 67 (32.2) 141(67.8) 
 Unknown 0 (0) 7 (100) 
Tumour laterality  Left breast 42 (29.2) 102 (70.8) 
 Right breast 52 (34.7) 98 (65.3) 
 Other (underarm) 3 (50.0) 3 (50.0) 
Morphology NST/IDC 85 (34.3) 163 (65.7) 
 Medullary  7 (26.9) 19 (73.1) 
 Others (lobular, mucinous) 5 (21.7) 18 (78.3) 
 Unknown  0 (0)  3 (100) 
Stage at BC diagnosis I 5 (100) - 
 II 92 (100) - 
 III - 157 (100) 
 IV - 46 (100) 
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Tumour grade (n=250) b Well differentiated 20 (38.5) 32 (61.5) 
 Moderately differentiated 55 (34.4) 105 (65.6) 
 Poorly differentiated  6 (23.1) 20 (76.9) 
    
Oestrogen receptor status 
(n=220) c 
Positive 32 (34.0) 62 (66.0) 
 Negative 45 (39.5) 69 (60.5) 
HTN: hypertension; BBD: benign breast diseases; BC: breast cancer; BMI: body mass index; WHR: waist-hip ratio;  
NST: Not Otherwise Specified; IDC: invasive ductal carcinoma.  
a Number missing or unreported 7 or less in smoking, alcohol, hypertension, BBD and family history of BC categories. 
bThere were 250 women with information on tumour grade, 12 patients with missing information on stage have been excluded. 
cThere were 220 women with information on oestrogen receptor status, 12 patients with missing information on stage were excluded. 
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Socio-demographic characteristics and later stage at diagnosis 
There was no association between age and the odds of later stage at diagnosis (p for linear 
trend (pt)=0.16; Table 3). After adjusting for age, there was positive trend in the odds of 
later stage with lower educational level (pt=0.002), with women with no formal education 
having 2.75 (95% CI 1.37, 5.52; p=0.004) times the odds of being diagnosed at a later 
stage relative to those with tertiary or higher education (Table 3; Figure 1a). Higher 
educational level was associated with having ever heard about breast cancer (p<0.001) 
and with believing in a cure for this disease (p<0.001), but the trend in the odds of later 
stage with educational level persisted, albeit attenuated, upon further adjustment for these 
two breast cancer awareness variables (p=0.02; Figure 1b). Similarly, the association 
between educational level and the odds of later stage at diagnosis persisted after further 
adjustment for health care access variables (i.e. region of residence, type of hospital and 
travelling time to diagnostic hospital) (Figure 2b).  
Muslim women were less likely to be diagnosed at later stages than Christian women 
(age-adjusted OR=0.46; 95% CI 0.24, 0.90; p=0.02), with this association strengthened 
slightly after further adjustment for educational level (OR=0.38; 95% CI 0.19, 0.75; 
p=0.005). Further adjustment for breast cancer awareness or health care access variables 
did not change, however, the magnitude of the ORs (Figures 1 and 2).  
The age-adjusted analyses showed no associations between later stage at breast cancer 
diagnosis and a woman’s marital status, self-reported personal income, or socioeconomic 
status (Table 3). There was also no association between later stage and self-reported 
alcohol consumption. Only 2 out of the 316 women in our study were ever smokers so 
the role of this lifestyle variable could not be assessed. 
Breast cancer awareness and later stage at diagnosis 
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Overall, 80.4% women had ever heard of breast cancer, but few displayed good 
knowledge of its causes (12.6%) or symptoms (13%) (Table 1). Only 59.5% of women 
believed in a cure or treatment for breast cancer, and only 42.4% of women practised 
breast self-examination (BSE). After adjustment for age, never having heard of breast 
cancer was significantly associated with an increased odds of later stage (OR=2.24; 95% 
CI 1.25, 4.03; p=0.01; Figure 1a). Women who did not believe in a breast cancer cure 
(OR=2.23; 95% CI 1.40, 3.56; p=0.001) and those who did not practice BSE (OR=1.89; 
95% CI 1.20, 2.99; p=0.01) were also more likely to be diagnosed at a later stage (Figure 
1a). These associations were slightly attenuated upon further adjustment for a woman’s 
educational level and religion. 
In contrast, there were no clear trends in the odds of later stage with knowledge of breast 
cancer causes or symptoms either in age-adjusted analyses or in those further adjusted for 
educational level and religion (Figure 1).  
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Figure 1: Odds of later stage at breast cancer diagnosis by: (a) a woman’s educational level, 
religion and breast cancer awareness adjusting for age; and (b) a woman’s educational level and 
religion adjusting for age and breast cancer awareness, and by breast cancer awareness variables 
adjusting for age, educational level and religion.  
  
pt= p-value for linear trend; BC: breast cancer  
 
pt: p-value for linear trend; BC: breast cancer 
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Access to health care and later stage at diagnosis 
The proportion of participants with later stage was higher at the three tertiary hospitals 
(National Hospital Abuja: 62.3% (43/69); University of Abuja Teaching Hospital 
Gwagwalada: 69.4% (68/98); and University of Nigeria Teaching Hospital, Enugu: 
83.8% (62/74)) than at the three secondary care hospitals in Abuja (50.8% (30/59)). These 
associations persisted after further adjustment for educational level and religion (Table 3; 
Figure 2a). In age-adjusted analysis, the odds of later stage were positively associated 
with the amount of travel time taken by the woman to reach the first healthcare provider 
she visited (pt=0.04; Table 3 and Figure 2a), but this trend was no longer significant upon 
further adjustment for educational level and religion (pt=0.97; Figure 2b).  
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Figure 2: Odds of later stage at breast cancer diagnosis by: (a) a woman’s educational level, 
religion and health care access adjusting for age; and (b) a woman’s educational level and religion 
adjusting for age and health care access, and by health care access variables adjusting for age, 
educational level and religion.  
 
 
 
pt: p-value for linear trend; BC: breast cancer  
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Clinical factors and later stage breast cancer diagnosis 
Invasive ductal carcinoma (non-otherwise specified (NST)) was the commonest 
morphological type (83.2%). Information on tumour grade was available for 79.1% 
women, with 10.8% of these being poorly differentiated (Table 2). ER status was known 
for 69.6% women, with 45.2% of these being ER-positive overall. X% of ER positive and 
y% of ER negative tumours were diagnosed at stages III/IV (Table 2), but age-adjusted 
analyses revealed no associations between later stage at breast cancer diagnosis and 
tumour grade, morphology, or ER (Table 3). There were also no clear trends in the odds 
of later stage with BMI or WHR at diagnosis, and no evidence of associations of later 
stage with a positive family history of breast cancer or with having ever been diagnosed 
with diabetes, hypertension, or benign breast disorders (Tables 3 and 4).  
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Table 3: Age-adjusted associations between socio-demographic, breast cancer awareness, health 
care access and clinical variables with odds of later stage breast cancer estimated using ordinal 
logistic regression  
Socio-demographic 
characteristics  
 Age adjusted OR (95% 
CI) 
p value  
Age at BC diagnosis 
(years) 
<40 1  
 40-49 1.44 (0.85, 2.42) 0.18 
 50-59 1.76 (0.94, 3.28) 0.08 
 >60 1.44 (0.69, 3.01) 0.33    (pt = 0.16) 
Marital Status Married 1  
 Unmarried 1.31 (0.77, 2.23) 0.32 
Educational level Tertiary/PG 1  
 Primary/Secondary 1.63 (1.01, 2.64) 0.045 
 None 2.75 (1.37, 5.52) 0.004   (pt =0.002) 
Religion Christian  1  
 Muslim 0.46 (0.24, 0.90) 0.02 
Do you have a 
personal income? 
Yes 1  
 No 1.21 (0.74, 1.99) 0.45 
Socio-economic class High 1  
 Middle 0.99 (0.53, 1.84) 0.97 
 Low 1.43 (0.79, 2.60) 0.24    (pt = 0.15) 
Breast Cancer 
Awareness  
   
Ever heard of BC Yes 1  
 No 2.24 (1.25, 4.03) 0.01 
Knowledge of BC 
causes 
Good  1  
 Fair 1.09 (0.50, 2.38) 0.82 
 Poor 1.47 (0.74, 2.79) 0.29    (pt = 0.18) 
Knowledge of BC 
symptoms 
Good 1  
 Fair 1.67 (0.81, 3.47) 0.17 
 Poor 2.02 (1.03,4.00) 0.04    (pt = 0.08) 
Practise of BSE Yes 1  
 No 1.89 (1.20, 2.99) 0.01 
Belief in a cure for BC  Yes 1  
 No 2.23 (1.40, 3.56) 0.001 
Health Care Access     
Region of residence North-Central 
(Abuja) 
1  
 South-Eastern 
(Enugu) 
2.21 (1.33, 3.68) 0.002 
Diagnostic hospital 
type 
Tertiary 1  
 Secondary 0.40 (0.22, 0.70)  0.001 
Travel time taken to 
diagnostic hospital 
(hrs)  
<1  1  
 1 - <2  1.42 (0.75, 2.71) 0.28 
 ≥ 2 2.14 (0.89, 5.13) 0.09   (pt =0.04) 
Clinical Characteristics 
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Socio-demographic 
characteristics  
 Age adjusted OR (95% 
CI) 
p value  
Previous HTN or 
diabetes 
Yes 1  
 No  1.40 (0.81, 2.42) 0.22 
Previous history of 
BBD 
Yes 1  
 No 1.46 (0.77, 2.77) 0.25 
Family History of BC Yes 1  
 No 1.07 (0.49, 2.34) 0.86 
BMI (kg/m2) < 25 (Normal weight) 1   
 25-29 (Overweight) 0.55 (0.32, 0.95) 0.03 
 >30 (Obese) 0.66 (0.38, 1.14) 0.14 
 Unknown 1.45 (0.40, 5.18) 0.57   (pt =0.41) 
WHR <0.80 (low) 1  
 0.8-0.85 (moderate) 2.80 (1.18, 6.68) 0.02 
 >0.85 (high) 2.20 (1.06, 4.60) 0.04   (pt =0.098) 
Tumour grade Well differentiated 1  
 Moderately 
differentiated 
0.93 (0.50, 1.72) 0.82 
 Poorly differentiated  1.42 (0.58, 3.49) 0.44 
 Unknown 1.56 (0.76, 3.23) 0.23   (pt =0.09) 
Oestrogen receptor 
status 
Positive  1  
 Negative 1.18 (0.70, 2.01) 0.531 
BC: breast cancer; BSE: breast self-examination; HCP: health care provider including traditional and spiritual healers; HTN: 
hypertension; BBD: benign breast disease; BMI: body mass index; WHR: waist-hip ratio; PG: post graduate; OR: odds ratio; CI: 
confidence interval; pt: p-value for linear trend   
 
 
Fully-adjusted model 
A woman’s educational level, religion, region of residence and belief in a cure for breast 
cancer were identified as being independent correlates of later stage at breast cancer 
diagnosis in the fully-adjusted model (Table 4). Notably, the association of lower 
educational level with the odds of later stage persisted in the fully-adjusted model, albeit 
with a slightly weakened trend (pt=0.033). The association of later stage with religion, 
though slightly attenuated when region of residence was included in the model, reflecting 
the fact that a higher percentage of Muslims resided in the North-Central than in the 
South-East region, also remained significant in the fully adjusted model (OR=0.46;95% 
CI 0.22, 0.94; p=0.033). This association also held when restricted to women diagnosed 
in Abuja (OR=0.42; 95% CI 0.20, 0.88; p=0.02). The association of belief in a breast 
cancer cure with later stage, which was slightly attenuated upon adjustment for 
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educational level and religion (Figure 1), was little affected with further adjustment for 
the other variables included in the fully-adjusted model (OR 1.81; 95% CI 1.09, 3.01; 
p=0.022). In contrast, the association between having ever heard of breast cancer and later 
stage, which was weakened upon adjustment for educational level and religion (Figure 
1), was further attenuated in the fully-adjusted analysis and no longer significant (Table 
4). 
Table 4: Fully-adjusted model showing associations between predictor variables and late stage 
breast cancer 
Variable  Categories Age adjusted 
OR (95% CI) 
p value  Fully-adjusted 
a OR (95% CI) 
p 
value  
Age at BC Diagnosis 
(years) 
<40 1   1  
 40-49 1.44 (0.85, 2.43) 0.18 1.53 (0.87, 
2.68) 
0.139 
 50-59 1.76 (0.94, 3.29) 0.08 1.63 (0.84, 
3.18) 
0.149 
 >60 1.44 (0.69, 3.02) 0.33 0.89 (0.38, 
2.08) 
0.789 
 pt   0.16  0.86 
Educational level  Tertiary/PG 1  1  
 Primary/Secondary 1.63 (1.01, 2.64) 0.045 1.48 (0.89, 
2.47) 
0.133 
 None 2.75 (1.37, 5.52) 0.004 2.35 (1.04, 
5.29) 
0.039 
 pt  0.002  0.033 
Religion Christian  1  1  
 Muslim 0.46 (0.24, 0.90) 0.02 0.46 (0.22, 
0.94) 
0.033 
Region of residence North-Central 
(Abuja) 
1  1  
 South-Eastern 
(Enugu) 
2.21 (1.33, 3.68) 0.002 2.18 (1.05, 
4.51) 
0.037 
Travel time taken to 
diagnostic hospital 
<1  1  1  
 1 - <2  1.42 (0.75, 2.71) 0.28 1.45 (0.72, 
2.93) 
0.300 
 ≥ 2 2.14 (0.89, 5.13) 0.09 1.50 (0.59, 
3.83) 
0.396 
 pt  0.04  0.786 
Ever heard of BC  Yes  1  1  
 No 2.24 (1.25, 4.03) 0.01 1.57 (0.80, 
3.09) 
0.189 
Belief in cure for BC Yes  1  1  
 No 2.23 (1.40, 3.56) 0.001 
 
1.81 (1.09, 
3.01) 
0.022 
WHR <0.80 (low) 1  1  
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 0.8-0.85 (moderate) 2.80 (1.18, 6.68) 0.02 2.22 (0.88, 
5.60) 
0.093 
 >0.85 (high) 2.20 (1.06, 4.60) 0.04 1.75 (0.84, 
4.16) 
0.166 
 pt  0.10  0.154 
Tumour grade  Well Differentiated 1  1  
 Moderately 
Differentiated 
0.93 (0.50, 1.72) 0.82 0.86 (0.45, 
1.65) 
0.647 
 Poorly 
Differentiated  
1.42 (0.58, 3.49) 0.44 1.27 (0.50, 
3.27) 
0.616 
 Unknown 1.56 (0.76, 3.23) 0.23 1.09 (0.49, 
2.42) 
0.828 
 pt  0.09  0.85 
BC: breast cancer; HCP: health care provider including traditional and spiritual healers; WHR: waist hip ratio; pt: p-value for linear 
trend; PG: post-graduate; pt: p-value for linear trend; OR: odds ratio; CI: confidence interval; 
a Mutually-adjusted for all the other variables in the table. 
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DISCUSSION 
In this study, we examined the relationship between socio-demographic, breast cancer 
awareness, access to health care and clinical factors with late stage diagnosis of breast 
cancer at six tertiary and secondary level hospitals in two distinct regions of Nigeria. The 
findings showed that 67.7% women were diagnosed at late (III/IV) stages. The study 
identified lower educational level, being Christian, poor breast cancer awareness and poor 
health care access as being independent correlates of later stage at breast cancer diagnosis 
in Nigeria. In contrast, clinical and tumour features were not found to be related to stage 
at breast cancer diagnosis.  
This study is unique being the first multi-centre study to investigate socio-demographic, 
breast cancer awareness, health care access and clinical determinants of late stage 
diagnosis of breast cancer in two different regions in Nigeria. As the study was hospital-
based, breast cancer cases that do not reach a secondary or tertiary health facility to be 
diagnosed could not be included. However, the majority of breast cancer cases in Nigeria 
are diagnosed at tertiary health facilities where facilities for diagnosis and treatment are 
available and given our high response rate of ~95%, it is highly likely that our findings 
are a true representation of the all breast cancer cases diagnosed histologically in the cities 
included. The mean age at breast cancer diagnosis was similar to that reported by other 
studies conducted in Nigeria(60, 202) and other SSA countries.(145, 179) Although some 
authors have associated younger age at diagnosis with later stage at presentation,(203) 
others have found the reverse.(199) We did not find an association between age at 
diagnosis and stage. 
Breast cancer awareness is low in most African countries.(63) Most women in our study 
had heard about breast cancer, but only a few had good knowledge of its causes or 
symptoms, in line with the findings reported by other Nigerian studies.(204, 205) Women 
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in our study who did not practice BSE had higher odds of presenting later than women 
who did. Other authors have reported an association between education and practise of 
BSE.(206) While BSE has not been shown to be effective in early detection of breast 
cancer, the awareness it generates may prove useful in low-resource settings.(207) 
Access to health care is an important determinant of stage at diagnosis. Previous authors 
have reported variations in late stage breast cancer by region of residence.(208) Residing 
in areas with poorer access to health care, or taking longer time to travel for care, may 
increase the likelihood of a late stage diagnosis.(208) Women diagnosed in Enugu had 
greater odds of later stage than those diagnosed in Abuja, perhaps reflecting differences 
in access to health care between the two cities. Abuja is a more affluent city with many 
secondary and tertiary health care facilities within easy reach whereas in Enugu 
participants had to travel long distances, often from rural areas, to get to the participating 
hospital which is located on the outskirts of the city. In addition, with the high prevalence 
of private practice and the frequent strike action in government hospitals, it is possible 
that only those who could not afford private care sought care at the participating hospital. 
High percentages of late stage at diagnosis have also been reported from other studies in 
South-Eastern and Western regions of Nigeria which cater to a predominantly more rural 
population than Abuja.(60, 202, 209) In other similar settings, less developed areas 
reportedly have more advanced stage at diagnosis than the cities.(203) We also found 
stage at diagnosis to be significantly better in secondary level facilities than at tertiary 
centres, perhaps because women may first present at secondary facilities, which may 
delay their presentation at tertiary hospitals, but more research is needed to confirm this.  
Level of education was a strong determinant of stage at diagnosis in our study. Women 
with no education had significantly higher odds of later stage disease than women with 
tertiary education. Several studies in Nigeria(139), other SSA countries(78) and other 
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developing countries (e.g. Brazil(203)) as well as multi-ethnic studies in the US(134) 
have associated lack of education with later stage diagnosis of breast cancer. Educational 
level was also positively correlated with knowledge of breast cancer symptoms in our 
study similar to findings by Marcu et al. in the United Kingdom.(210) Interestingly, the 
association of educational level did not appear to be fully mediated by differences in 
breast cancer awareness or health care access, but the variables examined here may be 
too crude to fully capture these domains. Nevertheless, this finding has important 
implications for the development of educational interventions that can potentially 
improve the stage at diagnosis of breast in developing countries. 
We found no associations between tumour characteristics and later stage at breast cancer 
diagnosis. Obesity has been identified as a strong risk factor for late stage diagnosis in 
breast cancer.(211) However, in our study there was no association between BMI, or 
WHR, and later stage. As factors associated with later breast cancer stage were not related 
to the tumour biology, but to woman’s characteristics, they must act through increasing 
the time from onset of symptomatic disease to diagnosis at a health care facility. There 
are reports from other SSA settings of long patient-level and system delays which could 
result in considerable change in stage.(78) We observed a long delay from time of a 
woman noticing the first breast cancer symptoms to diagnosis at the recruiting hospitals, 
in line with previous reports of 12.1 months in Nigeria(82) and 10 months in Ghana.(160) 
Racial disparities have also been documented in the US with African-Americans 
reporting longer delays from first contact to diagnosis and from diagnosis to breast cancer 
treatment than Whites and significantly more advanced stage at diagnosis.(67) 
In this study, Muslim women were diagnosed at earlier stages than Christian women. This 
finding contrasts with previous studies that have reported less breast cancer early 
detection practices among Muslim women. We speculate that the Muslim women in this 
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study may belong to a higher socio-economic class than the Christian women, therefore 
may have the financial ability to seek care more readily. Secondly, Muslim women may 
be less likely to work outside the home and therefore would have the time to seek help 
once a breast symptom is felt without having to obtain permission from employers to get 
medical care. However, more research is needed to confirm this.  
In SSA, ensuring early diagnosis and treatment of symptomatic women is crucial for 
stage-migration of the disease and, hence, achieve better outcomes. In our study, breast 
cancer awareness and poor access to health care were identified as independent 
determinants of later stage at diagnosis in Nigeria. Most of these factors are amenable to 
change by awareness creation, educational and behavioural change interventions to 
diagnose breast cancer at earlier stages. Stage migration interventions have proven to be 
successful and cost effective in several low- and middle-income countries such as 
India(28), Malaysia(29), South Africa(30), Tanzania(31) and Sudan(32) following 
educational interventions, and need to be followed by appropriate treatment. In Sudan, 
the implementation of a cancer awareness and breast examination intervention program 
using trained local volunteers improved the early detection of breast abnormalities in 
women in rural communities.(32) In Tanzania, late stage diagnosis (stages III/IV) was 
reduced by 51% over three years after trained health personnel delivered an educational 
intervention that focused on the signs and symptoms of cancer, and subsequently screened 
women by clinical examinations and taking pictures of suspicious lesions.(31) More 
research is needed to characterise delays and factors associated with diagnostic delays in 
Nigeria, as well as in other SSA populations(160), as such knowledge is crucial to the 
development of context appropriate breast cancer control programs.  
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CHAPTER 5 
 
Determinants of Diagnostic Delays in Nigerian Women with Breast Cancer 
It has been widely established that diagnostic delays (delays in terms of breast cancer 
presentation and diagnosis) significantly contribute to the late stage diagnosis of breast 
cancer (69). In the previous chapter, it was reported that the majority of Nigerian women 
are diagnosed with breast cancer at late stages (III & IV). However, little is understood 
about a woman’s journey to a breast cancer diagnosis, and why diagnostic delays occur 
in Nigerian women. This study was conducted to identify the extent and determinants of 
delays in women diagnosed with breast cancer and the impact of these delays on the stage 
of the disease. The sociodemographic, breast cancer awareness, health care access and 
clinical factors that may contribute to diagnostic delays in Nigerian women were 
examined.  Finally, the self-reported reasons that were formerly identified to deter the 
early presentation and diagnosis in Nigerian women are presented. 
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5.1. INTRODUCTION 
5.1.1. Background  
Breast cancer in SSA is often characterised by late presentation, an advanced stage of the 
disease at diagnosis, and a younger demographic than in the case of HICs (63). Research 
into the delays in terms of breast cancer presentation and diagnosis is crucial for cancer 
control because of the increasing evidence demonstrating an association between the time 
from the onset of the symptoms to the diagnosis and stage of the disease, and in turn to 
its impact on breast cancer survival (212). A delayed period of time prior to diagnosis has 
been identified as a significant contributor to the late stage diagnosis in Nigeria and other 
developing countries (69). Although screening programmes for breast cancer have been 
introduced in many HICs, this is not the case in most SSA countries, where a cancer 
diagnosis is usually made after the onset of symptoms and not by means of screening. 
With the tumour growth already causing symptoms, any additional delays can 
significantly worsen cancer outcomes, and therefore an early diagnosis of symptomatic 
breast cancer is crucial (75). The findings collated from a meta-analysis of 87 studies 
indicated that women who begin treatment 3-6 months after noticing breast cancer related 
symptoms have poorer chances of survival than women who wait < 3 months only (213). 
Longer waiting times or delays prior to diagnosis could lead to disease progression or 
treatment complications in women with breast cancer (69).  
The severity of the late stage at breast cancer diagnosis reported in the previous chapter 
(67.7% stage III/IV), i.e. with 14% having a tumour size greater than 2 cm and 38% 
greater than 5 cm, indicates that the tumours are not only detected at the symptomatic 
stage, but that, on average, they are detected sometime after they become palpable 
(around 2 cm). Reducing this pre-diagnostic symptomatic period would lead to an early 
stage at diagnosis and the potential of improved survival rates, but first the drivers of this 
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period need to be understood. Using the established tumour growth model curve by 
Weedon-Fekjaer et al. (35) a range of median tumour sizes reported in the systematic 
review presented in Chapter 2 were plotted against the average number of months since 
the tumour measured 3 cm and was hence definitely palpable (Figure 1). This figure 
suggests that women with larger tumour sizes were more likely to experience delays in 
seeking help after the tumour had become palpable at 3 cm (Figure 1). Targeting and 
shortening the pre-diagnosis symptomatic window is the action required for early 
diagnosis in the SSA setting.  
Figure 1: Relationship between tumour size and delays in diagnosis as predicted by the tumour 
growth model developed by Weedon-Fekjaer et al. (35)
 
5.2 BREAST CANCER DELAY: DEFINITION AND CLASSIFICATION 
5.2.1 Total Delay in Breast Cancer  
The total delay in breast cancer was first described by Pack and Gallo in 1938(214). With 
reference to breast cancer, total delay has been defined as the time lapsed from the 
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discovery of symptoms, which are constituted by a breast lump in the majority of women 
(215), to the start of breast cancer treatment (70). This time-period has been divided into 
two main intervals of patient delay and provider or system delay. Delays could occur at 
different stages of the pathway from when a woman first notices a symptom to her 
presentation to a health care provider (patient delay) and from the initial presentation to 
the diagnosis and commencement of treatment (provider delay) (69). Longer total delay 
exerts a negative influence on breast cancer survival, as it is associated with an advanced 
stage at diagnosis and poor prognosis (216). A previous study by Richards et al. 
conducted in London, United Kingdom in 1999 (217), estimated that approximately one 
third of the women experiencing symptoms of breast cancer, delayed seeking help for at 
least 3 months, whereas approximately a quarter of these women will delayed seeking 
care for a period of 6 months or longer (218). In Nigeria, Ezeome et al. reported a delay 
of > 3 months in over 70% of patients (60).  
5.2.2 Patient or Pre-contact Delay 
In 2014, Lee Caplan defined patient delay as a delay in seeking medical attention after 
noticing a potential breast cancer symptom (69). Others have defined patient delay as a 
time interval of over 3 months between symptom detection and the first medical 
consultation (6). There is substantial evidence to suggest that in women with breast 
cancer, patient delay exceeding 3 months is associated with late stage diagnosis and 
poorer chances of survival (219, 220). Nevertheless, this has not been previously studied 
in the Nigerian population.  
5.2.3 Provider or Post-contact Delay 
Provider delay, defined as the time from the first medical consultation to the beginning 
of the definitive treatment, has been further divided by some authors into diagnosis delay; 
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namely the time between the first medical consultation and the cancer diagnosis, and 
treatment delay; or the time between diagnosis and the beginning of treatment (221).  
However, the terms pre-contact and post-contact are preferred and will be used 
throughout this study. This is because the terms ‘patient’ and ‘provider delay’ assume that 
the responsibility for the first interval (time from when a symptom is first noticed to 
presentation at a care provider) is attributed entirely to the patient, whereas the 
responsibility for the second interval (time from first medical consultation to the 
beginning of definitive treatment) is attributed to the provider. Such mutually exclusive 
definitions are not appropriate in settings wherein there is no universal access to health 
care, as in the case of the SSA settings. For instance, a woman who has sought the 
assistance of a care provider and has been diagnosed with breast cancer may experience 
delays in returning for treatment following the initial consultation due to issues such as 
financial constraints, preference for unorthodox treatments (e.g. by traditional and 
spiritual healers), or a lack of belief in a cure for breast cancer. Therefore, delays after the 
first visit to a care provider should not be exclusively assigned to factors related to health 
care providers, as the factors affecting a woman’s decision to delay treatment may also 
play a substantial role. Similarly, a woman may delay a visit to the first care provider after 
noticing a breast symptom because there may be an industrial strike action and the 
hospitals within easy access of her residence may be closed. In this case, some element 
of the delay may be assigned to the health system. 
 
5.2.4 Factors Associated with Delays in the Breast Cancer Diagnosis 
There is a scarcity of information related to the delays occurring between symptom 
recognition and breast cancer diagnosis in women with symptomatic breast cancer in 
SSA. A search of the literature for studies of delayed presentation in breast cancer 
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returned 22 results, with the duration of the total delay ranging from 2 to 13.3 
months(133). However, only 5 of these previous studies (60, 81, 82, 139, 222) included 
relevant information on the factors associated with diagnostic delays in Nigerian women. 
These studies have suggested that cultural beliefs, fear of a breast cancer diagnosis and 
use of alternate medical practitioners, such as pharmacists and traditional healers, 
contribute to the aforementioned delays. However, none of these studies have examined 
the specific factors related to these delays in detail or reported on the magnitude of the 
impact that these factors have on the time to presentation and diagnosis. In some SSA 
countries, traditional healers represent an accessible, easily available and less expensive 
health care resource. Patients widely seek traditional treatment due to widespread beliefs 
in the efficacy of traditional and spiritual medicine (223). In Zimbabwe, the government 
legitimised traditional medicine in 1980 and this facilitated the collaborative work 
between traditional healers and the ministry of health. In Nigeria, in a study of 162 
patients with breast cancer, 17.5% visited a traditional healer before seeking orthodox 
care (60).  
In other sub-Saharan African countries, older age, a lower educational level and the 
distance to the health care providers have been associated with considerable diagnosis 
delays (78). In developed countries, an ethnic minority and low socio-economic status, 
along with younger age have been associated with treatment delays (224). Others have 
reported older age, symptoms other than breast lumps, fear of treatment and 
pregnancy/post pregnancy anxiety as contributing factors (225, 226). In Nigeria, with 
very few studies conducted on this topic, the strength of the current evidence in the 
country is inadequate to develop appropriate context-specific strategies to shorten the 
delays in women who are diagnosed with breast cancer. One major limitation of the 
previous studies is that they relied on hospital records, which may not have been obtained 
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in a standardised manner. Additionally, the reasons why women delay in seeking care are 
often not well documented in many LMICs, including Nigeria (63). 
 
5.3 ACCESS TO HEALTH CARE SERVICES   
Delay and Access to Health Care Services in the Nigerian Context 
The aforementioned definitions of delays in cancer treatment commencement constitute 
useful conceptual and analytical tools in many settings, but their definitions have been 
largely modelled on western health care systems, and often on the basis of countries where 
national public health systems are in place. In these contexts, the patient and provider 
delays can be partitioned because after the first provider contact, the healthcare system 
had an opportunity to cater for appropriate referral and the responsibility to guide the 
patient to the next diagnostic or treatment stage. However, in Nigeria, the pathway to 
cancer diagnosis and treatment is complex, as it is often the case in many LMICs (77). 
Several studies have reported that the time to diagnosis may be influenced by health care 
access and utilisation in many settings (77). Limited access to health care has been shown 
to contribute to diagnostic delays and disparities in breast cancer outcomes in many 
populations (227). However, this has not been fully explored in the Nigerian setting. In 
Nigeria, although the health care sector is largely driven by the public sector (66%), there 
is a substantial private sector that also provides health care to the population (228) with 
heterogeneity in the type and quality of the services provided in both sectors. The 
provision of health care in the country is the function of the 3 governmental tiers, namely 
the federal, state and local government (229). The primary health care (PHC) system is 
the first level of care and it is managed by the local government institutions. The state 
ministries of health and private medical practitioners provide support to the PHC system. 
Patients from the PHC are often referred to the secondary health care system that provides 
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the first level of specialist intervention offering laboratory and diagnostic services. The 
tertiary health care system is driven by the university teaching hospitals and specialist 
hospitals that provide care and treatment for breast cancer patients (229). Prior to the 
advancement of orthodox medicine, and in spite of the hierarchical health care system, 
traditional medicine which was the widely recognised health care system in the past, is 
still practised in many SSA countries and in Nigeria (230). In this study, we will consider 
the health care service to include both orthodox and unorthodox care providers, including 
traditional healers. Financial implications are also a major consideration for women who 
access healthcare in Nigeria, with a very small proportion of the Nigerian population 
covered by health insurance (228). Even in cases where health insurance is available, 
cancer treatment is often not included in the package provided. It is possible that these 
challenges experienced in terms of accessing health care may partially contribute to 
diagnostic delays in the country. 
While a reasonably small element of delay is inherently inevitable in cancer diagnostic 
pathways (231), it is likely for the delay identified in the case of a significant number to 
be largely preventable. Preventing diagnostic delays involves primarily identifying the 
factors that contribute to the delays in the Nigerian setting and using these as a foundation 
in the development of strategies seeking to reduce diagnostic delays in Nigerian women.  
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5.4 METHODS  
Study Design and Setting 
Starting from January 2014, within the framework of an ongoing multicentre case control 
study of breast cancer in Nigeria, namely the Nigerian Integrative Epidemiology of Breast 
Cancer Study (NIBBLE), potential cases were women aged >18 years who presented with 
symptoms highly suggestive of primary breast cancer at the surgical outpatient 
departments (SOPD) of six government hospitals in Nigeria and the oncology 
departments of two of these hospitals (NHA and UNTH). These women were 
subsequently found to have either malignant breast carcinoma or benign breast lesions. 
The present analysis was initially conducted on all women who presented with symptoms 
highly suggestive of primary breast cancer and was then restricted to those who were 
subsequently confirmed to have a newly-diagnosed primary invasive breast cancer. The 
controls in the NIBBLE study did not contribute to the analyses shown in this chapter. A 
detailed description of the study sites and setting and of the methodology used is provided 
in Chapter 3 of this thesis. 
Participant Recruitment  
A face-to-face interview with each eligible woman was conducted by a trained research 
nurse at each of the study sites. Three pre-tested and piloted structured questionnaires 
were used in order to collect information on various sociodemographic (e.g. age, marital 
status, religion, educational level, socioeconomic class and number of children), breast 
cancer awareness (e.g. previous knowledge of breast cancer, knowledge of treatment/cure 
for breast cancer, knowledge of breast cancer and symptoms), health care access (e.g. 
region of residence, type of facility where a diagnosis was made, time taken from the first 
symptom to the first provider, number of health care providers visited before a diagnosis 
was made) and clinical variables (e.g. previous history of benign breast disease, family 
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history of breast cancer, previously diagnosed hypertension or diabetes, body mass index, 
waist hip ratio and the stage at breast cancer diagnosis) and on the patient’s journey from 
the first symptom, and health care providers visited to their eventual presentation and 
diagnosis at the recruiting hospital. Information on the symptom duration was collected 
and patients were asked to provide reasons for the delays where applicable. All 
measurements were performed using a standardised protocol.  
Written informed consent was sought and received from all participants. Ethical approval 
for the study was obtained from the health research ethics committees (HRECS) at each 
study site, the National Health Research Ethics Committee Nigeria (NHREC), the 
University of Maryland Baltimore and the London School of Hygiene and Tropical 
Medicine. 
Statistical Analyses 
 
Outcome Variables in Delay Analyses 
Patient delay (pre-contact delay) was defined as the number of months from the first 
reported symptom to the patient’s first presentation to any care provider. Post-contact 
delay was defined as time in months from the presentation at the first care provider to 
diagnosis. Total delay in this study was defined as the time (in months) from the first 
reported symptom to the diagnosis at the recruiting hospital, i.e. pre-contact and post-
contact delays combined. When patients were unable to provide a date for when their first 
symptoms were noticed, they were asked to provide a month and a year. If the month was 
provided, the estimated date was the midpoint of the month – or in other words the 15th 
of that month. If they only provided information on the year when the symptom was 
noticed, the estimated date was the last day of the middle month of that year, namely June 
30th of that year. Previous studies have classified delay into “no delay” and “delay” using 
a cut-off period of 1 month (83) or 3 months (82). In our study, patient delay was defined 
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using the term “pre-contact delay” i.e. the delay prior to the first contact with the first care 
provider and was classified into “no delay” if it took less than 3 months from the onset of 
symptoms to the presentation to a care provider or “delay” if it took > 3 months. Care 
providers in this instance were orthodox (private or public hospitals, pharmacies, 
community clinics and private general practitioners) or unorthodox (traditional healers, 
churches and pastors). A time-period of < 3 months was classified as “no delay”, whereas 
a period of > 3 months was classified as “delay”. We further categorised women with 
delay into 3 groups of 3 to < 6 months, 6 months to < 12 months, and > 12 months. Despite 
the cut-off period of 1 or 3 months used in order to classify delays in previous studies, the 
factors associated with breast cancer delay have been reportedly similar (71). 
In women with breast cancer, the clinical stage of the patients was determined using the 
tumour node metastasis classification of the AJCC staging system (as described in 
Chapter 1). Patients were classified into stages I, II, III and IV with stages I/II being 
defined as early stage breast cancer and stages III/IV being defined as late stage breast 
cancer.  
Information on the total number of providers visited by the women was reported. We 
categorised women into 3 groups, namely women who had visited 1, 2 or > 3 providers 
before a diagnosis was made at the recruiting hospital. The type of the health facility 
visited was also recorded. Detailed information on whether a woman visited a private GP, 
public or private hospital, community health centre/clinic sister or nurse, or other 
providers such as traditional healers, chemists or churches was also collected. These were 
then categorised into three groups designated as “private clinic/hospital” (including 
private GP), “public clinic/hospital”, and “others”, with the latter encompassing 
traditional healers, churches, community health centres and clinic sisters due to the small 
numbers in this group. 
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Regression Analysis 
Delay (post-contact and total) were first examined as explanatory variables and their 
relationship to late stage at diagnosis was studied. Logistic regression was used to 
estimate the odds ratio for late (stages III/IV) versus early stages (stages I/II).  
Thereafter, pre-contact, post-contact and total delays were analysed as the outcome, with 
each constituting continuous variables in each case. Normal errors linear regression 
models were used in this instance. Initial boxplots and histograms were created for the 
continuous variable in order to identify potential outliers, check the plausibility of the 
delay times and prepare the data for analysis (Appendix 8: Figure 1). As the temporal 
distribution from the onset of symptoms to the final diagnosis was not normally 
distributed, this outcome was log transformed before modelling it as the outcome 
(Appendix 8: Figures 2 - 4). Beta coefficients represent the differences in the log delay 
times. As a result the exponentiated beta coefficients and their 95% CIs are presented as 
they provide a more meaningful comparison, namely the ratio of the geometric mean 
delay time associated with the comparison in question. Two linear regression models 
were implemented in order to examine the association of each of the factors (e.g. 
sociodemographic, breast cancer awareness, health care access and clinical factors) with 
the delay (pre-contact, post-contact and total) – first in all women presenting breast cancer 
symptoms and then restricting the examination to the women with a confirmed breast 
cancer diagnosis. Then in the fully adjusted models including the number of women 
presenting with breast symptoms and the ones diagnosed with breast cancer, a stepwise 
variable selection was performed to include variables that were significant at the 0.1 level 
from both initial linear regression models. Two variables, namely the stage at diagnosis 
in women with breast cancer and the number of providers visited, though significant at 
the 0.1 level were not included in the fully adjusted models as these were regarded as 
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consequences of the delay (stage) or part of the same pathway, and thus highly correlated 
(number of providers).  
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5.5 RESULTS 
Participant Characteristics  
There were 512 women who presented with breast symptoms and were recruited into the 
Nigerian Integrative Epidemiology of Breast Cancer Study (NIBBLE). Among these, 430 
(84%) had information in relation to the date of first symptom, the date of first contact 
and the date of diagnosis and were subsequently included in this study. Some, 266/430 
(61.9%) had histologically confirmed breast cancer. The characteristics of the study 
participants are presented in Tables 1 and 2. The majority of the women who presented 
with symptoms were married (73.2%), Christian (86.5%), had tertiary education (51.9%) 
and a personal income (70.5%). The median (IQR) number of children per woman was 3 
(1-5). Overall, 82.6% had previous knowledge of breast cancer, 78.6% resided in Abuja, 
and 16.3% had a previous history of benign breast disease. On average, women visited 2 
(1-3) median (IQR) care providers, including the hospital where the recruitment took 
place and where a breast cancer diagnosis was confirmed. The mean (SD) patient age was 
44.4 (11.8) in all women and 45.2 (11.3) in the women with breast cancer. In the case of 
all women with suspicious symptoms, the median (IQR) pre-contact delay, post-contact 
delay and total delay were 2.6 (0.6-8.3), 3.1 (0.8-8.7) and 7.8 (3.3-18.7) months, 
respectively. In women with breast cancer, these were 3.0 (0.8-8.5), 3.5 (0.8-8.3) and 7.6 
(3.9-18.2) months, respectively. The diagnostic journey of 80 randomly selected women 
from the onset of the first symptoms to the visits to the care providers is shown in Figure 
2 and suggests that a large number of women delay in seeking care (patient or pre-contact 
delay), with a similar proportion of women being delayed by the health care system 
(provider or post contact delay) (Figure 3). Only 18.1% of all women with symptoms and 
12.4% of the subset with breast cancer sought care within 3 months of noticing a breast 
symptom (Table 2).  
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Delay and Stage at Diagnosis Using Logistic Regression 
On average, women diagnosed in stages III/IV self-reported 36% longer total delay times 
than those in stages I/II. In the unadjusted analysis, when compared with the delays of < 
3 months, both post-contact and total delays showed a significant trend suggestive of late 
stage disease, pt= 0.028 and pt=0.004 for post-contact and total delays, respectively 
(Figure 4). 
Table 1: Characteristics of the study population of women presenting with breast symptoms in 
Nigeria 
Characteristics  All Women with 
Breast Symptoms 
N (%) 
Subset of women 
with Breast   
Cancer N (%)  
Sociodemographic Total no. of women a 430 (100)  266 (100) 
Age at diagnosis (years) Mean age (SD) 44.4 (11.8)  45.2 (11.3) 
Marital status Married  315 (73.2) 194 (72.9) 
Religion  Christianity  372 (86.5) 234 (87.9) 
 Islam  55 (12.8) 32 (12.1) 
Education  None 58 (13.5) 40 (15.0) 
 Primary/Secondary  148 (34.4) 99 (37.2) 
 Tertiary/Post-graduate  223 (51.9) 127 (47.8) 
Socioeconomic class Low 182 (42.3)  124 (46.6)  
(using household data) Middle 173 (40.2)  93 (35.0) 
 High 75 (17.5)  49 (18.4) 
Do you have a personal 
income?  
Yes 303 (70.5)  187 (70.3) 
 No  127 (29.5)  79 (29.7) 
Number of children  None  26 (6.0) 19 (7.1) 
 1-2 110 (25.6)  62 (23.3) 
 3-4 119 (27.7)  82 (30.9) 
 > 5  113 (26.2) 70 (26.3) 
 Not reported  62 (14.5) 33 (12.4) 
Breast cancer awareness     
Ever heard of breast 
cancer  
Yes 355 (82.6)  219 (82.3) 
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Characteristics  All Women with 
Breast Symptoms 
N (%) 
Subset of women 
with Breast   
Cancer N (%)  
 No  74 (17.2) 47 (17.7)  
Knowledge of BC 
symptoms b 
Poor 225 (52.3)  145 (54.5)  
 Fair 143 (33.3)  85 (32.0) 
 Good 62 (14.4)  36 (13.5) 
Belief in a cure for BC Yes  248 (57.7)  157 (59.0) 
 No  177 (41.7) 107 (40.2) 
 Don’t know  5 (0.6)  2 (0.8) 
Practise SBE Yes 194 (45.2) 116 (43.6)  
 No  210 (48.8)  135 (50.8)  
 Never heard of / 
Unknown 
26 (6.0)  15 (5.6) 
First symptom Breast lump 381 (88.6)  233 (87.6) 
 Other symptom * 49 (11.4)  33 (12.4) 
Health care access    
Region of residence North Central (Abuja) 338 (78.6)  192 (72.2) 
 South East (Enugu) 92 (21.4)  74 (27.8) 
Type of health facility 
where the diagnosis was 
made 
Tertiary  330 (76.7)  216 (81.2) 
 Secondary  100 (23.3) 50 (18.8)  
Journey time taken to first 
provider  
< 1 hour 263 (61.2) 152 (57.1) 
 1 hour - < 2 hours  61 (14.2) 39 (14.7) 
 >= 2 hours  27 (6.3) 18 (6.8) 
 Not reported  79 (18.3)  57 (21.4) 
Clinical     
Previous benign breast 
disease (BBD) 
Yes  70 (16.3) 44 (16.5) 
Previously diagnosed HTN 
or diabetes  
Yes 101 (23.5) 70 (26.3) 
Family history of BC Yes 36 (8.4)  22 (8.3) 
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Characteristics  All Women with 
Breast Symptoms 
N (%) 
Subset of women 
with Breast   
Cancer N (%)  
    
BMI  < 25 (normal weight) 131 (30.4)  78 (29.3) 
 25-29 (overweight) 134 (31.2) 91 (34.2) 
 > 30 (obese) 150 (34.9)  89 (33.5)  
WHR < 0.80 (low) 52 (12.1) 25 (9.4) 
 0.8-0.85 (moderate)  79 (18.4)  49 (18.4) 
 > 0.85 (high)  286 (66.5) 187 (70.3) 
aAll women: Unknown religion = 3 (0.7%), Unknown education = 1 (0.3%) Unknown knowledge of BC = 1 (0.2%), Unknown BBD 
= 4 (1.0%) Unknown BMI = 15 (3.5%) Unknown WHR = 13 (3%) 
Breast cancer: Unknown BBD = 1 (0.4%), Unknown BMI = 8 (3.0%) Unknown WHR = 5 (1.9%) 
*Other symptoms included underarm swelling, nipple discharge and change in the breast shape or size. 
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Table 2: Description of the outcome variables - time to diagnosis, number and type of providers 
visited and stage at diagnosis in Nigerian women 
Variables  Description All women with 
breast symptoms 
 N (%) 
Women with 
breast cancer 
only N (%) 
Total number of 
women  
  430 (100) 266 (100) 
Months to 
diagnosis  
Months from first 
symptom to 
presentation* (Pre-
contact delay) 
 
Median 
(IQR) 
 
2.6 (0.6-8.3) 
 
3.0 (0.8-8.5) 
Months from 
presentation to 
diagnosis (Post-
contact delay) 
Median 
(IQR) 
3.1 (0.79-8.7) 3.5 (0.8-8.3) 
Months from first 
symptom to diagnosis 
(Total delay) 
 
Median 
(IQR) 
 
7.8 (3.3-18.7) 
 
7.6 (3.9- 18.2) 
No. of providers 
contacted a  
1 142 (33.0) 83 (31.2) 
 2 193 (44.8) 121 (45.5) 
 3 70 (16.3) 44 (16.5) 
 4 16 (3.7) 13 (4.9) 
 5  5 (1.2) 4 (1.5) 
 6 2 (0.5) 1 (0.4) 
First provider 
contacted  
Private clinic/Hospital 130 (30.2) 85 (32.0) 
 Public clinic/Hospital 265 (61.6) 158 (59.4) 
 Others b 31 (7.2) 21 (7.9) 
Total delay 
categories  
< 3 months 78 (18.1) 33 (12.4)  
 3-< 6 months 80 (18.6) 56 (21.0) 
 6-< 12 93 (21.6) 68 (25.6) 
 12-< 18 64 (15.0) 41 (15.4) 
 >= 18 115 (26.7) 68 (25.6) 
Stage at diagnosis 
(n=255) 
I/II - 79 (31.0) 
 III/IV - 176 (69.0) 
 a All women: Unknown number of providers = 2 (0.5%) Unknown first provider = 4 (1.0%), 
BC: Breast cancer: Unknown first provider = 2 (0.7%),  
b Others for all women with breast symptoms = 31, (Traditional healer - 2, Church/pastor-3, Chemist/pharmacist - 14, Community-
based worker - 8 & Other hospital staff - 4) Others for women with breast cancer = 21 (Traditional healer - 1, Church/pastor - 3, 
Chemist/pharmacist - 8, Community-based worker - 6 & Other hospital staff - 3) 
*Presentation at any care provider 
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Figure 2: Pre- and post-contact diagnostic journey of 80 randomly selected women from the onset 
of the first symptoms to the first 4 visits to care providers 
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5.5.1 FACTORS ASSOCIATED WITH PRE- AND POST-CONTACT DELAYS  
Pre-contact delay  
In the unadjusted analysis in women with breast cancer, no factors associated with pre-
contact delays were identified (results not shown). In the fully adjusted analysis, only one 
factor, i.e. having 3-4 children compared to having none (OR 2.25; 95% CI 1.01, 5.03; 
p=0.048) was associated with delays in women with breast cancer. No factors associated 
with pre-contact delays in all women with symptoms were identified in the unadjusted 
and fully adjusted analyses. 
Post-contact delay 
In all women with breast symptoms, increasing age (pt=0.024), a lower educational level 
(pt=0.023), having 5 or more children (p=0.042), no personal income (OR 1.38; 95% CI 
1.00, 1.90; p=0.047) and an increasing number of providers visited (pt<0.001) were 
positively associated with post-contact delays in the unadjusted analysis, while the 
presentation at a secondary facility and having no previous history of benign breast 
disease (OR 0.45; 95% CI 1.01, 5.03; p=0.001) were inversely associated (Table 3). 
Patient knowledge of breast cancer symptoms was borderline significant (Table 3). In the 
fully adjusted analysis, the effect of having no personal income was amplified and no 
previous history of BBD remained significant (Table 4). The effect of a lower educational 
level on post-contact delays was no longer significant when knowledge of breast cancer 
symptoms was introduced into the model. 
In the unadjusted analysis for women with breast cancer, a lower educational level 
(pt=0.044), an increasing number of providers visited (pt=0.014) and the region of 
residence (OR 1.54; 95% CI 1.01, 2.36; p=0.047) were positively associated with post-
contact delays. Not having a personal income was borderline significant (OR 1.47; 95% 
CI 0.98, 2.22; p=0.064). The type of health facility visited (i.e. secondary) was inversely 
  
 
174 
  
associated with post-contact delays, whereas women with no previous history of benign 
breast disease were more likely to delay treatment (Table 3). In the fully adjusted analysis, 
only personal income and a previous history of BBD remained significantly associated 
with post-contact delays (Table 4). The effect of education was weakened, but still 
remained significant when the income variable was included in the model. However, it 
was further attenuated when knowledge of symptoms was introduced into the model. The 
effect of the region of residence on delays was no longer significant when the type of 
facility visited was included in the model (Table 4). 
Table 3: Factors associated with post-contact delays – unadjusted model  
Characteristics  Categories  All women with 
breast 
symptoms 
Unadjusted 
model  
Ratio (95% CI) 
P value  Women with 
breast cancer 
only  
Unadjusted 
model 
Ratio (95% CI) 
P value  
Sociodemographic      
Age at diagnosis < 40 1   1  
 40-49 1.12 (0.80, 1.58)  0.509 1.03 (0.67, 1.62) 0.862 
 50-59 1.28 (0.85, 1.95) 0.240 1.01 (0.58, 1.75) 0.982 
 > 60 1.71 (0.99, 3.06) 0.069 1.77 (0.85, 3.68) 0.128 
 P for trend per 10 
years  
 0.024  0.131 
Marital status  Married  1  1  
 Single  1.18 (0.84, 1.65) 0.329 1.35 (0.87, 2.09) 0.176 
Religion  Christian  1  1  
 Muslim  0.88 (0.55, 1.40) 0.594 0.85 (0.46, 1.56) 0.595 
Socioeconomic class High  1  1  
 Middle  0.92 (0.59, 1.42) 0.710 0.72 (0.42, 1.23) 0.227 
 Low  1.03 (0.66, 1.58) 0.910 0.87 (0.51, 1.46) 0.589 
 P for trend   0.750  0.829 
Educational level 
attained  
Tertiary/Postgra
duate 
1  1  
 Primary/Second
ary  
0.97 (0.70, 1.34)  0.852 1.05 (0.70, 1.59) 0.803 
 None  1.72 (1.09, 2.71) 0.019 1.83 (1.03, 3.26) 0.039 
 P for trend   0.023  0.044 
Personal income Yes 1  1  
 No 1.38 (1.00, 1.90) 0.047 1.47 (0.98, 2.22) 0.064 
Total number of 
children  
None  1  1  
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Characteristics  Categories  All women with 
breast 
symptoms 
Unadjusted 
model  
Ratio (95% CI) 
P value  Women with 
breast cancer 
only  
Unadjusted 
model 
Ratio (95% CI) 
P value  
 1-2 0.90 (0.47, 1.72) 0.747 1.09 (0.51, 2.38) 0.808 
 3-4 1.03 (0.54, 1.96) 0.932 0.94 (0.45, 1.98) 0.876 
 5 or > 1.9 (01.02, 3.71) 0.042 1.90 (0.89, 4.05) 0.094 
 P for trend   0.110  0.343 
Breast cancer 
awareness  
     
Ever heard of breast 
cancer  
Yes  1  1  
 No  1.15 (0.77, 1.71) 0.495 1.16 (0.68, 1.99) 0.572 
Practise SBE Yes 1  1  
 No  1.08 (0.79, 1.47) 0.627 1.10 (0.75, 1.64) 0.609 
 Never heard of 
SBE 
0.98 (0.51, 1.87) 0.944 0.83 (0.36, 1.89) 0.652 
Knowledge of BC 
symptoms 
Good  1  1  
 Fair  1.25 (0.79, 1.98) 0.337 1.23 (0.79, 1.93) 0.361 
 Poor  1.51 (0.98,2.33) 0.063 1.38 (0.89, 2.11) 0.142 
 P for trend  0.060  0.176 
Belief in a cure for 
BC 
Yes 1  1  
 No  1.22 (0.90, 1.65) 0.192 1.18 (0.89, 1.57) 0.243 
First symptom  Breast lump 1  1  
 Other symptom 0.83 (0.52, 1.32) 0.434 0.80 (0.45, 1.44) 0.464 
Health care access       
Region of residence  North Central 
(Abuja) 
1  1  
 South East 
(Enugu)  
1.39 (0.96, 2.01) 0.084 1.54 (1.01, 2.36) 0.047 
Facility type Tertiary  1  1  
 Secondary  0.69 (0.48, 0.99) 0.045 0.69 (0.42, 1.13) 0.140  
Time taken to first 
provider  
< 1 hour  1  1  
 > 1 hour-< 2 
hours  
0.84 (0.55, 1.28) 0.411 0.76 (0.50, 1.14) 0.176 
 > 2 hours 1.06 (0.56, 2.00) 0.848 0.79 (0.45, 1.38) 0.408 
 P for trend  0.771  0.182 
No. of providers 
visited before 
diagnosis 
1 1  1  
 2 1.41 (0.95, 2.10) 0.088 1.27 (0.91, 1.77) 0.165 
 >= 3 2.25 (1.45, 3.49) <0.001 1.63 (1.10, 2.41) 0.014 
 P for trend   <0.001  0.014 
Clinical       
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Characteristics  Categories  All women with 
breast 
symptoms 
Unadjusted 
model  
Ratio (95% CI) 
P value  Women with 
breast cancer 
only  
Unadjusted 
model 
Ratio (95% CI) 
P value  
Previous benign 
breast disease (BBD) 
Yes 1  1  
 No  0.61 (0.42, 0.89) 0.01 0.45 (0.28, 0.73) 0.001 
Previously diagnosed 
HTN or diabetes  
Yes  1  1  
 No 1.12 (0.78, 1.60) 0.529 1.32 (0.84, 2.08) 0.220 
Family history of BC Yes 1    
 No 0.94 (0.54, 1.61) 0.809 0.86 (0.42, 1.75) 0.668 
BMI  < 25 (normal 
weight) 
1  1  
 25-29 
(overweight) 
0.22 (0.07, 0.72) 0.01 0.28 (0.04, 1.81) 0.180 
 > 30 (obese) 0.20 (0.06, 0.62) 0.005 0.22 (0.03, 1.36) 0.100 
 Unknown  0.21 (0.07, 0.65) 0.007 0.22 (0.03, 1.37) 0.101 
 P for trend   0.990  0.987 
WHR < 0.80 (low) 1  1  
 0.8-0.85 
(moderate)  
1.87 (1.07,3.24) 0.027 1.72 (0.76, 3.89) 0.191 
 > 0.85 (high)  1.53 (0.95, 2.45) 0.077 1.38 (0.67, 2.82) 0.380 
 P for trend   0.122  0.103 
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Table 4: Factors associated with post-contact delays - fully adjusted model  
 
 
 
Patient Characteristics  
All women with breast symptoms Breast cancer  
Unadjusted  P value Fully 
adjusted*#  
P value  Unadjusted  P value  Fully adjusted*#  P value  
Age at diagnosis < 40 1   1  1  1  
 40-49 1.12 (0.80, 1.58) 0.509 1.14 (0.79, 1.65) 0.470 1.03 (0.67, 1.62) 0.862 1.17 (0.74, 1.86) 0.495 
 50-59 1.28 (0.85, 1.95) 0.240 1.03 (0.65, 1.64) 0.884 1.01 (0.58, 1.75) 0.982 0.91 (0.51, 1.65) 0.761 
 > 60 1.71 (0.99, 3.06) 0.069 0.96 (0.49, 1.88) 0.902 1.77 (0.85, 3.68) 0.128 1.15 (0.50, 2.66) 0.731 
 P for trend per 10 years   0.024  0.561  0.131  0.702 
Educational level attained  Tertiary/Postgraduate 1  1  1  1  
 Primary/Secondary  0.97 (0.70, 1.34)  0.852 0.81 (0.57, 1.13) 0.216 1.05 (0.70, 1.59) 0.803 0.96 (0.63, 1.47) 0.164 
 None  1.72 (1.09, 2.71) 0.019 1.16 (0.69, 1.95) 0.577 1.83 (1.03, 3.26) 0.039 1.34 (0.72, 2.50) 0.358 
 P for trend   0.023  0.578  0.044  0.454 
Personal income Yes 1  1  1  1  
 No 1.38 (1.00, 1.90) 0.047 1.49 (1.04, 2.00) 0.030 1.47 (0.98, 2.22) 0.064 1.51 (0.98, 2.31) 0.060 
Total number of children  None  1    1    
 1-2 0.90 (0.47, 1.72) 0.747 0.87 (0.46, 1.64) 0.681 1.09 (0.51, 2.38) 0.808 0.98 (0.47, 2.01) 0.963 
 3-4 1.03 (0.54, 1.96) 0.932 1.04 (0.54, 1.94) 0.898 0.94 (0.45, 1.98) 0.876 0.89 (0.43, 1.82) 0.746 
 5 or > 1.94 (1.02, 3.71) 0.042 1.88 (0.96, 3.67) 0.064 1.90 (0.89, 4.05) 0.094 1.73 (0.80, 3.74) 0.161 
 P for trend   0.110  0.310  0.343  0.901 
Region of residence  North Central (Abuja) 1  1  1  1  
 South East (Enugu)  1.39 (0.96, 2.01) 0.084 1.15 (0.79, 1.68) 0.466 1.54 (1.01, 2.36) 0.047 1.31 (0.83, 2.06) 0.241 
Facility type Tertiary  1  1  1  1  
 Secondary  0.69 (0.48, 0.99) 0.045 0.76 (0.52, 1.11) 0.153 0.69 (0.42, 1.13) 0.140 0.76 (0.46, 1.26) 0.285 
Knowledge of BC 
symptoms 
Good  1  1  1  1  
 Fair  1.25 (0.79, 1.98) 0.337 1.19 (0.75, 1.88) 0.459 1.23 (0.79, 1.93) 0.361 1.19 (0.75, 1.88) 0.459 
 Poor  1.51 (0.98,2.33) 0.063 1.30 (0.82, 2.06) 0.270 1.38 (0.89, 2.11) 0.142 1.30 (0.82, 2.06) 0.270 
 P for trend  0.060  0.166  0.176  0.391 
Previous BBD Yes 1  1  1  1  
 No  0.61 (0.42, 0.89) 0.01 0.61 (0.42, 0.89) 0.010 0.45 (0.28, 0.73) 0.001 0.43 (0.27, 0.70) 0.001 
Previously diagnosed HTN 
or diabetes  
Yes  1  1  1  1  
 No 1.12 (0.78, 1.60) 0.529 1.41 (0.97, 2.05) 0.070 1.32 (0.84, 2.08) 0.220 1.39 (0.87, 2.22) 0.164 
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*The variable selection for the fully adjusted model was performed by including all variables significant at the 0.1 level from Tables 3 (Unadjusted post-contact delay) and 5 (Unadjusted total delay) #Adjusted for all variables in 
the table 
BC: breast cancer; BBD: benign breast disease; HTN: hypertension
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Figure 3: Proportion of women with pre- and post-contact delays 
 
 
The first five bars towards 0 represent women with the majority of their delay being post-contact and the last five bars towards 1 
represent those with majority of their delay being pre-contact. 
5.5.2 FACTORS ASSOCIATED WITH TOTAL DELAY  
The unadjusted analyses showed total delay in all women with breast symptoms to be 
associated with the number of children a woman had, the type of facility visited, the 
increasing number of providers visited and having no previous history of benign breast 
disease (Table 5). In the fully adjusted analyses, the type of facility visited (OR 0.68; 95% 
CI; 0.51, 0.92; p=0.013), having no previous history of BBD (OR 0.64; 95% CI; 0.47, 
0.88; p=0.006) remained significant with the trend for an association, with an increasing 
number of children being borderline significant (pt= 0.056) (Table 6). 
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In women with breast cancer, there was no association between any sociodemographic or 
breast cancer awareness factors and the total delay. However, the total delay in breast 
cancer was positively associated with factors measuring the access to health care, such as 
an increasing number of providers visited (pt=0.014), and clinical factors including 
having no previous history of hypertension or diabetes (OR 1.41; 95% CI 1.03, 1.94; 
p=0.032) and no previous history of BBD. (OR 0.56; 95% CI 0.39, 0.81; p=0.002) (Table 
5). In the fully adjusted analyses in women with breast cancer, the total delay was only 
associated with having no previous history of BBD (Table 6).  
Previous benign breast disease and delays to diagnosis 
BBD was associated with both post-contact and total delays in women with all symptoms 
and in those with breast cancer, in both the unadjusted and the fully adjusted analyses 
(Tables 3-6). Among all women with breast symptoms, the median (IQR) post-contact 
delay (months) was 2.67, (0.7-8.2) in those with no previous history of BBD, and 5.19 
(2.0-15.6) in those with a previous history of BBD. Similarly, the median (IQR) total 
delay (months) was 7.6 (3.2-17.0) months in women with no previous BBD and 13.5 (5.6-
28.6) in those with a previous history of BBD. 
Barriers to seeking and obtaining care  
The most common reason given by women for the delay in seeking care was believing 
that it was not a serious problem (58.4% of all women with symptoms; 64.1% of women 
with breast cancer) (Table 7). Fear of a diagnosis was reported by 11.8% and 10.5% of 
all women with symptoms and of those with breast cancer, respectively. Financial 
constraints were mentioned by 10% of women with symptoms and 11% of those with 
breast cancer. Only 1.4% of women with breast symptoms and 2.2% of women with 
breast cancer attributed the delay to their belief in traditional medicine (Table 7). 
Sensitivity Analyses 
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In sensitivity analyses conducted among women with breast cancer, six women with stage 
IV breast cancer and 17 women with stage III breast cancer who experienced total delay 
of < 3 months, likely to be implausible delay times, were excluded from the analyses. 
However, similar results to the previous findings were obtained. In the fully adjusted 
analysis, having 3 or more children remained the only factor significantly associated with 
pre-contact delay in women with breast cancer (OR 2.37; 95% CI1.02, 5.52 p=0.046). 
Post-contact delay remained associated with having no previous history of benign breast 
disease (OR 0.35; 95% CI 0.20, 0.59; p<0.001). Total delays in women with breast cancer 
also remained associated with having no previous history of benign breast disease (OR 
0.52; 95% CI 0.36, 0.76 p=0.001). 
Figure 4: Unadjusted odds ratio of late stage (III/IV) at diagnosis for total delay, post- contact 
delay, number of providers visited and time taken to first provider  
Total Delay:  < 3months
3 months to <6 months
6 months to < 12 months
>=12 months
Post-Contact Delay: < 3months
3 months to < 6months
6 months to < 12 months
>=12 months
Number of providers visited: 1 provider
2 providers
>=3 providers
Time taken to first provider: <1hour
1hour-<2hours
>=2hours
0.3 0.5 1.0 2.0 4.0 8.0
16.0
Odds Ratio of late stage (III/IV) at diagnosis
pt = 0.004 
pt = 0.001 
pt = 0.028 
pt = 0.164 
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Table 5: Factors associated with total delay in Nigerian women – unadjusted model  
Characteristics  Categories  All women  
Unadjusted 
model  
Ratio (95% CI) 
P 
value  
Breast 
cancer  
Unadjusted 
model  
Ratio (95% 
CI) 
P value  
Sociodemographic      
Age at diagnosis < 40 1  1   
 40-49 1.11 (0.84, 1.48) 0.459 1.22 (0.88, 
1.70) 
0.227 
 50-59 0.90 (0.65, 1.26) 0.545 0.78 (0.53, 
1.15) 
0.204 
 > 60 1.11 (0.72, 1.71) 0.631 1.34 (0.81, 
2.19) 
0.252 
 P for trend per 10 
years 
 0.799  0.464 
Marital status  Married  1  1  
 Single  1.07 (0.82, 1.40) 0.608 0.94 (0.68, 
1.28) 
0.681 
Religion  Christian  1  1  
 Muslim  0.89 (0.62, 1.27) 0.515 0.75 (0.48, 
1.16) 
0.189 
Socioeconomic class High  1  1  
 Middle  0.99 (0.69, 1.42) 0.973 0.73 (0.48, 
1.09) 
0.121 
 Low  0.91 (0.64, 1.29) 0.590 0.76 (0.52, 
1.12) 
0.163 
 P for trend   0.491  0.271 
Educational level 
attained  
Tertiary/Postgradu
ate 
1  1  
 Primary/Secondar
y  
0.91 (0.70, 1.18) 0.475 1.07 (0.79, 
1.45) 
0.936 
 None  1.26 (0.88, 1.81) 0.207 1.24 (0.82, 
1.89) 
0.513 
 P for trend   0.209  0.293 
Personal income Yes 1  1  
 No 1.13 (0.87, 1.47) 0.359 1.22 (0.90, 
1.66) 
0.200 
Total number of 
children  
None  1  1  
 1-2 0.93 (0.55, 1.55) 0.775 1.02 (0.57, 
1.82) 
0.937 
 3-4 1.17 (0.70, 1.96) 0.540 1.24 (0.71, 
2.17) 
0.453 
 5 or > 1.35 (0.81, 2.26) 0.255 1.37 (0.77, 
2.42) 
0.279 
 P for trend   0.015  0.362 
Breast cancer 
awareness  
     
Ever heard of breast 
cancer  
Yes  1  1  
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Characteristics  Categories  All women  
Unadjusted 
model  
Ratio (95% CI) 
P 
value  
Breast 
cancer  
Unadjusted 
model  
Ratio (95% 
CI) 
P value  
 No  1.09 (0.80, 1.50) 0.586 1.01 (0.69, 
1.46) 
0.978 
Practise SBE Yes 1  1  
 No  1.09 (0.86, 1.40) 0.470 1.17 (0.88, 
1.56) 
0.290 
 Never heard of 
SBE 
1.41 (0.81, 2.46) 0.222 1.34 (0.71, 
2.51) 
0.367 
Knowledge of BC 
symptoms 
Good  1  1  
 Fair  1.00 (0.67, 1.45) 0.986 1.23 (0.79, 
1.94) 
0.817 
 Poor  1.22 (0.86, 1.73) 0.274 1.38 (0.90, 
2.11) 
0.322 
 P for trend   0.206  0.176 
Belief in a cure for BC Yes 1  1  
 No  1.04 (0.83, 1.31) 0.709 1.18 (0.89, 
1.57)  
0.243 
First symptom  Breast lump 1  1  
 Other symptom 0.93 (0.64, 1.37) 0.728 1.05 (0.68, 
1.63) 
0.820 
Health care access       
Region of residence  North Central 
(Abuja) 
1  1  
 South East 
(Enugu)  
1.20 (0.87, 1.59) 0.281 1.26 (0.96, 
1.72) 
0.157 
Facility type Tertiary  1  1  
 Secondary  0.66 (0.50, 0.87) 0.004 0.90 (0.63, 
1.28) 
0.544 
Time taken to first 
provider  
< 1 hour  1  1  
 > 1 hour - < 2 hours  0.84 (0.60, 1.18) 0.319 0.76 (0.50, 
1.14) 
0.176 
 > 2 hours 0.98 (0.61, 1.57) 0.924 0.79 (0.45, 
1.38) 
0.408 
 P for trend  0.651  0.562 
No. of providers visited 
before diagnosis 
1 1  1  
 2 1.42 (1.07, 1.88) 0.015 1.27 (0.91, 
1.77) 
0.165 
 > 3 1.90 (1.36, 2.65) <0.00
1 
1.63 (1.10, 
2.40) 
0.014 
 P for trend   <0.00
1 
 0.014 
Clinical       
Previous benign breast 
disease (BBD) 
Yes 1  1  
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Characteristics  Categories  All women  
Unadjusted 
model  
Ratio (95% CI) 
P 
value  
Breast 
cancer  
Unadjusted 
model  
Ratio (95% 
CI) 
P value  
 No  0.61 (0.45, 0.83)   0.002 0.56 (0.39, 
0.81) 
0.002 
Previously diagnosed 
HTN or diabetes  
Yes  1  1  
 No 1.24 (0.94, 1.65)  0.131 1.41 (1.03, 
1.94) 
0.032 
Family history of BC Yes 1  1  
 No 0.89 (0.58, 1.38) 0.615 1.04 (0.62, 
1.72) 
0.891 
BMI  < 25 (normal 
weight) 
1  1  
 25-29 
(overweight) 
0.72 (0.31, 1.70) 0.452 0.54 (0.16, 
1.81) 
0.312 
 > 30 (obese) 0.60 (0.25, 1.41) 0.237 0.46 (0.14, 
1.53) 
0.202 
 Unknown  0.52 (0.22, 1.23) 0.138 0.40 (0.19, 
1.34) 
0.136 
 P for trend  0.140  0.535 
WHR < 0.80 (low) 1  1  
 0.8-0.85 
(moderate)  
1.37 (0.88, 2.12) 0.159 1.33 (0.76, 
2.32) 
0.311 
 > 0.85 (high)  1.23 (0.85, 1.79) 0.268 1.21 (0.75, 
1.96) 
0.431 
 P for trend   0.852  0.237 
BC: breast cancer; HTN: hypertension; BBD: benign breast diseases; BMI: body mass index; WHR: waist-hip ratio; CI: confidence 
interval 
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Table 6: Factors associated with the total delay - fully adjusted model  
 
 
 
Patient Characteristics  
All women with breast symptoms Breast cancer  
Unadjusted  P 
value 
Fully 
adjusted*#  
P value  Unadjusted  P value  Fully 
adjusted*#  
P 
value  
Age at diagnosis < 40 1  1  1   1  
 40-49 1.11 (0.84, 
1.48) 
0.459 1.21 (0.89, 
1.63) 
0.226 1.22 (0.88, 
1.70) 
0.227 1.37 (0.96, 
1.96) 
0.079 
 50-59 0.90 (0.65, 
1.26) 
0.545 0.89 (0.61, 
1.28) 
0.523 0.78 (0.53, 
1.15) 
0.204 0.84 (0.55, 
1.28) 
0.429 
 > 60 1.11 (0.72, 
1.71) 
0.631 0.89 (0.54, 
1.46) 
0.647 1.34 (0.81, 
2.19) 
0.252 1.41 (0.81, 
1.46) 
0.223 
 P for trend per 10 
years  
 0.799  0.702  0.464  0.702 
Educational level 
attained  
Tertiary/Postgraduate 1  1  1  1  
 Primary/Secondary  0.91 (0.70, 
1.18) 
0.475 0.85 (0.64, 
1.13) 
0.268 1.07 (0.79, 
1.45) 
0.936 0.99 (0.63, 
1.57) 
0.756 
 None  1.26 (0.88, 
1.81) 
0.207 1.13 (0.75, 
1.71) 
0.566 1.24 (0.82, 
1.89) 
0.513 1.13 (0.69, 
1.31) 
0.980 
 P for trend   0.209  0.481  0.293  0.481 
Personal income Yes 1  1  1  1  
 No 1.13 (0.87, 
1.47) 
0.359 1.21 (0.92, 
1.58) 
0.170 1.22 (0.90, 
1.66) 
0.200 1.23 (0.89, 
1.70) 
0.170 
Total number of 
children  
None  1  1  1  1  
 1-2 0.93 (0.55, 
1.55) 
0.775 0.91 (0.55, 
1.50) 
0.701 1.02 (0.57, 
1.82) 
0.937 1.04 (0.59, 
1.83) 
0.889 
 3-4 1.17 (0.70, 
1.96) 
0.540 1.13 (0.68, 
1.88) 
0.631 1.24 (0.71, 
2.17) 
0.453 1.22 (0.70, 
2.12) 
0.478 
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 5 or > 1.35 (0.81, 
2.26) 
0.255 1.32 (0.77, 
2.27) 
0.307 1.37 (0.77, 
2.42) 
0.279 1.36 (0.76, 
2.46) 
0.300 
 P for trend   0.015  0.056  0.362  0.689 
Region of residence  North Central 
(Abuja) 
1  1  1  1  
 South East (Enugu)  1.18 (0.87, 
1.59) 
0.281 1.00 (0.73, 
1.36) 
0.977 1.26 (0.92, 
1.72) 
0.157 1.23 (0.88, 
1.73) 
0.220 
Facility type Tertiary  1  1  1  1  
 Secondary  0.66 (0.50, 
0.87) 
0.004 0.68 (0.51, 
0.92) 
0.013 0.90 (0.63, 
1.28) 
0.544 0.98 (0.67, 
1.44) 
0.927 
Knowledge of BC 
symptoms 
Good  1    1    
 Fair  1.00 (0.67, 
1.45) 
0.986 0.99 (0.68, 
1.44) 
0.944 1.00 (0.67, 
1.45) 
0.986 1.23 (0.78, 
1.94) 
0.370 
 Poor  1.22 (0.86, 
1.73) 
0.274 1.16 (0.79, 
1.69) 
0.449 1.22 (0.86, 
1.73) 
0.274 1.32 (0.84, 
2.06) 
0.223 
 P for trend  0.206  0.246  0.206  0.246 
Previous BBD Yes 1  1  1  1  
 No  0.61 (0.45, 
0.83)  
 0.002 0.64 (0.47, 
0.88) 
0.006 0.56 (0.39, 
0.81) 
0.002 0.54 (0.37, 
0.78) 
0.001 
Previously diagnosed 
HTN or diabetes  
Yes  1  1  1  1  
 No 1.24 (0.94, 
1.65) 
 0.131 1.32 (0.98, 
1.78) 
0.069 1.41 (1.03, 
1.94) 
0.032 1.32 (0.95, 
1.86) 
0.100 
BC: breast cancer; BBD: benign breast diseases; HTN: hypertension; BMI: body mass index; WHR: waist-hip ratio; CI: confidence interval 
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*The variable selection for the fully adjusted model was performed by including all variables significant at the 0.1 level from Tables 
3 (Unadjusted post-contact delay) and 5 (Unadjusted total delay) #Adjusted for all variables in the table 
 
Table 7: Self-reported reasons for delays in seeking care given by the participants in the NIBBLE 
study  
Reasons for 
delays  
 Total number of 
responses in all 
women with 
breast symptoms 
N (%)  
Total number of 
responses in all 
women with 
breast cancer N 
(%)  
Total number 
of responses 
received 
 279 (100) 181 (100)  
Poor 
knowledge of 
BC  
Ignorance of the 
nature of illness (did 
not think it was a 
serious problem)  
163 (58.4) 116 (64.1) 
Fear  Fear of diagnosis and 
treatment (possibility 
of a cancer 
diagnosis) 
33 (11.8) 19 (10.5) 
Financial 
constraints  
Limited financial 
resources (lack of 
resources, no money 
for transportation to 
hospital)  
28 (10.0) 20 (11.0) 
No permission Partner/Husband did 
not give their consent  
2 (0.7) 1 (0.6)  
Other 
commitments  
No one to look after 
children, job, exams, 
too busy, family 
member sick  
6 (2.1) 6 (3.3) 
Health care 
system related  
Doctors’ strike  3 (1.0) 2 (1.1) 
Belief in 
traditional 
medicine 
Receiving traditional 
treatment 
4 (1.4) 4 (2.2) 
Others  Psychological issues, 
pregnancy, lack of 
knowledge on how to 
access care, thought 
it was a spiritual 
attack 
41 (14.6) 13 (7.2) 
*Categories are not mutually exclusive as some women gave more than one response 
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5.6 DISCUSSION 
 
In this chapter, I identified the extent of the pre-, post-contact and total delays in Nigerian 
women and examined the sociodemographic, breast cancer awareness, health care access 
and clinical determinants of these delays in all women who presented with breast 
symptoms and a subset of those women with histologically confirmed breast cancer. The 
findings showed that on average, there was a total (median (IQR)) delay of 7.8 (3.3-18.7) 
months from when a symptom was initially noticed to when a definitive diagnosis was 
made. The study identified having no personal income and a previous history of BBD as 
factors positively associated with the post-contact delay in all women with breast 
symptoms and in the women with breast cancer. The total delay was inversely associated 
with contact with a secondary health facility rather than a tertiary facility and no previous 
history of BBD in all women with symptoms. The pre-contact delay was only associated 
with having 3-4 children compared with having none in women with breast cancer. 
The median total delay found in this study was comparable to reports from various 
African countries including Nigeria (60), Uganda (79), Libya (232) and South Africa (77), 
but it was reported to be significantly longer than the total delays reported in HICs such 
as Canada (73), Germany (75) and the USA .(76) In contrast to the HICs where less than 
20% of women report a total delay of over 3 months (75), only 18.1% of all women with 
symptoms and 12.4% of women with breast cancer in this study sought treatment within 
3 months of noticing a symptom. This finding is similar to the reports from Malaysia 
(233) and Nigeria where ~70% of women were diagnosed after a delay of over 3 months 
(60). 
An association between diagnostic delay and stage at diagnosis has been consistently 
confirmed in the literature.(79, 220). Delays have been reportedly found to be associated 
with later stage at diagnosis in studies conducted in various countries including Thailand 
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(72), Uganda (79) and Rwanda (78) and in a systematic review by Richards et al. (220). 
In my PhD research, as expected, both post-contact and total delays were significantly 
associated with higher odds of a late stage disease. Women who visited 2 or more 
providers before a diagnosis was confirmed, also had higher odds of late stage (III/IV) 
disease, similar to results by Pace et al. in Rwanda (78). There was no association between 
the age at diagnosis and the aforementioned delays in this study, as has been reported by 
other authors (79).  
Women who did not have a personal income were more likely to delay seeking help than 
those who did. A similar finding has been reported in the case of patient delays by Facione 
et al. in the United States (234). In unadjusted analyses, although a significant trend for 
longer post-contact delay was found for women with no education compared to those with 
tertiary education in all women and in women with breast cancer, this finding did not 
persist in the fully adjusted model. Surprisingly, there was no association between 
educational level and the total delay in this study, in line with findings from Uganda (79). 
Interestingly, women with poor financial ability rather than no education or poor 
knowledge of breast cancer symptoms and causes were more likely to experience post-
contact delays. This finding suggests that even among women with a higher educational 
level or with previous knowledge of breast cancer, the absence of the financial ability to 
seek care may still result in a significant proportion of these women reporting diagnostic 
delays. 
Women who initially sought care at secondary facilities were less likely to delay than 
those who did so at tertiary facilities. Possibly, women first seek help at secondary 
facilities and are subsequently referred to a tertiary facility. In some cases there may be a 
significant delay following the initial contact with the health care system that may be an 
interplay of patient and system level factors, thereby prolonging the time following the 
referral, and prior to the presentation at the tertiary facility. 
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A distinct group of women with a previous history of BBD were identified, who were 
more likely to delay (post-contact and total delays) compared to the women with no 
previous history of BBD. This was an unexpected finding, as one would reason that 
women with a previous history of BBD have had previous contact with the health care 
system and would therefore be better at navigating the system when they notice another 
breast symptom and thus urgently seek care. This contrasted with what was found in this 
study. Some studies that have investigated this matter did not find an association between 
previous BBD and delays (79). However, two precedents were found in the literature, 
where women with previous BBD became complacent about breast symptoms and 
consequently reported longer delays than women with no previous breast symptoms (72, 
77). 
Pre-contact/patient delays and post-contact/provider delays were both important 
components of the total delay, as a bimodal trend  was observed showing a large 
proportion of women who themselves delay a long time and strongly need education on 
breast awareness and seeking adequate help. Another similarly large group of women 
who are delayed in the system for a long time and need education on pushing for referrals 
was also identified. This group of women are those for whom the system is failing, and 
institutional bottlenecks as well as a lack of clear referral pathways may contribute to 
their delay. Deciphering the characteristics of these two groups of women will help target 
the different interventions needed to shorten delay times. 
The most important reasons reported by women for their delays in seeking help for breast 
symptoms were the belief that the symptom was not a serious problem, fear of a diagnosis 
of breast cancer and financial constraints to pay for the diagnosis and treatment. These 
findings are similar to the reports collated from other studies in Nigeria (81, 222), Uganda 
(79) and South Africa (77). 
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This is the first multi-centre study to examine the determinants of diagnostic delays in 
Nigerian women. A PubMed search identified only 5 previous studies to date that had 
characterised delays in Nigerian women (60, 81, 82, 139, 222). This study is therefore an 
important contribution to the scarce literature in this area. Secondly, detailed information 
was collected in the questionnaire to enable the characterisation of a woman’s journey 
from her first symptom to the first 6 care providers visited.  
An important limitation of this study is the possibility that women may not be able to 
accurately recall past events related to their breast disease. It has been shown that women 
do not provide an accurate account of the beginning of their breast symptoms (216). 
Consequently, this may affect the measurement of patient or pre-contact delays. However, 
in this study, the research assistants employed means of using significant life events and 
calendar prompts to obtain information from women who did not initially recall when the 
first symptom was noticed, thereby minimising recall errors. The extent to which such 
errors were random (non-differential) or systematic (differential, e.g. by educational 
level) is not known. Secondly, owing to concerns of ‘social desirability’, women might 
have under-estimated delays or might have avoided mentioning previous visits to 
traditional or alternate care providers, due to concerns about how these would be 
interpreted by the interviewer (216). Although previous studies have reported significant 
proportions of Nigerian women visiting traditional or alternate care providers (60), we 
did not observe this in our study. Additionally, the enrolment interview was conducted at 
the time when a woman was clinically diagnosed and understandably, some women were 
not emotionally ready to provide a clear account of their symptoms or their diagnostic 
journey. Finally, this study included only the women who sought care at a health care 
facility for their symptoms, therefore the findings may not be generalisable to patients 
with breast symptoms who never reach a health care facility. 
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5.7 CONCLUSIONS 
This study confirms previous reports that long delays to diagnosis exist in Nigerian 
women with breast cancer and that these delays were associated with higher odds of a late 
stage (III/IV) disease. Diagnostic delays, through their impact on tumour progression, can 
significantly affect breast cancer survival in SSA. Women should be educated on the need 
to seek help once a symptom is noticed and health care practitioners should be encouraged 
to make prompt referrals in order to reduce provider delays in this setting. By 
understanding the determinants of delay, it may be possible to develop targeted 
interventions to reduce delays and improve breast cancer survival in SSA.  
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CHAPTER 6 
 
6.1 DISCUSSION AND CONCLUSIONS  
The objectives of this PhD thesis were, as stated in Chapter 1, to: 1. Systematically review 
the published literature on the stage at diagnosis of breast cancer in sub-Saharan Africa 
and identify the reasons for variations in the stage at diagnosis across this region; 2. 
Design and implement a multi-centre study at 6 government hospitals in Nigeria; and 3. 
Identify the sociodemographic, breast cancer awareness, health care access and clinical 
determinants of (i) Stage at breast cancer diagnosis and (ii) Diagnostic delays in Nigerian 
women with breast cancer. This chapter provides a critical assessment of the major 
findings presented in this thesis, and reviews the implications for research and policy in 
SSA. 
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6.2 SUMMARY AND SYNTHESIS OF RESEARCH FINDINGS 
This PhD thesis focused on breast cancer, the most common female cancer worldwide 
and one of the most common types in SSA, and a type of cancer of significant global 
health importance. A major contribution made to the literature has been to provide a 
clearer understanding of the magnitude and reasons for the variation in the percentage of 
the late stage diagnosis of breast cancer and its associated factors in the region. 
Additionally, the determinants of late stage at diagnosis and of diagnostic delays in 
Nigeria have been described to provide insights on how downward stage-migration of 
breast cancer can be achieved, including reductions in the delays in a woman’s journey 
to diagnosis. 
6.2.1 Stage at diagnosis of breast cancer in sub-Saharan Africa 
The first objective sought to review the literature on the stage at diagnosis of breast cancer 
in SSA to examine the relevant trends over time and to identify the reasons for variations 
across the region. A systematic review and a meta-analysis were undertaken in order to 
achieve this objective, as previously reported in Chapter 2. Overall, 83 studies from 17 
SSA countries were identified. This review highlighted the limited information available 
on the stage at diagnosis in the region, particularly from middle Africa where no published 
studies were identified, and the limited data available from Southern Africa in recent 
years, where only 2 studies have been published after year 2000. Furthermore, we did not 
identify any studies from population based cancer registries. Secondly, the results 
revealed that majority (77%) of women with breast cancer in SSA were diagnosed at 
advanced stages, although South African non-black women reported a significantly better 
stage at diagnosis than black women in South Africa and from other SSA regions. A key 
finding of this review was the significant inter-study variation in the percentage of late-
stage disease at diagnosis across SSA. However, the reasons for this variation were 
somewhat unclear, as no clear differences were seen in the study design, age at breast 
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cancer diagnosis, the type of health facility visited or the staging methods used. The only 
exceptions were the associations with the degree of urbanisation and the calendar time. 
Studies conducted in mixed settings (urban and rural settings) were more likely to report 
a later stage at diagnosis as opposed to the studies conducted in urban settings only. 
Additionally, the stage at diagnosis improved in the region over time, comparing the time-
period starting from year 2000 and later to the time-period including year 1980 or earlier. 
Nevertheless, and despite improvements having been made over time, the percentage of 
late stage at diagnosis in SSA in 2010 was still higher than it was for US white and black 
women 40 years ago, i.e. prior to the introduction of mammographic screening.  
6.2.2 Determinants of the stage at diagnosis of breast cancer in Nigerian women  
In order to investigate the third objective of my PhD thesis, I designed and implemented 
a multi-centre case control study of breast cancer in Nigeria, namely the Nigerian 
Integrative Epidemiology of Breast Cancer Study (NIBBLE). Within this larger study, I 
studied the factors affecting the stage at diagnosis of breast cancer cases (objective 3(i) 
of my PhD), i.e. women diagnosed with histologically confirmed invasive breast cancer 
and recruited within the initial 2.5-year period of the NIBBLE study. I examined four 
categories of factors - i.e. sociodemographic, breast cancer awareness, health care access 
and clinical factors - and how these affected the stage at diagnosis of breast cancer in 
Nigerian women (Chapter 4). Findings showed that women with a lower educational 
level, those who did not believe in a cure for breast cancer, were Christian and resided in 
rural areas, were more likely to be diagnosed at a later stage. There was no association 
between later stage and the age at diagnosis or clinical characteristics such as tumour 
grade and oestrogen receptor status. In line with the findings from other SSA studies, the 
study showed that Nigerian women with breast cancer are diagnosed, on average, at a 
younger age than women in western countries, reflecting the much younger age structure 
of the SSA populations. 
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A higher percentage of late stage at breast cancer diagnosis in SSA populations could 
occur as a result of breast cancer being particularly aggressive in these populations or 
because of diagnosis delays. The findings presented in Chapter 4 suggest that 
sociodemographic, breast cancer awareness and health care access factors, rather than the 
clinical factors associated with increased tumour growth rates, are the key determinants 
of later stage at diagnosis in Nigerian women. 
6.2.3 Diagnostic delays and its associated factors in Nigerian women with breast 
cancer  
The objective 3(ii) of my PhD, which sought to investigate a woman’s journey from the 
first reported symptom to a confirmed diagnosis of breast cancer, was also examined 
using data from the NIBBLE study conducted on all women who presented with breast 
symptoms, irrespective of whether the final diagnosis was breast cancer or BBD. Detailed 
information on a woman’s diagnostic trajectory was collected using a pre-tested and 
piloted structured questionnaire (Chapter 3). The findings from this analysis showed that 
there were significant delays from the first self-reported symptoms to the diagnosis of 
breast cancer or BBD. On average, all women with breast symptoms took approximately 
3 months from their first reported symptom to presentation at any health care provider 
(including alternative providers, such as traditional and spiritual healers). From their first 
contact with a care provider, it took another 3 months for a confirmed diagnosis of breast 
cancer or BBD to be made. The total delay in all women with symptoms was 7.8 months. 
On average, women visited two care providers before a diagnosis was made, although the 
number of providers visited ranged from 1-6. There was also an increasing trend of 
increased delay with a higher number of providers visited. Women who were diagnosed 
in stages III/IV self-reported longer delays as opposed to women in stages I/II. The factors 
associated with delays to diagnosis were examined using the conceptual framework 
described in Chapter 1. Sociodemographic, breast cancer awareness, health care access 
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and clinical factors were investigated and their associations with the pre-, post-contact 
and total delays were subsequently examined. Findings showed that pre-contact delay in 
women with breast cancer was only associated with one factor, i.e. having 3 or more 
children. Post-contact delays were associated with a lack of a personal income and 
inversely associated with having no previous history of BBD while the total delay was 
inversely associated with visiting a secondary facility and no having previous history of 
a benign breast disease. The three most important self-reported reasons for delays to the 
first presentation at a care provider included ignorance/not believing it was a serious 
problem, fear of a cancer diagnosis and financial constraints.  
6.3 CONTRIBUTION OF THESIS TO CURRENT KNOWLEDGE  
One of the most significant contributions of this thesis to the current knowledge in the 
field is the publication of the first comprehensive systematic review and meta-analysis of 
the stage at diagnosis of breast cancer in sub-Saharan Africa (Chapter 2) (133). Prior to 
the publication of this review, there had been no detailed synthesis of the literature on 
stage at diagnosis, a crucial prognostic indicator of breast cancer outcomes in SSA. This 
review provides an original framework to assess the quality of the previous studies on 
stage at diagnosis in SSA. Although we found a wide range of estimates in the percentage 
of late stage at diagnosis across the region, and the reasons not being entirely clear, we 
did note that the stage at diagnosis was better in non-black African populations in SA 
than in black populations in SA and across East and Western Africa. Secondly, we found 
some improvements in the stage at diagnosis of breast cancer over time.  
A second important contribution of this thesis is the finding on the determinants of stage 
at diagnosis of breast cancer in Nigerian women. This is the first study that has 
investigated the determinants of later stage at diagnosis of breast cancer in Nigerian 
women. These findings stating that breast cancer awareness and health care access 
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factors, which are amenable to intervention, rather than intrinsic tumour characteristics 
and clinical factors, are the major determinants of stage at diagnosis in Nigerian women 
delivers a clear message on what factors need to be addressed by the non-governmental 
and governmental organisations involved in breast cancer control in Nigeria and SSA. By 
providing a long-term perspective on possible policy and research interventions, this 
thesis demonstrates the importance of developing research interventions based on 
evidence derived from conducting epidemiological studies in specific populations.  
Thirdly, while previous studies have investigated the factors associated with the delays 
to diagnosis in women with breast cancer in Nigeria, none qualified as a multi-centre 
study in two distinct regions of the country. These findings identify a distinct group of 
women, with a previous history of benign breast diseases as a target group when 
developing relevant interventions to reduce diagnostic delays in SSA women. While one 
would reason that these women have had previous contact with the health care system for 
a breast lump, and therefore should seek treatment early, this is not what these findings 
suggest. It does appear that women with a previous history of BBD develop a false sense 
of security and believe that because a previous breast lump was non-cancerous, any 
subsequent breast lumps do not require serious attention. This is similar to the findings of 
Poum et al. in Thailand (72). 
6.4 STRENGTHS AND LIMITATIONS OF THE THESIS 
The strengths and limitations of the specific methods used for each of the study objectives 
have been discussed in the previous relevant chapters. This section focuses on the 
strengths and limitations of the entire thesis project. 
Study setting/location 
The choice of Nigeria as a study location could be considered as a strength of this research 
project. Firstly, Nigeria is SSA’s most populous country with a population of well over 
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180 million inhabitants which is more than half of the population of Western Africa. 
Therefore, any information on breast cancer from Nigeria is significant for policy not just 
for the country but for SSA. Secondly, Nigeria has one of the highest age-standardised 
incidence rates of breast cancer in SSA, contributing 15% to the estimated 681,000 new 
cases of breast cancer that occurred in Africa in 2008. Thirdly, my close affiliation with 
the research department of the Institute of Human Virology Nigeria afforded an increased 
level of access, and facilitated the recruitment of well-trained field staff and an 
experienced data manager that might have been difficult to achieve elsewhere (Chapter 
3). 
Design and implementation of the research study  
This PhD thesis provided the opportunity to design and implement from the beginning, a 
multi-centre case-control study of breast cancer in Nigeria. An important strength of this 
study was the opportunity to collect primary data in the Nigerian population and develop 
a new dataset that can be used in future research studies on breast cancer in Nigeria where 
other research questions can be investigated. The case-control design is most commonly 
used with breast cancer given that breast cancer is a seemingly rare disease. While this 
PhD thesis was primarily focused on breast cancer cases and the data analysed pertained 
to women with breast symptoms or histologically confirmed breast cancer, further 
research could be conducted using both cases and controls.  
Limitations  
As with any research endeavour, particularly one conducted in SSA, there were 
challenges and several limitations to the research described in my thesis. An important 
limitation of this study was the inability to reach the sample size of the cases initially 
calculated for this study. This was due to several long intervals of strike actions over the 
course of the research project. Secondly, following the initial training of field staff at the 
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initiation of the study, field staff had to undergo consistent retraining owing to the high 
turn-over of staff members working on the project. 
6.5 IMPLICATIONS FOR RESEARCH, POLICY AND PRACTICE 
This section considers the research, policy and practice implications of this work, and the 
generalisability of my findings to other SSA settings. 
6.5.1 Implications for research  
The findings presented in this thesis highlight the next steps for future research on stage 
at diagnosis and downward stage-migration of breast cancer in SSA. Firstly, the 
systematic review and meta-analysis revealed the dearth of information on stage at 
diagnosis of breast cancer from Middle Africa, Southern Africa and from the population-
based cancer registries (PBCRs). Following the publication of this review, only one study 
has been done to report on the stage at diagnosis of breast cancer using data from the 
PBCR, and this study was conducted in Middle Africa (235). This research highlights the 
need for more studies from these SSA regions. More population-based studies in 
collaboration with cancer registries are needed on the stage at diagnosis of breast cancer 
in SSA. Secondly, the paper on the determinants of the stage at diagnosis of breast cancer 
in Nigerian women is the first paper to examine these factors in the Nigerian setting. 
Given that Nigeria is a large country with differences in religion, education and culture 
across the country, it would be important to replicate this study in other regions of the 
country where the percentage of late stage diagnosis and its determinants may differ from 
the findings reported in North Central and South Eastern Nigeria. An important 
subsequent step would be to estimate cancer survival in Nigerian women with breast 
cancer. I had originally planned to include this component in my PhD study but the 
smaller than anticipated sample size and the delays in patient recruitment caused by 
reasons outside my control (e.g. due to strikes) precluded this. However, considering that 
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the women in this study and their relatives gave consent to be contacted at a future date, 
it would be useful to follow-up these women and describe survival in association with 
stage at diagnosis in Nigerian women. 
Research is also required in order to assess the impact of the interventions that aim to 
achieve downward stage-migration in SSA.  
 
6.5.2 Implications for policy and practice 
Policy Implications 
This research study has important implications for policy and practice. National efforts 
are required to increase awareness about the benefits of early detection and downward 
stage-migration even in the absence of screening. This thesis highlights the evidence in 
the literature that suggests that HICs, such as the USA, achieved stage-migration to a 
lower stage at diagnosis prior to the introduction of population-wide mammographic 
screening by means of an increase in breast cancer awareness and early detection of the 
symptomatic disease through BSE and CBE. However, a low educational level and poor 
knowledge of breast cancer symptoms and the signs, which were important findings in 
this study, may indicate a limited awareness of the benefits of BSE and CBE. There is 
therefore a need for synchronised awareness campaigns organised by the government, 
health care providers and organisations working in cancer prevention and control. 
Information on breast health and how to readily identify symptoms and who to contact in 
those circumstances should constitute the ‘standard of care’ and should be integrated into 
existing programmes or clinics such as HIV and reproductive health clinics. Health 
professionals at the primary and secondary health care level should be encouraged to 
incorporate CBE into their practice and to ensure quick referrals for any suspicious 
symptoms. 
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Practice Implications 
Interventions that aim to achieve downward stage migration of breast cancer in SSA have 
been proven successful in many settings within and outside SSA, as previously discussed 
in Chapter 4. However, there has been no previous intervention of this type implemented 
in Nigeria. 
The positive association found between a later stage at diagnosis with the increasing 
number of care providers visited and the delays to diagnosis indicates that the health care 
system and factors that influence a woman’s journey from her first reported symptom to 
when she seeks care and is informed of her diagnosis need to be addressed. This study 
identified the important reasons why women delay in seeking help for their breast 
symptoms. Most women did not consider their breast problem to be serious and hoped it 
would heal on its own. We found that on average women visit 2-3 providers before a 
diagnosis is made. This is in contrast with the findings from Rwanda, where women visit 
4-5 providers on average. This finding suggests that when a woman makes contact with 
the health care system and is referred to a centre for further management, there may be 
factors outside the health care system, such as financial capability and inability to find 
childcare while she is away from home that could result in the median total time delay of 
~7 months found in this study. In our study, we identified a distinct group of women with 
a previous history of benign breast disease who were more likely to delay seeking help 
than women with no previous breast symptoms, similar to the findings in Thailand by 
Poum et al. (72). Interventions seeking to shorten delay times should target this group of 
women who may have a false sense of security and belief that they have a lower cancer 
risk owing to their previous history of benign breast disease. 
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6.6 CONCLUSIONS 
Breast cancer remains a significant global health issue in sub-Saharan Africa. This thesis 
set out to review the literature on the stage at diagnosis of breast cancer across SSA and 
to investigate the reasons for variations across the region. Additionally, stage at diagnosis 
and the factors associated with stage and delays to diagnosis were investigated in SSA’s 
most populous country, Nigeria. It was found that there is a vast variation in the 
percentage of late stage breast cancer across SSA with an improvement in stage at 
diagnosis over time. These findings also highlight the significant difference in late stage 
at diagnosis between women in SSA and US black and white women, with stage at 
diagnosis still being higher in SSA in 2010 than it was 40 years before in the US. The 
factors identified in this thesis as determinants of stage at diagnosis and diagnostic delays 
in Nigerian women are breast cancer awareness factors and health care access factors, 
which are amenable to intervention, rather than intrinsic clinical factors. This thesis has 
demonstrated the need for research into stage at diagnosis from certain regions of Africa 
where information is lacking, and offered recommendations for strategies aimed at 
improving stage at diagnosis with the goal of achieving better breast cancer outcomes and 
survival in the region. 
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APPENDICES 
APPENDIX 1: SYSTEMATIC REVIEW PROTOCOL 
Title: Stage at Diagnosis of Breast Cancer in Sub-Saharan Africa: A Systematic Review and Meta-analysis 
Reviewers: Elima Jedy-Agba, Valerie McCormack and Isabel dos-Santos-Silva 
Background 
Breast cancer is by far the most common cancer affecting women worldwide(230). In 2012, there were 1.67 
million new cases of breast cancer constituting 25% of all cancers worldwide of which 883,000 new cases 
occurred in less developed regions(5). Breast incidence rates in sub-Saharan Africa (SSA) are increasing, 
and although they remain among the lowest in the world, mortality rates from this disease are as high as 
those in high-income countries due to poor survival.  
Stage at diagnosis is a major determinant of survival from breast cancer, with early disease (stages I/II) 
being associated with a better prognosis than late stage disease (stages III/IV). In high-income countries 
mortality rates from breast cancer have declined sharply in recent decades due to earlier stage at diagnosis, 
better diagnosis and improved treatment. However, in SSA where systems and facilities for accurate and 
timely diagnosis are scarce, the majority of breast cancer patients present late and are diagnosed at an 
advanced stage(90-96), in part contributing to poor outcomes(87, 97, 98). Variations in stage of breast 
cancer at diagnosis across SSA, and over time in some of its settings(30), have been previously reported in 
individual settings(47, 87, 89, 90, 94) but, to our knowledge, have not been examined systematically across 
SSA.  
In this study, we will systematically review the published literature on stage at presentation of breast cancer 
in SSA countries, examine trends over time, and investigate possible sources of between-study 
heterogeneity. The findings may help to identify locally-appropriate approaches for early detection and 
treatment of this disease.  
Objectives 
The main objective of this review is to ascertain the distribution of stage at diagnosis of breast cancer 
patients in SSA. 
The specific aims of the systematic review are: 
(i) To provide an overview of stage at diagnosis of breast cancer across SSA; 
(ii) To identify and investigate the extent and sources of variations in stage at diagnosis of breast 
cancer across SSA and over time; 
(iii) To compare the frequency of late stage breast cancer in SSA to the corresponding figures for 
Black and White women in the US over a similar time period. 
 
Search Strategy 
The search strategy will aim to identify all published studies conducted in SSA on stage at diagnosis of 
breast cancer.  
Inclusion criteria 
Studies will be included if they met the following inclusion criteria: 
 Studies that reported on the distribution of stage at diagnosis of primary invasive breast cancer in 
women in any sub-Saharan African country (as defined by the United Nations(99));  
 Studies conducted and published before 1st January 2014; 
 Studies published in any language (no language restrictions will be imposed);  
Exclusion criteria 
Studies will be excluded if they were: 
 Not conducted in humans; 
 Not conducted in SSA (articles from North Africa – i.e. Algeria, Egypt, Libya, Morocco, Sudan, 
Tunisia, Western Sahara – and those among African-Americans will be excluded);  
 Studies with no information on breast cancer; 
 Studies which included only male patients *; 
 Meeting abstracts, review papers, reports, and commentaries;  
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 Studies whose eligibility criteria restricted patient entry to those with a particular stage (e.g. 
metastatic breast cancer only).  
* Studies that include both male and female breast cancer cases recruited over a given period of time will 
not be excluded even if data are not presented separately by gender because the number of male cases is 
expected to be rather small. 
 
Database searches 
The databases to be searched will include: 
 EMBASE 
 Medline 
 Web of Science 
 Africa Wide Information (including African Journals Online) 
Only these four databases will be searched as it is expected that saturation will be reached with the majority 
of studies appearing in all databases.  
 
Search Terms 
Keywords and Medical Subject Headings (MeSH) will be used to search the databases listed above. Broad 
search terms such as “breast cancer”, “Sub-Saharan Africa or SSA” will be used. A complete list of search 
terms will be developed and used across all four databases [see Webappendix-Text3]. Hand-searching of 
references from retrieved articles, meeting abstracts, review papers, reports and commentaries will also be 
performed to identity any additional papers not captured by the electronic searches. 
 
Title and abstract screening 
The databases listed above will be searched and the citations retrieved will be downloaded into the Endnote 
software. Any duplicate articles identified by more than one data will be removed.  
The titles and abstracts will be screened by one reviewer, with a random sample being also screened 
independently by a second reviewer. Any study excluded from the review will be documented and the 
reason(s) for exclusion noted in a systematic way. 
Full text screening and data extraction 
The full text of all the papers identified during the abstract screening step will be retrieved for full text 
screening to confirm eligibility and, if eligible, to extract relevant data. For each eligible paper data will be 
abstracted on the number of patients with breast cancer who presented in each one of the four stages (I, II , 
III and IV) or in early (i.e. stages I and II combined) and late (i.e. III and IV combined) stages if data were 
only presented in these aggregated categories. If a study provides numbers of patients in each specific 
American Joint Committee Cancer Tumour Node Metastases (TNM) category (e.g. T2, N0, M0) these will 
also be extracted. Information on the following variables will also be extracted: country, study design, study 
population and type of clinical setting (e.g. primary, secondary, tertiary, population-based cancer registry), 
years when breast cancer patients were diagnosed, age at time of diagnosis, methods and classification used 
to ascertain tumour stage. Whenever available data will also be extracted on reproductive history (e.g. age 
at menarche, age at first birth, parity and menopausal status at presentation); tumour’s characteristics (e.g. 
histology, size, grade, node positivity, receptor status); and time from first symptoms to breast cancer 
diagnosis. In the course of the data abstraction, should there be any eligible papers resulting from the same 
study, only the one with the most complete information on stage will be included in the systematic review. 
The full-text of any potentially eligible studies identified through hand searches will also be reviewed using 
the methodology described above. 
The full-text review and data extraction will be done independently by two reviewers using an adapted 
version of a pre-tested data entry form(103). Any discrepancies will be resolved by discussion among the 
reviewers. 
Assessment of Methodological Quality of the Papers 
The quality of the papers included in the review will be assessed independently by two reviewers using an 
adapted version of a standardised form(103), which was developed using an approach similar to that of the 
Cochrane collaboration. The quality assessment form will be designed to capture three broad categories of 
items which will aim to assess the potential for selection bias and information bias as well as the availability 
of data on other variables relevant to stage. Each item within these three categories will be allocated a score 
ranging from 0 (if it did not meet the criteria or if the information provided was unclear) to a maximum of 
2 or 4, depending on the item. The overall quality of the study will be expressed as a sum of the item-
specific scores. The higher the score the higher the quality of the paper. 
  
Data Analysis 
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The extracted data will be analysed using the STATA Statistical Software version 13 (StataCorp, Texas). 
An initial descriptive analysis will be done to provide information about the study population, study design, 
the region of Sub-Saharan Africa, stage at presentation and other variables described above in the section 
on data abstraction. These results will be presented in both narrative and tabular form.  
The percentage (p34) of breast cancer patients diagnosed at late stages (III and IV) will be the primary 
outcome of interest in this review. This will be defined as the percentage p34=n34/n where n34 is the number 
of women who presented at stages III or IV and n is the total number of women with known stage 
information. The suite of metan and metaprop commands will be used to graphically display population-
specific late stage percentages and, if appropriate, to estimate pooled percentages using random effect 
models. Between-study heterogeneity will be examined using the I2-statistics and the P-value for 
heterogeneity (Cochrane’s Q statistic) test. Meta-regression analysis will be performed to identify 
independent sources of heterogeneity (e.g. calendar year, country/region, type of clinical setting). Small 
study bias will be assessed using funnel plots and the Egger test. 
The findings on late stage breast cancer in SSA will be compared with those from African-American and 
Caucasian populations in the United States (US), for the same time period, using data from the US 
Surveillance Epidemiology and End Results (SEER) database. The SEER database includes data on all 
cancer incident cases from nine population-based cancer registries in the US.  
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APPENDIX 2: PRISMA 2009 CHECKLIST 
Section/topic  # Checklist item  
Reported on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key 
findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, 
and study design (PICOS).  
5, 6 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
3, Webappendix- 
Text 1 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
5, 6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) 
in the search and date last searched.  
5, 6 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  Webappendix-Text 3 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
5, 6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
5, 6 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications 
made.  
6 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the 
study or outcome level), and how this information is to be used in any data synthesis.  
7,  
Webappendix Text 4 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  7 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for 
each meta-analysis.  
6,7 
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within 
studies).  
Page 5, 
Webappendix 
Text 4 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were 
pre-specified.  
8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, 
ideally with a flow diagram.  
Webappendix 
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the 
citations.  
Webappendix -
Table1, 
References 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Supplementary 
Text 4 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) 
effect estimates and confidence intervals, ideally with a forest plot.  
Figures 1b, 
Figure 2, 
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Webappendix 
Figures 2 and 3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Figures 1b, 
Figure 2, 
Webappendix 
Figures 2 and 3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Webappendix- 
Figure 4 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  Table 2 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., 
healthcare providers, users, and policy makers).  
11 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
12, 13 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  11, 13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic 
review.  
13 
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APPENDIX 3: SYSTEMATIC REVIEW SEARCH STRATEGY  
Database Search Terms 
Embase  1. (breast cancer* or breast neoplasm* or breast carcinoma* or breast sarcoma* or 
breast    tumour* or breast tumour* or breast malignanc*).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept, rare disease supplementary concept, unique identifier] 
2. (Stage or presentation or grade or clinical features or clinical findings).mp. [mp=title, 
abstract, original title, name of substance word, subject heading word, keyword 
heading word, protocol supplementary concept, rare disease supplementary concept, 
unique identifier] 
3. (Africa or sub-saharan Africa or Angola or Benin or Botswana or Burkina Faso or 
burundi or cameroun or cape Verde or Chad or central african republic of comoros or 
Congo or Cote d'Ivoire or democratic republic of congo or equatorial guinea or eritrea 
or ethiopia or Gabon or Gambia or Ghana or Guinea or Guinea-Bussau or kenya or 
Lesotho or Liberia or Madagascar or Malawi or Mali or Mozambique or Namibia or 
Niger or Nigeria or Rwanda or Soa Tome or Senegal or seychelles or sierra Leone or 
somalia or south Africa or Swaziland or Togo or Uganda or Tanzania or Zambia or 
Zimbabwe).mp. [mp=title, abstract, original title, name of substance word, subject 
heading word, keyword heading word, protocol supplementary concept, rare disease 
supplementary concept, unique identifier] 
4. 1 and 2 and 3 
5. exp Breast Neoplasms/ 
6. cancer staging.mp. or exp Neoplasm Staging/ 
7. Africa, Western/ or South Africa/ or Africa, Eastern/ or Africa.mp. or "Africa South 
of the Sahara"/ or Africa, Central/ or Africa/ or Africa, Southern/ 
8. 1 or 5 
9. 2 or 6 
10. 3 or 7 
11. 8 and 9 and 10 
 
Africa-wide 
Information  
1.breast cancer* or breast neoplasm* or breast carcinoma* or breast sarcoma* or breast 
tumour* or breast tumour* or breast malignanc* 
2.breast neoplasms 
3. Stage or presentation or grade or clinical features or clinical findings 
4.Neoplasm staging 
5. Africa 
6. Africa or sub-saharan Africa or Angola or Benin or Botswana or Burkina Faso or 
burundi or cameroun or cape Verde or Chad or central african republic of comoros or 
Congo or Cote d'Ivoire or democratic republic of congo or equatorial guinea or eritrea 
or ethiopia or Gabon or Gambia or Ghana or Guinea or Guinea-Bussau or kenya or 
Lesotho or Liberia or Madagascar or Malawi or Mali or Mozambique or Namibia or 
Niger or Nigeria or Rwanda or Soa Tome or Senegal or seychelles or sierra Leone or 
somalia or south Africa or Swaziland or Togo or Uganda or Tanzania or Zambia or 
Zimbabwe 
7.1 or 2 
8.3 or 4 
9. 5 or 6 
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10.7 and 8 and 9 
Medline 1.(breast cancer* or breast neoplasm* or breast carcinoma* or breast sarcoma* or 
breast tumour* or breast tumour* or breast malignanc*).mp. [mp=title, abstract, subject 
headings, heading word, drug trade name, original title, device manufacturer, drug 
manufacturer, device trade name, keyword] 
2. (Stage or presentation or grade or clinical features or clinical findings).mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original title, device 
manufacturer, drug manufacturer, device trade name, keyword] 
3.(Africa or sub-saharan Africa orAngola or Benin or Botswana or Burkina Faso or 
burundi or cameroun or cape Verde or Chad or central african republic of comoros or 
Congo or Cote d'Ivoire or democratic republic of congo or equatorial guinea or eritrea 
or ethiopia or Gabon or Gambia or Ghana or Guinea or Guinea-Bussau or kenya or 
Lesotho or Liberia or Madagascar or Malawi or Mali or Mozambique or Namibia or 
Niger or Nigeria or Rwanda or Soa Tome or Senegal or seychelles or sierra Leone or 
somalia or south Africa or Swaziland or Togo or Uganda or Tanzania or Zambia or 
Zimbabwe).mp. [mp=title, abstract, subject headings, heading word, drug trade name, 
original title, device manufacturer, drug manufacturer, device trade name, keyword] 
4.exp breast cancer/ 
5.1 or 4 
6.exp cancer staging/ 
7.2 or 6 
8. "Africa south of the Sahara"/ or South Africa/ or Africa/ or Central Africa/ or 
Africa.mp. 
9. 3 or 8 
10. 5 and 7 and 9 
 
Web of 
Science 
1. Topic= (breast cancer* or breast neoplasm* or breast carcinoma* or breast sarcoma* 
or breast tumour* or breast tumour* or breast malignanc*)  
2.Topic=(Stage or presentation or grade or clinical features or clinical findings) 
3.Topic=(Africa or sub-saharan Africa or Angola or Benin or Botswana or Burkina 
Faso or burundi or cameroun or cape Verde or Chad or central african republic of 
comoros or Congo or Cote d'Ivoire or democratic republic of congo or equatorial 
guinea or eritrea or ethiopia or Gabon or Gambia or Ghana or Guinea or Guinea-Bussau 
or kenya or Lesotho or Liberia or Madagascar or Malawi or Mali or Mozambique or 
Namibia or Niger or Nigeria or Rwanda or Soa Tome or Senegal or seychelles or sierra 
Leone or somalia or south Africa or Swaziland or Togo or Uganda or Tanzania or 
Zambia or Zimbabwe)  
4.1 and 2 and 3  
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APPENDIX 4: ASSESSMENT OF STUDY QUALITY 
The methodological quality of the papers included in the review was evaluated by adapting a standardized 
quality assessment form previously used by Eng et al.(103). Each paper was scored separately on ten 
individual parameters within three broad categories aimed at evaluating the potential for biases in the way 
breast cancer patients were recruited or in the way stage at diagnosis was assessed and reported, as well as 
the availability of information on stage-related variables. A full list of all items considered is given below. 
 
Minimizing selection bias  
1. Timing of data collection 
Score 0 if unclear  
Score 2 if retrospective  
Score 4 if prospective  
 
2. Study Design  
Score 0 if unclear 
Score 1.5 if opportunistic case series 
Score 2.5 if consecutive case series 
Score 4 if population-based study 
 
3. Percentage of overall study sample size for which information on stage is provided 
Score 0 if unclear 
Score 2 if < 80% of total cases 
Score 4 if ≥ 80% of total cases 
Minimizing information bias 
4. What staging criteria was used? 
Score 0 if staging criteria was not reported  
Score 4 if TNM or Manchester criteria were used 
 
5. Staging methods 
Score 0 if unclear 
Score 2 if clinical only  
Score 4 if clinical and imaging and other complementary exams 
 
6. How were data on stage at presentation reported?  
Score 0 if unclear  
Score 2 if only data for aggregated categories of early (stages I and II combined) and late stage 
(stages III and IV combined) were given 
Score 4 if data provided separately for each one of the four stages (I, II, III and IV) 
Assessment of other important variables related to stage at presentation 
7. Age at presentation (e.g. mean, median or age-categories)  
Score 0 if not reported  
Score 1 if reported 
 
8. Menopausal status at presentation 
Score 0 if not described 
Score 1 if described 
 
 
9. Year of Diagnosis 
Score 0 if not reported 
Score 1 if reported  
 
10. Tumour grade 
Score 0 if not reported  
Score 1 if reported 
More weight was given to the items in the selection and information bias categories with each one being 
given a score between 0 and 4, as indicated above.  
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The category of other variables related to stage at diagnosis included items on the availability of information 
on age at diagnosis, year at diagnosis, menopausal status at diagnosis and tumour grade. Tumour size was 
not included in this category because this variable is a component of the TNM staging, and the latter was 
included as an item in the information bias category. Tumour receptor status was also considered but not 
included because receptor testing is not routinely carried out in most SSA settings. For each of the four 
items in this category, a score of 0 was assigned if no information on that variable was provided or a score 
of 1 if such information was given.  
Individual item-specific scores were summed up across the three categories to arrive at a total score for 
each study. The total score for a study could range from 0 to 28. The lower the score the poorer the 
methodological quality of the study, i.e. the higher the likelihood it would have been affected by bias. We 
did not use an arbitrary cut off point to classify studies as being high vs. low quality; instead, we reported 
the individual scores for each study. 
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APPENDIX 5: ETHICAL APPROVALS 
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APPENDIX 6: DATA COLLECTION INSTRUMENTS 
Baseline Questionnaire on Determinants of Stage at Presentation  
  
The Interview: 
 
Study Site:  
 
Interviewer name: __________________________________________  
 
Interviewer code:  
 
Date of Interview: _ _ /_ _ / _ _ _ _  
     Day Mo   Year 
Type of interview:  
 Face-to-face at hospital clinic     
 Face-to-face at home      
 Telephone        
 Other. Please specify________________________  
Language used: 
 English        
 Other, but no translation assistance required    
  Other, with translation assistance     
   If other language please specify which one: 
   Hausa    
   Yoruba   
   Igbo   
   Other    Please specify_____________________   
The Participant: 
 
Full name of the participant:_____________________________________________ 
Date of birth: _ _ /_ _ / _ _ _ _  
   Day Mo   Year 
 
Study ID:  
 
Hosp ID:   
  
 
Notes for Interviewer: 
To the participant: “Thank you for agreeing to take part in this research study. I am going to start by asking you a 
few questions about your beliefs and attitudes towards breast illnesses.”  
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Section 1. Patient’s Knowledge, Attitudes and Practices 
 
1.1. Have you heard of self-breast examination (SBE)? 
a. Yes        
b. No                             
c. I have heard of SBE, but don’t know what it means   
 
1.2. If you have heard of SBE, who showed you how to do it? Tick only one option. 
  
a. Breast cancer awareness campaign       
 b. Nurse, doctor or other health professional       
 c. Relative or friend         
 d. Other. Please specify________________________________________   
 f. Have heard of SBE, but have never been shown how to do it     
 g. Have never heard of SBE / have heard but don’t know what it means    
 
1.3. Have you ever practiced SBE? 
a. Yes           
b. No          
                       
c. Have never heard of SBE / have heard but do not know what it means    
 
1.4. If you have ever practiced SBE how frequently, on average, did you practice this before the start of 
your current breast problem?    times/per year     
Never practiced SBE  
 
1.5. In the past, prior to the start of your current breast problem, had you ever had a clinical breast 
examination (CBE) done by a health care professional?  
a. Yes       
b. No       
c. Can’t remember/Not sure    
 
1.6. Have you ever had mammography (i.e. an x-ray of the breast)?  
a. Yes          
b. No          
c. Can’t remember/Not sure    
d. I don’t know what mammography means    
Notes for Interviewer: 
Do NOT read out the choices below to the participant. Only tick what she says.  
If the participant answered “No” or “I have heard of SBE, but don’t know what it means” to question 6 above, tick box g) 
below  
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1.7. If you have ever had mammography, what was the reason for undergoing it? 
a. There was a problem with my breasts      
b. There was nothing wrong with my breasts but my doctor thought I  
  should have mammography to detect early signs of cancer (i.e. screening)  
c. Can’t remember/Not sure       
d. Never had mammography       
 
1.8. Before the start of your current breast problem, had you ever heard of breast cancer?  
a. Yes       
b. No             
c. Can’t remember   
 
1.9. If you had heard about breast cancer previously what was your main source of information? Tick all 
appropriate options. 
 
a. Friend/Relative      
b. Another family member with breast cancer   
c. Radio/TV/Magazine      
d. Breast cancer awareness campaigns/NGOs   
e. Church/Religious organization     
f. Nurse/doctor       
g. Traditional healer      
h. Other. Please specify______________________   
i. Never heard about breast cancer before    
 
1.10. Which of the following do you believe may cause breast cancer? 
a. A woman’s lifestyle (e.g. her diet and alcohol intake) Yes  No  Not sure  
b. Having breastfed for long periods    Yes  No  Not sure  
c. Getting older      Yes  No  Not sure  
d. Having other family member affected with breast cancer Yes  No  Not sure   
e. A curse      Yes  No  Not sure  
f. An injury to the breast     Yes  No  Not sure  
g. A bite from an insect     Yes  No  Not sure  
h. Caught from others suffering from the disease  Yes  No  Not sure  
i. Other. Please specify_________________________  Yes  No  Not sure  
 
 
1.11.Which of the following do you think are signs of breast cancer? 
Notes for Interviewer: 
 
Do NOT read out the choices below to the participant. Only tick what she says.  
If the participant answered “No” or “Can’t remember” to question 1, tick box i) below   
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a.  A lump or thickening in an area of the breast  Yes  No  Don’t know     
b.  A painful breast     Yes  No  Don’t know          
c. A change in the size or shape of the breast  Yes  No  Don’t know      
d. Dimpling of the skin or a wound on breast  Yes  No  Don’t know     
e. Fluid coming from the nipple in a woman  
who is not breastfeeding    Yes  No  Don’t know     
f. A swelling or lump in the armpit   Yes  No  Don’t know      
g. A change in the shape of the nipple   Yes  No  Don’t know     
h. Other. Please specify__________________   Yes  No  Don’t know     
 
1.12. How common do you think breast cancer is among Nigerian women?  
a. The most common cancer    
b. Frequent, but not the most common cancer  
c. A rare cancer      
d. Don’t know      
 
1.13. Do you think breast cancer can be cured if caught early?  
a. Yes, it can be cured if caught early   
b. No, there is no treatment     
c. I don’t know if breast cancer can be cured   
 
1.14. Before noticing your current breast problem, had you ever heard of the following treatment options 
for patients with breast cancer? 
a. Surgery  Yes   No   Not sure      
b. Hormone therapy Yes   No   Not sure  
c. Chemotherapy  Yes   No   Not sure  
d. Radiotherapy  Yes   No   Not sure   
 
 
Section 2. Patient’s Breast Symptoms 
 
 
2.1. What was the first change you noticed on your breast? Tick all appropriate boxes. 
a. A lump or thickening in an area of the breast        
b. Pain in the breast           
Notes for the interviewer: 
To the participant: “Thank you. I am going to ask you now a few questions about your current breast problem.”  
 
Notes for Interviewer: 
Do NOT read the choices below to the participant. Only tick what she says.  
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c. Dimpling of the skin or a wound          
d. Fluid coming from the nipple         
e. A swelling or lump in the armpit     
f. A change in the shape of the nipple    
g. I did not notice any change myself    
h. Other. Please specify_______________________  
 
2.2. Using the picture (i) below, mark which breast (R or L), and which part of that breast, the change was 
first noticed and tick the corresponding option below. 
  (i)       (ii) 
    
 
a. Right upper inner quadrant (UIQ)   
b. Left upper inner quadrant (UIQ)    
c. Right upper outer quadrant (UOQ)   
d. Left upper outer quadrant (UOQ)   
e. Right lower inner quadrant (LIQ)   
f. Left lower inner quadrant (LIQ)    
g. Right lower outer quadrant (LOQ)  
h. Left lower outer quadrant (LOQ)   
i. Under the armpit     
j. Can’t remember    
2.3. When was this breast change first noticed? 
  
Notes for Interviewer: 
Ask the participant on which breast (right or left) the change was noticed. Show her the picture below and then ask 
her to show you where the change was located and mark the spot on diagram (i). Diagram (ii) is only to help you to 
identify the breast quadrants.  
Notes for Interviewer: 
 
- Try to obtain the exact date from the participant. You can try to jog her memory by referring to special events 
(e.g. festivals, religious and family celebrations, school holidays). If the woman cannot remember the day enter 
month and year only. If she cannot remember the date ask how many days/weeks/months/years (as appropriate) 
ago.  Tick the “Can’t remember” box ONLY if she is unable to provide an approximate date.  
 
-  Enter this date in the timeline of key events provided on the last page of the questionnaire.  
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Date: _ _ /_ _ / _ _ _ _ ,  or ____weeks, or ____months, or ___years ago  
     Day Mth  Year      Can’t remember   
 
2.4. Who first noticed this change? Tick only one box  
a. Myself        
b. Husband/partner        
c. Doctor or nurse         
d. Traditional healer      
e. Other. Please specify_____________________                    
 
2.5. When the change in your breasts was first noticed, what did you think it was? Tick only one box. 
 
a. A spiritual attack            
b. An infection/boil            
c. An insect bite         
d. Breast lump or cancer           
e. Blocked milk duct/complication of recent breastfeeding            
f. Worried but didn’t know what it was             
g. Nothing serious to worry about      
h. Other. Please specify_______________________________    
 
2.6. Whom did you first tell when you first noticed a change in your breasts? Tick only one box 
 
a. Family member or member of household     
b. Neighbour/Friend       
c. Church pastor/elder       
d. Doctor/Nurse at clinic or hospital     
e. Chemist/pharmacist       
f. Traditional healer       
g. Other. Please specify _____________________________   
 
2.7. How long did it take from when the change(s) in your breast were first noticed to when you first told 
{Interviewer: enter option selected in 2.6 above} _____________________________________?  
____days, or ____weeks, or _____months,  or _____years       Can’t remember   
 
Notes for Interviewer: 
Do NOT read out the choices below to the participant. Only tick the boxes that correspond to  what she says.  
Notes for Interviewer: 
Do NOT read out the choices below to the participant. Only tick what she says.  
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2.8. Did you delay telling {Interviewer: enter option selected in 2.6 above}______________________________  
about your breast problem(s) because of: 
  
a. Did not think the problem was serious      
 b. Hoped the problem would go away      
 c. Embarrassed to talk about problems in my breasts     
 d. Fear of being told that it could be serious      
 e. Fear of treatment        
 f. Fear of being rejected        
 g. Other. Please specify____________________________________   
 g. No delay as I told them as soon as I noticed the change in my breast   
 
Section 3. Patient Navigation Pathway 
Contact 1 
 
3.1. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
_________________________________________________________________________  
3.2. What type of care provider did you visit?  
 
Notes for Interviewer: 
To the participant: “Thank you for all your help so far. I am now going to ask you a few questions about all the facilities 
you visited to seek help after noticing a change in your breast. I will ask you to start from the earliest to the latest 
facility you visited to seek any type of help (medical, traditional or spiritual care) after your initial symptoms until you 
arrived at this hospital.” 
  
- Complete a contact form (1, 2, 3, etc) for each  contact/provider the participant had until the participant arrived at 
your hospital. Use additional forms if she mentions more than 6 providers and staple them to this questionnaire. 
 
- For each contact, the date of first visit and the type of provider should be entered below and on the timeline of key 
events shown on the last page before moving to the next questions. 
 
- The date of first visit is that of the first appointment/test with that care provider. Try to jog the participant’s memory 
by referring to festivals, family events, public and school holidays, etc. If she cannot remember the exact date of visit, 
record month and year only. If, for instance, she mentions ‘3 months ago’ record that below. The “Can’t remember” 
option should be used ONLY if she cannot give any approximate date.   
 
- Home is the place where the woman usually lives. Temporary residence elsewhere (e.g. due to her illness or for other 
reason) should not be considered. 
Notes for Interviewer: 
 
Do NOT read out the choices below to the participant. Only tick what she says.  
Notes for Interviewer: 
Do NOT read the choices provided for each question to the participant. Only tick what she says.  
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Care Provider Tick only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
g. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
j. Other. Please specify 
__________________ 
 
     
 
3.3. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
  Can’t remember  
3.4. How far away is this provider from your home? _____km,  or _____miles    Don’t Know  
 
3.5. How long did it take you to get there from your home? ____hrs and/or ____ mins  
           Can’t remember  
3.6. Which means of transport did you use? 
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi)      
d. Bus       
e. Other. Please specify__________________  
 
3.7. What was your reason for visiting this provider at the time you did? Tick all appropriate boxes 
a. Symptoms did not go away          
b. Symptoms worsened            
c. Advice from people/family/friends            
d. Other. Please specify___________________  
 
3.8. How long did it take from first noticing the change(s) in your breast to your first visit to this care 
provider?  
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.9.  What was the cause of the delay? Tick all appropriate boxes. 
 
Notes for Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If the “Other” option is selected enter details in the 
box provided. 
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 Delay caused 
by woman  
I delayed 
because:  
Fear of:  
 diagnosis 
 treatment 
 
 Did not 
think it was 
a serious 
problem 
 No transport 
money 
 Other 
financial 
constraints 
Partner /Husband 
 Did not give 
permission 
 Fear of rejection 
 No one to 
look after 
children 
 Other 
reason 
If Other (explain):                                                             
 
 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
appointment to 
see a doctor 
 The doctor 
told me it was 
not serious/ 
there was 
nothing to worry 
about 
 Other reason 
If Other (explain):                                                             
 
 
3.10. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry     
b. Tests done but I was never told the results    
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
e. Told I had something else but no treatment offered     
f. Please specify (i) type of diagnosis___________________  
g. Told I had something else and treatment offered    
h.    Please specify: (i) type of diagnosis________________   
                (ii) type of treatment___________________   
i. Referred to another provider/facility     
j. Not applicable (this provider is one of the study hospitals)   
 
3.11. Did you visit any other provider? 
      a. Yes    (To the interviewer: go to the next page) 
   b. No    (To the interviewer: skip to page 20) 
Contact 2 
 
3.12. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
________________________________________________________________________  
3.13. What type of care provider did you visit?  
Care Provider Tick 
only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Only tick what she says.  
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Tick what she says. 
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d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
f. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
j. Other. Please specify 
__________________ 
 
 
 
3.14. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
  Can’t remember  
3.15. How far away is this provider from you’re your home? ____km, or ___miles  Don’t know  
 
3.16. How long did it take you to get there from your home? _____hrs and/or ____ mins   
           Can’t remember  
3.17. Which means of transport did you use?  
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi, mini-cab)    
d. Bus       
e. Other. Please specify__________________  
 
3.18. What was your reason for visiting this care provider at the time you did? Tick all appropriate boxes 
a. Symptoms did not go away      
b. Symptoms worsened             
c. Previous provider was not helpful     
d. Treatment(s) given by previous provider didn’t work   
e. Too long to get test results from previous provider       
f. Advice from people/family/friends             
g. Referred from previous provider     
h. Other. Please specify___________________________   
3.19. How much time went by between the date of first visit to provider 1 to date of first visit to provider 
2?   
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.20. What was the cause of the delay? Tick all appropriate boxes   
 Delay caused 
by woman  
I delayed 
Fear of:  
 diagnosis 
 treatment 
 Did not 
think it was 
 No transport 
money 
Partner /Husband 
 Did not give 
permission 
 No one to 
look after 
children 
 Other 
reason 
Notes to Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If “Other” is selected enter details in the box below. 
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because:   a serious 
problem 
 Other 
financial 
constraints 
 Fear of rejection 
If Other (explain):                                                             
 
 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
appointment to 
see a doctor 
 The doctor 
told me it was 
not serious/ 
there was 
nothing to worry 
about 
 Other reason 
If Other (explain):                                                             
 
 
3.21. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry      
b. Tests done but I was never told the results     
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
i. Please specify type of treatment_________________   
e. Told I had something else but no treatment offered      
i. Please specify (i) type of diagnosis_______________   
f. Told I had something else and treatment offered    
i. Please specify: (i) type of diagnosis_______________  
a. (ii) type of treatment______________  
g. Referred to another provider/facility     
h. Not applicable (this provider is one of the study hospitals)   
 
3.22. Did you visit any other provider?  
 a. Yes  (To the interviewer: go to the next page) 
 b. No  (To the interviewer: skip to page 20) 
Contact 3 
 
3.23. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
__________________________________________________________________________   
3.24. What type of care provider did you visit?  
Care Provider Tick 
only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
f. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Only tick what she says.  
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j. Other. Please specify 
__________________ 
 
 
 
3.25. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
    Can’t remember
  
3.26. How far away is this provider from your home? ____km, or ____miles  Don’t know  
 
3.27. How long did it take you to get there from your home? _____hrs and/or ____ mins   
              Can’t remember
  
3.28. Which means of transport did you use?  
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi, mini-cab)     
d. Bus       
e. Other. Please specify__________________    
 
3.29. What was your reason for visiting this care provider at the time you did? Tick all appropriate boxes 
a. Symptoms did not go away     
b. Symptoms worsened            
c. Previous provider was not helpful    
d. Treatment(s) given by previous provider didn’t work  
e. Too long to get test results from previous provider      
f. Advice from people/family/friends            
g. Referred from previous provider    
h. Other. Please specify_______________________  
3.30. How much time went by between the date of first visit to provider 2 to date of first visit to provider 
3?  
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.31. What was the cause of the delay? Tick all appropriate boxes 
 Delay caused 
by woman  
I delayed 
because:  
Fear of:  
 diagnosis 
 treatment 
 
 Did not 
think it was 
a serious 
problem 
 No transport 
money 
Partner /Husband 
 Did not give 
permission 
 Fear of rejection 
 No one to 
look after 
children 
 Other 
reason 
Notes to Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If “Other” is selected enter details in the box below. 
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 Other 
financial 
constraints 
If Other (explain):                                                             
 
 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
appointment to 
see a doctor 
 The doctor 
told me it was 
not serious/ 
there was 
nothing to worry 
about 
 Other reason 
If Other (explain):                                                             
 
 
3.32. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry     
b. Tests done but I was never told the results    
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
i. Please specify type of treatment_______________  
e. Told I had something else but no treatment offered     
i. Please specify (i) type of diagnosis_____________  
f. Told I had something else and treatment offered    
i. Please specify: (i) type of diagnosis_____________  
a. (ii) type of treatment____________  
g. Referred to another provider/facility     
h. Not applicable (this provider is one of the study hospitals)   
 
3.33. Did you visit any other provider?  
  a.  Yes  (To the interviewer: go to the next page) 
  b.  No   (To the interviewer: skip to page 20) 
Contact 4 
 
3.34. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
___________________________________________________________________________   
3.35. What type of care provider did you visit?  
Care Provider Tick 
only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
f. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Only tick what she says.  
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j. Other. Please specify 
__________________ 
 
 
 
3.36. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
Can’t remember  
3.37. How far away is this provider from your home? ____km, or ___miles  Don’t know  
 
3.38. How long did it take you to get there from your home? _____hrs and/or ____ mins   
        Can’t remember  
3.39. Which means of transport did you use? 
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi, mini-cab)     
d. Bus       
e. Other. Please specify__________________    
 
3.40. What was your reason for visiting this care provider at the time you did? Tick all appropriate boxes 
a. Symptoms did not go away     
b. Symptoms worsened            
c. Previous provider was not helpful    
d. Treatment(s) given by previous provider didn’t work  
e. Too long to get test results from previous provider      
f. Advice from people/family/friends            
g. Referred from previous provider    
h. Other. Please specify_______________________  
3.41. How much time went by between the date of first visit to provider 3 to date of first visit to provider 
4?  
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.42. What was the cause of the delay? Tick all appropriate boxes  
 Delay caused 
by woman  
I delayed 
because:  
Fear of:  
 diagnosis 
 treatment 
 
 Did not 
think it was 
a serious 
problem 
 No transport 
money 
 Other 
financial 
constraints 
Partner /Husband 
 Did not give 
permission 
 Fear of rejection 
 No one to 
look after 
children 
 Other 
reason 
If Other (explain):                                                             
 
Notes to Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If “Other” is selected enter details in the box below. 
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 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
appointment to 
see a doctor 
 The doctor 
told me it was 
not serious/ 
there was 
nothing to worry 
about 
 Other reason 
If Other (explain):                                                             
 
 
3.43. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry     
b. Tests done but I was never told the results    
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
i. Please specify type of treatment_______________  
e. Told I had something else but no treatment offered     
i. Please specify (i) type of diagnosis_____________  
f. Told I had something else and treatment offered    
i. Please specify: (i) type of diagnosis_____________  
a. (ii) type of treatment____________  
g. Referred to another provider/facility       
h. Not applicable (this provider is one of the study hospitals)   
 
3.44. Did you visit any other provider?  
  a.  Yes   (To the interviewer: go to the next page) 
 b.  No   (To the interviewer: skip to page 20) 
Contact 5 
 
3.45. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
_________________________________________________________________________    
3.46. What type of care provider did you visit?  
 
Care Provider Tick 
only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
f. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
j. Other. Please specify 
__________________ 
 
 
 
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Only tick what she says.  
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3.47. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
  Can’t remember  
3.48. How far away is this provider from your home? ____km, or ___miles   Don’t know  
 
3.49. How long did it take you to get there from your home? _____hrs and/or ____ mins   
           Can’t remember  
3.50. Which means of transport did you use? 
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi, mini-cab)     
d. Bus       
e. Other. Please specify__________________    
 
3.51. What was your reason for visiting this care provider at the time you did? Tick all appropriate boxes 
a. Symptoms did not go away     
b. Symptoms worsened            
c. Previous provider was not helpful    
d. Treatment(s) given by previous provider didn’t work  
e. Too long to get test results from previous provider      
f. Advice from people/family/friends            
g. Referred from previous provider    
h. Other. Please specify_______________________  
3.52. How much time went by between the date of first visit to provider 4 to date of first visit to provider 
5?  
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.53. What was the cause of the delay? Tick all appropriate boxes   
 Delay caused 
by woman  
I delayed 
because:  
Fear of:  
 diagnosis 
 treatment 
 
 Did not 
think it was 
a serious 
problem 
 No transport 
money 
 Other 
financial 
constraints 
Partner /Husband 
 Did not give 
permission 
 Fear of rejection 
 No one to 
look after 
children 
 Other 
reason 
If Other (explain):                                                             
 
 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
 The doctor 
told me it was 
not serious/ 
there was 
 Other reason 
Notes to Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If “Other” is selected enter details in the box below. 
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appointment to 
see a doctor 
nothing to worry 
about 
If Other (explain):                                                             
 
 
3.54. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry     
b. Tests done but I was never told the results    
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
i. Please specify type of treatment______________   
e. Told I had something else but no treatment offered     
i. Please specify (i) type of diagnosis_____________  
f. Told I had something else and treatment offered    
i. Please specify: (i) type of diagnosis_____________  
a. (ii) type of treatment____________  
g. Referred to another provider/facility     
h. Not applicable (this provider is one of the study hospitals)   
 
3.55. Did you visit any other provider?  
  a.  Yes   (To the interviewer: go to the next page) 
 b.  No   (To the interviewer: skip to page 20) 
Contact 6 
 
3.56. What is the name of the provider (e.g. hospital, clinic, traditional healer) you visited? 
_______________________________________________________________________   
3.57. What type of care provider did you visit?  
 
Care Provider Tick 
only 1 
option  
a. Private doctor (General Practitioner)  
b. Community clinic sister/doctor  
c. Private hospital sister/nurse/doctor  
d. Public hospital sister/nurse/doctor  
e. Social worker or counsellor  
f. Chemist/pharmacist  
g. Home/community based care worker  
h. Traditional healer/herbalist  
i. Church Pastor/Elder  
j. Other. Please specify 
__________________ 
 
 
 
3.58. Date of first visit: _ _ /_ _ / _ _ _ _, or ___days, or ___weeks, or ___months, or ___years ago  
  Can’t remember  
Notes for Interviewer: 
 
Do NOT read out the choices provided for each question to the participant. Only tick what she says.  
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3.59. How far away is this provider from your home? ____km, or ___miles   Don’t know  
 
3.60. How long did it take you to get there from your home? _____hrs and/or ____ mins   
        Can’t remember  
3.61. Which means of transport did you use?  
a. Own car      
b. Lift from relative/friend     
c. Rented car (e.g. taxi, mini-cab)     
d. Bus       
e. Other. Please specify__________________    
 
3.62. What was your reason for visiting this care provider at the time you did? Tick all appropriate boxes. 
a. Symptoms did not go away     
b. Symptoms worsened            
c. Previous provider was not helpful    
d. Treatment(s) given by previous provider didn’t work  
e. Too long to get test results from previous provider      
f. Advice from people/family/friends            
g. Referred from previous provider    
h. Other. Please specify_______________________  
3.63. How much time went by between the date of first visit to provider 5 to date of first visit to provider 
6?  
a. Less than 2 weeks     
b. 2-4 weeks      
c. 1-3 months      
d. 4-6 months      
e. More than 6 months     
 
3.64. What was the cause of the delay? Tick all appropriate boxes   
 Delay caused 
by woman  
I delayed 
because:  
Fear of:  
 diagnosis 
 treatment 
 
 Did not 
think it was 
a serious 
problem 
 No transport 
money 
 Other 
financial 
constraints 
Partner /Husband 
 Did not give 
permission 
 Fear of rejection 
 No one to 
look after 
children 
 Other 
reason 
If Other (explain):                                                             
 
 Delay caused 
by clinic 
 They gave me 
medicine and told 
me to come back 
after ___ weeks 
 There was a 
delay for test 
results 
 It took a 
_____weeks 
or____Months 
before I got an 
appointment to 
see a doctor 
 The doctor 
told me it was 
not serious/ 
there was 
nothing to worry 
about 
 Other reason 
If Other (explain):                                                             
 
Notes to Interviewer: 
 
If the delay was greater than 1 month, ask the question below. If “Other” is selected enter details in the box below. 
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3.65. What was the outcome of the contact with this provider? Tick all appropriate boxes. 
a. Reassurred and told not to worry      
b. Tests done but I was never told the results     
c. Told I had breast cancer but no treatment offered    
d. Told I had breast cancer and treatment offered    
i. Please specify type of treatment__________________  
e. Told I had something else but no treatment offered      
i. Please specify (i) type of diagnosis________________  
f. Told I had something else and treatment offered    
i. Please specify: (i) type of diagnosis________________  
a. (ii) type of treatment_______________  
g. Referred to another provider/facility     
h. Not applicable (this provider is one of the study hospitals)   
 
3.66. Did you visit any other provider?  
 a.  Yes  (To the interviewer: use additional contact forms)  
 b.  No  (To the interviewer: go to the next page) 
Section 4. Local Health Care Services 
 
 
 
 
 
 
4.1. Do you still live in the same area where you lived when you your current breast problem was first 
noticed? 
a. Yes          
b. No, I moved to another area because of my illness  
         (e.g to be close to relatives/friends, medical facilities)    
c. No, I moved somewhere else for other reasons     
  
4.2.Is there any health care service or hospital located within easy access or reach of where you lived when 
your current breast problem was first noticed? 
a. Yes               
b. No   
 
4.3.If there is a health centre near where you lived when your current breast problem was first noticed 
please indicate type of health facility: 
a. Primary Health Centre           
b. General Hospital            
Notes for Interviewer: 
 
To the participant: “Many thanks. I am now going to ask you a few question about the health care services available 
where you live at the time when you first noticed your breast changes”. 
 
- The questions below refer to the place where the woman lived when her current breast problems were first noticed.  
   
249 
 
c. Teaching Hospital                                      
d. Private Hospital       
e. Other. Please specify__________________________   
f. There is no health care service/hospital where I live(d)   
  
4.4. Did you visit this health center within easy access of your home for your current breast problem? 
 
a. Yes   Contact no.___ {To Interviewer: Enter contact no. from section 3 here}          
b. No   
c. There is no health care service/hospital where I live(d)  
 
 
4.5. If you did NOT visit the health center near your home, what was the main reason for that? Tick all 
appropriate options. 
 
a. I did not want my neighbours to see me going to the health center   
b. The clinic was too expensive        
c. The health center had little experience in dealing with breast conditions                                   
d. It took too long to get an appointment there      
e. Its doctors/nurses asked you to go elsewhere      
f. It took too long to get test results       
g. I had a private doctor in another hospital who I wanted to see first   
h. I wanted to go to a center close to where my children live     
i. Other. Please specify______________________________________   
 
 
Section 5. Patient’s Perception of Family/Community Support 
 
 
 
Note to Interviewer:  
 
If the participant replies “Yes”, find out which provider number does it refer to and add the number in the space 
provided below.  
 
Note to Interviewer:  
 
Do NOT read out the choices below to the participant. Only ticks what she says. 
 
Note for Interviewer: 
 
To the participant: “Many thanks for your help so far. I am now going to ask you a few questions about the 
support you are getting from your family and community.”   
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5.1. After your breast problem was noticed who decided what to do next? 
a. You       
b. Your husband/partner      
c. You jointly with your husband partner    
d. Other family member      
e. Other. Please specify________________  
 
5.2. Did you try to hide your breast problem from: 
a. Your husband      
b. Your children      
c. Other relatives      
d. Some friends       
e. Some of your neighbours     
f. Others. Please specify_____________________  
g. I did not try to hide the problem from anyone   
 
5.3. Who usually accompanies you during your visits to the clinic/hospital? 
a. Your husband/partner      
b. Your children      
c. Others. Please specify______________________  
d. A friend       
e. No one       
  
5.4. Would you prefer to be accompanied by someone else? If so, by whom: 
a.   Yes, by husband/partner      
b.   Yes, by your children       
c.   Yes, by a friend       
e.   Yes, by someone else. Please specify___________   
f.   No, I am happy as it is       
 
5.5. Since the start of your health problems, have you felt that you are being supported by your:  
a. Family?  Yes   No   Not sure      
b. Friends?  Yes   No   Not sure      
c. Community?  Yes   No   Not sure    
d. Employer(s)?  Yes   No   Not sure    
 
5.6.  Who is covering/will cover your health related expenses? 
a. Self        
b. Family/Friends       
c. National Health Insurance Scheme (NHIS)   
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d. Employer       
e. Church/Pastor/Elder      
f. Other. Please specify________________________  
g. Don’t know       
 
5.7. If you held a job outside your home prior to your current breast problem do you still hold the same 
job?  
 
a. Yes, I still hold the same job       
b. No, I had to move to a different job because of my breast health problem  
c. No, I am no longer able to hold a job because of my breast problem  
d. No, I move to a different job for reasons unrelated to my health problem  
e. I did not have a job prior to the start of my current health problems   
 
5.8. Are you getting additional help to carry out your home chores because of your breast problem? 
a. Yes, from my husband/partner or children     
b. Yes, from other relatives       
c. Yes, from friends        
d. Yes, from others. Please specify___________________________   
e. No, I feel the need but there is no one available/willing to help   
f. No, I haven’t felt the need to get any additional help    
 
 
 
Section 6. Hurdles to Seeking Help for Breast Condition 
 
 
6.1. After your breast problem was first noticed how long (in total) did it take for you to reach this hospital? 
 
   
_____weeks,  or _____months,  or _____years and ______months  
Notes for Interviewer: 
 
To the participant: “Many thanks. To finish off this interview I would like to ask you a few questions on factors that 
may have affected the way in which you sought medical help for your breast condition”.  
 
Notes for Interviewer: 
Check consistency of her answer with the timeline of key events you completed throughout the interview. 
Note to Interviewer: 
Tick option e) if the woman did not have a job outside her home before the start of her current breast problem. 
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 Can’t remember  
 
6.2. If more than 3 months, which of the following factors do you think contributed to the delay in reaching 
this hospital? 
  
Note for Interviewer:  
- To be completed ONLY if there was a delay of more than 3 months.  
- Below is a list of potential barriers a woman might face that prevent her from seeking early help after her breast 
problem was noticed. Read out this list.  
Ask her to answer “Yes”, “No” or “Not sure” for each of the factors as it applies to her particular circumstances. Tick 
only one answer per factor. If the woman mentions a factor not listed enter the details in the “Other” box. 
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Personal barriers 
 Yes No Not sure 
1. Did not think it was a serious problem    
2. Embarrassed or worried about what the doctor might find    
3. Did not believe breast problem could be taken care of in the hospital    
4. Fear of treatment caused delay    
5. Fear of dying caused delay    
6. Believe in traditional medicine (TM) and wanted to try it first    
7. Other. Please specify_________________________________________     
Family/Community barriers 
8. Husband did not give permission     
9. Fear of rejection by husband/family members    
10. No one at home to look after the children    
11. Family/community members believe in traditional medicine (TM) / recommended TM 
over western medicine 
   
12. Was confused with the advice I was getting from others (e.g. relatives, friends, others) on 
where to go for help  
   
13. Fear of rejection by community members    
14. Other. Please specify________________________________________     
Economic barriers 
15. Employed and could not get time off work to go to the hospital so delayed    
16. Could not afford transportation to the hospital    
17. Could not afford treatment so delayed    
18. Was worried of loosing my job so delayed    
19. Too many other financial commitments    
20. Other. Please specify________________________________________     
Health Service Barriers {To Interviewer: Do NOT include access to traditional or alternative medicines}  
21. Clinic/hospital(s) located too far away from home    
22. Difficulty in getting earlier appointment(s) to see the doctor    
23. Was told by doctors in other clinic/hospital that my problem was not serious    
24. Had to wait a long time to be told of test results     
25. Was given treatment but it did not work    
26. The clinic/hospital(s) I went first did not have the necessary resources     
27. It took a long time before I was finally sent to this hospital    
28. Other. Please specify________________________________________     
Other barriers    
29. Please specify_____________________________________________     
Notes for Interviewer: 
To the participant:  “Many thanks for your time and help with this study. Very much appreciated” 
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TIMELINE OF KEY EVENTS: SUMMARY 
 
 
 
 
 
 
 
Contacts  Date symptoms were 
first noticed 
Contact 1 Contact 2 Contact 3 Contact 4 Contact 5 Contact 6 
Care Provider        
Date of first visit        
        
Contacts  Contact 7 Contact 8 Contact 9 Contact 10 Contact 11 Contact 12 
Care Provider       
Date of first visit       
       
Notes for Interviewer:  
This section should be competed by you as the interview progresses. 
It will help you to keep track of key dates of a woman’s journey. Please check that the dates follow a logical sequence (e.g. the date of first visit to provider 2 should not come before date 
of first visit to provider 1).  
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The Nigerian Integrative Epidemiology of Breast Cancer (NIBBLE) 
Study 
Main Risk Factor Questionnaire 
Study Site:  
Study ID:   Hosp ID:  
 Interviewer code:   
Date Of Interview:         __ __ / __ __ / __ __ __ __ 
Day   Mo    Year 
 First name: ____________________ Last name: ____________________________ 
Phone no:     Phone no 2:    
Contact Address: _____________________________________________________ 
   _____________________________________________________ 
   
Name of next of kin 1: ________________________________________________ 
Relationship of next of kin:___________________________________________ 
Phone no of next of kin :      
Contact Address: _____________________________________________________ 
  of next of kin _____________________________________________________ 
Name of next of kin 2: ________________________________________________ 
Relationship of next of kin 2:___________________________________________ 
Phone no of next of kin 2:      
Contact Address: _____________________________________________________ 
  of next of kin _____________________________________________________ 
Date of First Diagnosis:   __ __ / __ __ / __ __ __ _ 
     DAY  MO  YEAR 
Section A: Background Information 
1. What is your date of birth? _ __ / __ __ / __ __ __ __  Age:  years 
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       DAY   MO   YEAR 
2. Where do you work:  _____________________________________________________ 
                         Office number   Street name  
 
               _____________________________________________________ 
                      City            State   
3. Do you have a personal income? a. Yes   b. No   
4. If yes, what was the type of job you held most recently:  
a. Housework    b. Petty Trader/Odd jobs  
c. Unskilled occupations (e.g. Security guard, porter, farmer)  
d. Non-Manual skilled occupations (office workers)  
e. Manual skilled occupations (bricklayers, coalminers, trader)  
f. Managerial and lower professionals (managers, teachers)  
g. Professional (doctor, lawyer, nurse, pharmacist, accountant)       
5. For how long have you been doing this work: years    Months 
6. What is the range of annual income for yourself, your husband or others in your household? 
a. Less than N150,000/year b. N150,000-N500,000/year c More than N500,000/year 
7. What religion do you practice: 
a. Christianity   b. Islam   c. Traditional  d. None  
e. Others  please specify: _____________________  
8. Please tell us about your tribe, that of your parents and grandparents. If the tribe is not listed, please 
write it in the “others” row under the person’s name: 
No Tribes Family members 
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You Father Mother Father’s 
father 
Father’s 
mother 
Mother’s 
father 
Mother’s 
mother 
a. Fulani        
b. Hausa        
c. Igbo        
d. Ijaw        
e. Kanuri        
f. Nupe        
g. Yoruba        
h. Others        
 
9. What is your marital status: 
a. Married     b. Single     c. Separated  
d. Divorced    e. Widowed   f. Cohabiting  
g. Others,    please specify: _____________________ 
10. What type of marital arrangement do you have: 
a. Monogamous (Living together)   b. Polygamous (All living together)     
c. Monogamous (Living separately)  d. Polygamous (Living separately)    
e. Not married and living alone     f. Not married and living with family  
g. Not married and living with Boyfriend    h. Not married but living with friends  
11. What is the highest level of education that you attained: 
a. No formal schooling   b. Koranic school only      c. Vocational only  
d. Less than 5 years of formal schooling (Did not complete primary school)    
e. Completed primary school only (6 years)  
f. Some high school (7 – 11 years)         
g. Completed high school (12 years)        
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h. Had post high school education but not university  
i. Completed university education      
j. Postgraduate degree       
Section B: Determination of household wealth (Modified Filmer-Prichett Index) 
12. House ownership 
a. Owned    b. Rented   c. Other  
Specify______________ 
13. Type of house 
a. Stand-alone family unit    b. Duplex  
c. 2-3 bedroom apartments  d. Self-contained (studio) apartment  
e. Single room            f. Others , please specify: __________________ 
14. How many people live in your home  
15. Source of water 
a. Go to fetch    b. Surface well in residence  
c. Deep well in residence  d. Borehole in residence  
e. Municipal water supply  f. Bottled water   
g. Public water tap   h. Surface water (river, pond)  
i. Tanker    j. Others , please specify: ____________ 
16. Do you do anything to make your water safer to drink 
a. Yes   b. No  
17. What do you do to make your drinking water safer to drink (Mark all that apply) 
b. Filtering    b. Boiling  
c. Adding chemicals   d. Others , please specify: ________________ 
18. What is your main source of cooking fuel 
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a. Gas    b. Electricity   
c. Kerosene stove   d. Firewood/charcoal  
e. Others,   please specify: ________________________________ 
19. Do you have a separate room for cooking where you live (like a kitchen) 
a. Yes                      b. No  
20. What type of toilet facility do you use 
a. Water cistern   b. Aqua privy  
c. Pit toilet    d. None  
21. Which of these goods do you or your partner own  
a. Car     b. Motorcycle  
c. Refrigerator    d. TV   
e. Bicycle    f. Electric fan  
22. What would you consider your social class 
Participants view                           Interviewer’s view 
a. Lower class                a. Lower class    
b. Lower middle class         b. Lower middle class   
c. Upper middle class          c. Upper middle class   
d. Upper class               d. Upper class    
 
Section C: Reproductive History 
 
22. At what age did you start having regular menstrual periods?  years don’t know 
 
23. How long ago was your last menstrual period?  years  months days 
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24. Have your menstrual periods stopped for 1 year or more? Please do not include times when  
      your periods stopped because of pregnancy, breast-feeding, or serious illness.  
 Yes    No  
 
25. 25.  How old were you when you had that period before your periods stopped for 1 year or more?  
 
 years 
26. 26.  Did your menstrual periods stop because of: 
 
a. The periods stopped by themselves 
b. Past surgery  
c. Past medical treatment 
d. Current treatment for any cancer 
 
27. 27.  Have you ever taken any medications (oestrogen, progestin, or other female hormones) for 
 menopause? If No Skip to 30 
 
 Yes    No  
 
28. How old were you when you first took these medications for menopause? 
  
  years 
 
29. How many years in total did you take these medications for menopause? 
 
  years 
 
30. Have you ever used hormonal contraceptives, in the form of birth control pills, implants, or injections? 
If  no skip to 33 
  
 Yes    No  
 
31. How old were you when you first started taking hormonal contraceptives? 
  
  years 
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32. In total, how many years did you use hormonal contraceptives for? 
 
  years 
 
33. Have you ever been pregnant? If No skip to question 35  
  
 Yes    No  
 
 IF YES: 
 
 a. How many pregnancies have you had?    
 
. b.  How many live births have you had?       
 
 c. How old were you when you had your first live birth?   
 
 d. How old were you when you had your last live birth?  
 
 e. Did you ever breast-feed a child for one month or longer? 
   
  Yes    No  
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34. Pregnancy history 
 1st PREGNANCY 2nd PREGNANCY 3rd PREGNANCY 
What was the outcome of your 
pregnancy?  
   
Use the following code for outcome of pregnancies –  
Currently pregnant  1  Single live birth    2 
Multiple birth   3  Stillbirth    4 
Miscarriage   5  Tubal or ectopic pregnancy 6 
Induced abortion  7  Don’t know    9 
During what month and year (was your 
baby born / did this pregnancy end)? 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ 
MO    YEAR 
How long was this pregnancy in months? ____ ____ ____ 
IF SINGLE LIVE BIRTH OR 
STILLBIRTH: 
Did you have a boy or a girl? 
 
IF MULTIPLE LIVE BIRTHS OR 
STILLBIRTHS: 
 
   ____ 
 # of BOYS 
  
   ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS   
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IF SINGLE OR MULTIPLE LIVE 
BIRTH(S): 
Did you breast-feed (this child / these 
children)? 
 
IF YES: 
For how many months did you breast-feed 
(this child / these children)?  
 
 
YES   
NO    
 
 
 
    
 
 
YES   
NO    
 
 
 
     
 
 
YES   
NO   
 
 
 
 
     
 4th PREGNANCY 5th PREGNANCY 6th PREGNANCY 
What was the outcome of your pregnancy?  
 
 _____ 
 
 
 _____ 
 
 
 _____ 
 
Use the following code for outcome of pregnancies –  
Currently pregnant  1  Single live birth    2 
Multiple birth   3  Stillbirth    4 
Miscarriage   5  Tubal or ectopic pregnancy 6 
Induced abortion  7  Don’t know    9 
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During what month and year (was your 
baby born / did this pregnancy end)? 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ 
MO    YEAR 
How long was this pregnancy in months? ____ ____ ____ 
IF SINGLE LIVE BIRTH OR 
STILLBIRTH: 
Did you have a boy or a girl? 
 
IF MULTIPLE LIVE BIRTHS OR 
STILLBIRTHS: 
 
   ____ 
 # of BOYS 
  
   ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS   
IF SINGLE OR MULTIPLE LIVE 
BIRTH(S): 
Did you breast-feed (this child / these 
children)? 
 
IF YES: 
For how many months did you breast-feed 
(this child / these children)?  
 
 
YES   
NO    
 
 
 
    
 
 
YES   
NO    
 
 
 
     
 
 
YES   
NO   
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 7th PREGNANCY 8th PREGNANCY 9th PREGNANCY 
What was the outcome of your pregnancy?  
 
 _____ 
 
 
 _____ 
 
 
 _____ 
 
Use the following code for outcome of pregnancies –  
Currently pregnant  1  Single live birth    2 
Multiple birth   3  Stillbirth    4 
Miscarriage   5  Tubal or ectopic pregnancy 6 
Induced abortion  7  Don’t know    9 
During what month and year (was your 
baby born / did this pregnancy end)? 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ _ 
MO    YEAR 
 
__ __ /__ __ __ 
MO    YEAR 
How long was this pregnancy in months? ____ ____ ____ 
IF SINGLE LIVE BIRTH OR 
STILLBIRTH: 
Did you have a boy or a girl? 
 
IF MULTIPLE LIVE BIRTHS OR 
STILLBIRTHS: 
 
   ____ 
 # of BOYS 
  
   ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS 
 
   ____ 
 # of BOYS 
  
  ____ 
 # of GIRLS   
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IF SINGLE OR MULTIPLE LIVE 
BIRTH(S): 
Did you breast-feed (this child / these 
children)? 
 
IF YES: 
For how many months did you breast-feed 
(this child / these children)?  
 
 
YES   
NO    
 
 
 
    
 
 
YES   
NO    
 
 
 
     
 
 
YES   
NO   
 
 
 
 
     
 
35. Have you ever taken a drug for infertility to try to become pregnant, or because your periods stopped unexpectedly? 
 
 Yes    No  
       
 IF YES: 
 
a. What type of medication? 
    
i. Pill  ii. D&C   iii. Others , please specify: ____________ 
      3 
b. How old were you when you first started to take this medication? 
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   years 
 
c. How many months in total did you use this treatment? 
 
  years 
 
d. Which, if any, of the following drugs did you take? 
 
     YES  NO  Don’t know 
  Clomid         
  Pergonal        
  Serophene        
  hCG         
  Other        Please specify: ______________________ 
 
Section D: Medical History 
 
36. Has a doctor ever told you that you had cancer, leukaemia, or a malignant tumour? 
  
 Yes    No  
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 IF YES: 
 
 CANCER #1 CANCER #2 CANCER #3 
What type of cancer did you have?    
How old were you when this cancer was first diagnosed 
in years? 
  
 
  
 
  
 
In what year were you diagnosed with this cancer?     
How was the cancer treated? 
 
   
 
37. Has a doctor ever told you that you had benign breast disease, such as non-cancerous cyst or a breast lump? 
  
 Yes    No  
 
 IF YES: 
 
a. How old were you when this was first diagnosed?  
 
b. How was the benign breast disease, such as non-cancerous cyst or a breast lump 
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Traditional   Surgery   Medical treatment   No treatment  
 
Section E: Lifestyle factors  
Smoking 
38. Do you smoke cigarettes or any other tobacco containing products? If No skip to No 44. 
a.  Yes                      b. No  
39. Have you ever smoked up to 100 cigarettes (5 packets) in total in your entire life? If No skip to No 44 
b. Yes                      b. No  
 IF YES: 
 
40. How old were you when you started smoking regularly?  years 
41. When you smoke, how often do you smoke? 
 <1/month         > 1/month but < 1/week       At least 1/week but < 1/day       Daily     
42. When you smoke, how many sticks of cigarettes do you smoke daily?  
1          2-10          11- 20           More than 20 
43. Are you currently exposed to second hand smoke (passive smoking) in your working place or at home?  
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Drinking 
 
44. Do you drink alcohol? If No skip to No 49 
a.  Yes                 b. No  
45. Have you ever drank at least a measure of alcohol - bottle of beer, a glass of alcoholic wine, a shot of “hot” drink or more or regularly taken any 
alcohol containing medicines - in the past 5 years? If No skip to No 49 
b. Yes                 b. No  
46. How old were you when you first started drinking regularly?  years 
47. How often did you drink alcohol in the last 1 year? 
  <1/month         > 1/month but < 1/week       At least 1/week but < 1/day      Daily         
48. How many measures of alcohol do you usually drink at a time on the days when you drink?  
      1          2-5          5 - 10           More than 10 
Physical activity 
49. What is your usual walking pace 
 Slow/Casual    Normal     Brisk   Very brisk/striding   
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 Unable to walk  
50. How many flights of stairs/staircase (not individual steps) do you climb daily? 
None   1 – 2   4 – 5   5 – 9   10 – 14  15 or more 
51. During the past year, what was the average amount of time you spent per week on each of the activities listed below 
Activity 0 1–4 
mins 
5–
19 
mins 
20–
59 
mins 
One 
hour 
1–
1.5 
hrs 
2–3 
hrs 
4–6 
hrs 
7–
10 
hrs 
11+ 
hrs 
Walking to and from 
work 
          
Jogging           
Running           
Bicycling (including 
stationary bikes) 
          
Dancing – church, 
social occasions etc 
          
Table tennis/Lawn 
Tennis 
          
Soccer           
Squash           
Golf           
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Hiking/Walking            
Swimming           
Aerobics           
Weight lifting or 
resistance exercises 
          
Other vigorous 
activities, please 
specify: ________ 
          
 
52. During the past year, how many hours per week did you spend on the activities listed below 
Activity 0 
hours 
One 
hour 
2-5 
hrs 
6-
10 
hrs 
11-
20 
hrs 
21-
40 
hrs 
41-
60 
hrs 
61-
90 
hrs 
Over 
90 
hrs 
Standing or 
walking around at 
work or away from 
home (hrs/week) 
         
Standing or 
walking around at 
home (hrs./week) 
         
Sitting while 
working or while 
away from home 
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include time you 
were driving or 
sitting in a vehicle 
(hrs/week) 
Sitting at home 
watching TV 
(hrs/week) 
         
Sitting at home 
doing other things – 
resting, working on 
computer, reading, 
eating (hrs/week) 
         
 
53. In an average week, how many days do you usually exercise (include brisk walking or more strenuous activity)? 
None    1 day   2 days   3 days     4 days    
5 days       6 days          7 days 
54. Do you have doctor confirmed – 
a. Hypertension        b. Diabetes    
c. Any other chronic illness,         please specify: __________________  
d. None at all 
                
 
 
 
274 
 
 
  
Section F: First Degree – (Parents, Brothers and Sisters and Children) - Family History of Cancer 
 
55.  
No Which of your relatives 
was diagnosed with 
cancer?  
What type of cancer 
does/did he/she 
have? 
How old was he/she 
when the cancer was 
first diagnosed? 
How was the cancer 
treated – orthodox or 
unorthodox or both? 
     
     
     
     
     
     
     
     
 
Section G. Measurements 
 
56. Anthropometric measurements
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a. Standing Height  
(cm) 
 
b. Sitting Height  
(cm) 
 
c. Weight   
(kg) 
 
d. Waist   
(cm) 
 
e. Hip   
(cm) 
 
f. Blood pressure   Sys   
   Dias
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57. What was your weight at age 18       (kg) 
 
58. What was your weight at age 30?       (kg) 
 
59. What was your weight at age 40?       (kg) 
 
60. Somatotype images 
 
 
 
END: Thank you very much for taking the time to complete this interview.  
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Clinicopathological Information Form 
Section 1 – Clinical and Pathological Information 
 
Note to Clinician: This form is to be completed by the attending clinician during the patient’s first visit.  
Sections on Morphology, Histology and Grade for which information is not available until after a biopsy is done 
and results received can be completed afterwards. 
Please tick the appropriate options. 
 
 
Clinical Information 
Diagnosis 
Date  (Day  / Month / Year) 
 __ __ / __ __ / __ __ __ 
__ 
□1 New primary 
□2 Recurrence (not to be 
included) 
 
Histology   
□1 Invasive malignant 
neoplasms 
□2 In-situ malignant neoplasm 
□3 Benign breast disease  
 
Grade (differentiation) 
□1 Well  
□2 Moderately 
□3 Poorly 
□4 Not specified  
 
Presenting Signs 
□1 Lump  
□2 Skin changes 
□3 Nipple discharge 
□4 Ulceration 
□5 Axillary nodes 
□6 Metastases 
Laterality   
□1 Left     
□2 Right     
□3 Bilateral 
 
Morphology 
□1 Ductal  
□2 Lobular   
□3 Medullary   
□4 Mucinous/colloid  
□5 Papillary  
□6 Tubular 
□7 Paget’s Disease 
□8 Ductular 
□9 Inflammatory 
□10 Other ___________ 
 
Receptor staining scores 
ER (0,1+,2+,3+): ___ 
PR (0,1+,2+,3+): _____ 
HER2 (0,1+,2+,3+): _____ 
TNM Clinical Staging 
Tumour Node (No. 
lymph nodes 
affected) 
Distant 
Metastases 
□TX  (NK) 
□T0 (no primary) 
□Tis (in situ) 
□T1 (<2cm) 
□T2 (>2 to 5 cm) 
□T3 (>5cm) 
□T4 (chest wall/ 
skin/inflammatory) 
□NX (NK) 
□N0 (0)  
□N1 (1-3) 
□N2 (4-9) 
□N3 (10+) 
 
□MX (NK) 
□MO (none) 
□M1 (present) 
 
STAGE (0, I, IIA, IIB, IIIA, IIIB, IIIC, IV): ____  
 
Metastases present/suspected at diagnosis 
□1 None □4 Lung  
□2 Bone □5 Brain  
□3 Liver □6 Metastases but site NK 
 
Basis of diagnosis 
□1 Clinical only □4 Cytology  
□2 Imaging □5 Histology of primary  
□3 Surgery □6 Histology of metastases 
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Dates  Day/Mo/Year 
First attended this hospital   
First Clinical Examination  
First Clinical Diagnosis  
Patient first informed of diagnosis  
First Histology  
Result of Histology  
Interval between first presentation to hospital and commencement 
of definitive treatment (In months) 
 
 
 
Section 2 -Treatment 
Treatment Intended Actual Radiotherapy and 
Chemotherapy only  
  Date 
received 
Response to 
Treatment 
Side-effects No of cycles 
recommended 
No of 
cycles 
attended 
Surgery           
(Lumpectomy)
  
      
Surgery 
(Mastectomy)
  
      
Radiotherapy
  
      
Axillary 
lymphectomy 
      
Tamoxifen
  
      
Chemotherapy
  
      
Herceptin       
 
 
 
 
  
                
 
 
 
279 
 
APPENDIX 7:  LABORATORY STANDARD OPERATING PROCEDURES 
Breast Biopsies  
This procedure will be done by the collaborating surgeon/site investigator at the hospital. The biopsy sample 
can be obtained through either TruCut biopsy needles, excisional or incisional biopsies. The research 
associate is expected to liaise with the site collaborator and get information on the dates when the 
participants have been booked to come in for their biopsies. She should be present on the days when biopsies 
are done.  
The fixation process outlined below is intended to ensure that tissue samples collected from study 
participants are collected, fixed and preserved in a safe and efficient manner while contamination and loss 
of molecular and structural integrity are minimal. It is important that the procedure is done similarly across 
all sites to ensure that reliable and comparable results are obtained. 
1. Fixation should be performed as soon as possible after the specimen is collected. Optimally tissue 
should be fixed within 4 hours of biopsy. 
2. Have materials and equipment ready. Have the container containing 10% neutral pH buffered 
formalin labeled and ready. 
3. Record time from when biopsy is done to when tissue is fixed. Record this time as ‘time from 
resection to fixation’. 
4. Perform fixation at room temperature (25º C). 
5. The volume of the fixative should be at least 10-15 times greater than the volume of the tissue (i.e., 
10-15 ml for every gram of tissue). 
6. If needed particularly in cases of large tissue, dissect the tissue before fixation to ensure adequate 
penetration of the fixative. This can be done either by surgeon or research associate using a surgical 
blade to slice or make incisions on the tissue. 
7. It is recommended that specimen should be thin slices of tissue in order to be adequately fixed. If 
this is not possible, do not use specimens that are over 4-5 mm in thickness. 
8. For sites in Abuja, duration of fixation should be overnight to 24 hours but no more than 48 hours 
before the sample reaches the IHVN laboratory in Abuja. 
9. For sites outside Abuja, duration of fixation should be overnight to 48 hours and fixed tissue should 
be transported to the pathology laboratory at the site for embedding in paraffin blocks. Blocks 
should be stored by the site collaborator or research associate until transported to Abuja in monthly 
or 2 monthly batches depending on the number collected. 
10. Record time from fixation to when sample is received at the IHVN laboratory in Abuja. Record 
this time as ‘time from fixation to laboratory’. 
 
Embedding of breast tissue prior to transportation 
1. For samples collected outside Abuja, tissue should be processed, embedded and made into paraffin 
blocks at the pathology laboratory at the site before transporting it to Abuja.  
2. All blocks should be properly labeled.  
3. Paraffin blocks should be stored at or below room temperature. Excessive exposure to sun or 
extreme temperatures should be prevented. 
4. Blocks should be stored in moisture resistant cardboard boxes or plastic storage boxes. 
5. Record storage location 
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Transport of biopsy specimens 
For sites within Abuja, sample collection should be done on Mondays-Thursdays and no biopsy specimens 
should be collected on Fridays. This is to avoid logistic issues in transporting samples on the last working 
day of the week or over the weekend to the IHVN laboratory. 
For centers outside Abuja, biopsy specimens should be fixed in formalin and sent to the hospital’s pathology 
laboratory where these tissue will be embedded in paraffin and then tissue blocks stored and sent to the 
IHVN laboratory in Abuja on a monthly or 2 monthly basis depending on the number of specimens retrieved 
every month at each specific site. 
Tissue Fixation  
• 10% Neutral Buffered Formalin (10% NBF) is used for the fixation of tissue.  
Note: Fixation time is dependent on tissue size. Small tissue pieces (10x10x3 mm), specimens less than 3 
mm thickness (e.g. CNB) may be placed in fixative directly. Specimens greater than 3 mm thicken (e.g. 
mastectomy) must be dissected immediately, and the final tissue samples (ideally less than 2 mm thick) 
should be placed in fixative as soon as possible. Loss of antigenicity due to delayed fixation cannot be 
recovered. If large specimens cannot be dissected immediately, they should be incised (“bread loafed”) to 
a thickness of 3 mm or less, and the entire specimen should be placed in fixative immediately. The fixative 
should freely circulate around all surfaces of the specimen. Temporary storage of specimens at 4 C to delay 
fixation is not acceptable. This is true regardless of biopsy method (e.g. CNB or trimmed or incised 
excisional specimens).  The fixation time starts when tissue is placed in formalin, and ends when the fixation 
portion of the automated tissue processor ends. Given that most automated tissue processors provide only 
two to three hours of fixation, several hours of fixation prior to automated processing is usually required. 
Therefore, it is advisable to allow all specimens to fix overnight prior to automated tissue processing. The 
optimal length of fixation is 24 hours (12 hours minimum, 36 hours maximum). Longer fixation times may 
be acceptable if using robust antigen recovery, but this should be verified empirically. 
 
Slide baking and deparaffination 
It is advised that paraffin slides be baked at 60 degrees C for between 1-14 hrs. This temperature must not 
be exceeded as a higher temperature may result in antigen destruction. Insufficient baking may also lead to 
uneven immunoreactivity. For the simpler techniques, sections will adhere well to clean slides with no 
coating, particularly if they have been well dried; but to ensure that sections and cells will not detach from 
slides during the longer procedures of immunohistochemical staining, an adhesive is usually applied to the 
slide before the section is picked up or the cells are allowed to settle. This is an essential precaution if heat 
induced antigen retrieval method have to be used. Among the many slide coating that have been suggested 
and universally accepted are poly-L lysine and Histogrip from Invitrogen. Positively charged slides are now 
sold commercially. 
Antigen Recovery 
During routine tissue fixation, tissue specimens are typically fixed in 10% buffered formalin for long period 
of time, prior to embedding in paraffin. The formalin preserves the tissue by forming cross-linking aldehyde 
bonds. While excellent for the preservation of cellular morphology, the formalin cross-linking often 
denatures and disrupts the epitopes of investigational interest. Antigen retrieval is the process by which the 
cross-linked molecules are unmasked so that proper antibody-antigen reaction can take place. Tissue section 
pretreatments are therefore essential for obtaining the best possible results when attempting to detect 
epitopes in formalin-fixed, paraffin embedded tissue sections. These pretreatments are also excellent for 
increasing antigenicity (e.g. staining signal) in archival material. There are two main types of antigen 
retrieval namely: 
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 Heat induced epitope retrieval (HIER) 
This is the technique of heating a slide in buffer prior to staining. Heating provides the energy not to only 
rupture the hydroxyl bonds formed by the fixative with the protein antigen, freeing some antigens, but also 
to release tissue –bound calcium ions which contribute to tighter bonds with the fixative. HIER is a major 
step forward in IHC and has been found to be effective in not only formalin fixed tissue. HIER is carried 
out after the section has been cut, baked, deparaffinized and hydrated. There is a myriad of available heating 
sources for HIER such as autoclaves, microwave and pressure cooker but the source selected should be one 
that allows for sustained high temperature and uniform heating. When using microwave, the same no of 
coupling jars filled with buffer should be kept in the oven at all time to maintain consistency of heating. At 
least 2-3 heat/cool cycles are needed (5-10 minutes each) with replenishment of evaporated buffer in 
between each cycle. These slides should be cooled in their original containers at room temperature and not 
allowed to air-dry. The duration of heating is inversely proportional to the maximum temperature reached. 
The actual amount of time to heat the slides in the buffer should be determined in each laboratory according 
to the overall fixation time. After a certain amount of time, heating will not produce anymore benefit and 
will result in deterioration in morphology.  
Assay development  
Studying gene expression at the protein level on histological slides is best done with IHC. Almost any 
protein can be measured provided that a sufficiently sensitive and specific primary antibody is available. 
No two antibodies are identical in their abilities to immunostain fixed tissue and the assay for each new 
antibody must be individually “tweaked” for optimum performance. 
The first step, referred to as Level I, determines the need and optimum type of antigen retrieval (AR), as 
well as confirms the specificity of the antibody. AR is the generic term for methods used to expose antigens 
that have been masked by tissue fixation (usually in 10% formalin). Without AR, many antibodies are 
unable to generate an IHC signal in routine archival tissue. With AR, most antibodies can successfully 
generate a staining signal, although the chemistry is poorly understood and the best strategy has to be 
determined empirically. Sometimes the resulting IHC signals are unexpected, (e.g. a cytoplasmic signal is 
observed using an antibody against a putative nuclear protein, etc.), revealing unwanted cross-reactivity of 
the primary antibody or, occasionally, novel biology. There are several AR strategies, most employing 
either pre-incubation with various proteolytic enzymes or heating slides in buffers of varying chemical 
composition (salts, chelators, and denaturing agents) and pH. Level I involves heating slides at 120C for 
10 minutes in a pressure cooker in a panel of 5 AR buffers (none; Tris-HCL at pH 9; sodium-citrate at pH 
6; sodium-citrate at pH 3; Tris-EDTA at pH 8; and 10% urea in saline) representing the most useful and 
popular in the IHC literature. Tris-HCL at pH 9 (T9) works best for the majority of antibodies in our 
experience, but there are exceptions. Level I testing is usually performed on control slides of tissue arrays 
composed of many types of normal and cancerous tissues (3mm cores arrays 5X6 = 30 total tissues), so 
there is a high likelihood that one or more cell/tissue type will be positive for a given antibody/protein. We 
can start with a moderately high concentration (5 g/ml) of primary antibody or the manufacturer’s 
recommended dilution to eliminate inadequate reagent as a cause of failure, although in many cases this is 
too high and causes background staining and occasional spurious signals.  
 
The second step, referred to as Level II, then optimizes the assay's sensitivity to detect the maximum range 
of expression possible for a given protein (e.g. from entirely negative to highly positive) by tittering the 
primary antibody concentration, and sometimes the detection system, under one AR condition. 
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Immunohistochemistry procedure 
1. Bake 3-4 um thick section for 1hr at 58°C. 
2. Deparaffinze and hydrate the baked slides as below ; 
a. Xylene           5 min 
b. Xylene           5 min 
c. Xylene           5 min 
d. 100% EtOH      20 dips 
e. 100% EtOH      20 dips 
f. 100% EtOH      20 dips 
g.  95% EtOH      20 dips  
h. Water           1 min 
i. Transfer the slides to PT Module for antigen recovery 
3. Rinse slides with distilled water (3times) and place in TBS-20 or PBS 
4. Rinse the slides 3 times with water and place in TBS-20 for at least 5 min. 
5. Clean around tissue section with tissue paper and circle the section with a PAP Pen 
6. Block endogenous peroxidase with hydrogen peroxide -------5 mins 
7. Rinse with buffer ( PBS or TBS)-----------------------------------2 mins  
8. Apply ultra V block enough to cover sections-------------------5 mins 
9. Rinse with buffer -----------------------------------------------------2 mins 
13. Optional Step: Apply Protein block for additional blocking, if needed. 
Incubate for 1hr. at RT. 
14. Add primary antibody (check incubation time for antibody) --------60 mins 
15. Rinse with buffer -----------------------------------------------------------2 mins 
16. Add primary antibody enhancer -----------------------------------------20 mins 
17Apply HRP polymer conjugate--------------------------------------------30 mins 
18. Rinse with buffer -----------------------------------------------------------2 mins 
19. Prepare DAB solution (1 drop chromogen to 1 mls DAB substrate and mix) and use immediately 
20. Add the DAB solution prepared above to cover sections ---------------5 mins 
21. Rinse with buffer --------------------------------------------------------------2 mins 
22. Counterstain with haematoxylin --------------------------------------------2 mins 
23. Rinse with Distilled water----------------------------------------------------2 mins 
24. Blue with PBS 
25. Wash in distilled water  
26. Dehydrate, clear and mount in DPX as below:                  
a. 95% EtOH                20 dips 
b. 100% EtOH               20 dips 
c. 100% EtOH               20 dips  
d. 100% EtOH               20 dips 
e. Xylene                   1 min 
f. Xylene                   30 sec 
g. Xylene                   30 sec 
 
**** PAP Pen should wash off after going through all of the above steps, if not then take a cotton swab 
with Xylene on it and rub the PAP Pen off the slide before coverslipping. 
NOTE: Section should not be allowed to dry at any point during the staining procedure. 
Apply 200ul of solution/reagent to each section or enough to cover section on slide 
      ** 1 drop = 50 ul 
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Results:  
Positive staining:                          Brown 
Negative staining and other tissue elements:     Blue 
 
NB: Negative and Positive control should be included in each batch of staining. 
 
APPENDIX 8: CONSENT FORM/INFORMATION SHEET 
Consent Form  
Consent for participation as someone who has breast cancer or someone who does not, in a 
research protocol 
 
Title of Study: Nigerian Integrative Epidemiology of Breast Cancer Study (NIBBLE) 
Health Research Ethics Committee’s approval number: HREC/01/01/2007-09/06/2013   
 
Name(s) and affiliation(s) of researcher(s) of applicant(s): This study is being conducted by 
Dr. Clement Adebamowo of the Institute of Human Virology, Nigeria (Principal Investigator)  
Sponsor(s) of research: The research is partly supported by a training grant from the National 
Institutes of Health (NIH), the Training Programme in Nigeria for Non-Communicable Research 
(TRAPING) Grant. 
 
Why have I been invited to participate in this research: You have been invited to participate 
in this research either because your doctors have diagnosed that you have breast cancer in which 
situation, you are referred to as a case for the purposes of this research or we have verified that 
you have no cancer or hormonal diseases in which case you are designated as a control for this 
research. 
Purpose(s) of research: The purpose of this research is to examine the various reasons that 
contribute to development of breast cancer such as diet, traits inherited from ancestors, education, 
marital status, number of children and other factors in a woman’s everyday life by comparing their 
occurrence between cases and controls. We will also examine how these factors differ among 
individuals who have breast cancer according to the different types of breast cancer that they have 
based on some of the tests that we will conduct on the cancer. We will also ask questions about 
your journey from when you first noticed your breast symptom to a diagnosis of breast cancer. 
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Procedure of the research - what shall be required of each participant: We will ask questions 
about your health, daily living and family life. We will measure your height, weight and hips size. 
A trained nurse will take 3 tablespoons of blood and a stool sample from you. The blood will be 
used to examine the risk that you have inherited any factor (called genes) that may increase your 
chances of getting breast cancer. In the stool, we will examine the pattern of germs in the stool 
and how they may affect digestion of certain food items.  
If you have been diagnosed with breast cancer, as part of your care, your doctor will do a biopsy 
to confirm the diagnosis and determine the type of breast cancer you have. Leftovers from this 
biopsy will be provided to the research team for tests on the genes and type of breast cancer that 
you have. The result of some of these tests will be provided to your doctor to aid in your treatment. 
Approximate total number of participants that would be involved in the research: We expect 
to invite 1,000 women with breast and 2,000 women without to participate in this research.  
Expected duration of research and of participant(s)’ involvement: Participation in this study 
should take not more than 2 hours of your time. If you have cancer, we will contact you on phone 
every 3 months for 2 years to ask about your health and how well you are responding to treatment. 
Risk(s): Some of the questions that we will ask may make you feel uncomfortable. In addition, 
the risks of drawing blood may include temporary discomfort from the needle stick, bruising, 
bleeding, and, rarely, infection. The possibility of a sharps injury is also a potential safety risk to 
participants and staff therefore will ensure safe and prompt disposal of sharps used in the 
procedure. However, the research staff who will work with you are competent and have been 
trained on how to ask questions and take blood samples as gently and as carefully as possible. 
These should reduce the discomfort associated with the questions. Though unlikely, should any 
of the aforementioned adverse effects occur, the study nurse will immediately take you to the 
general outpatient clinic for prompt review and management. 
Costs to the participants, if any, of joining the research: Your participation in this research 
will not cost you anything.  
Compensation: You will be given N1000 ($7.5) to contribute to the cost of your transportation 
to hospital. This will be given to you by the study nurse at the end of the session.  
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Confidentiality: All information provided in this study will be confidential. All forms will be 
coded and information will be entered into password protected computers. We will do all that is 
in power to ensure that your identity and the information that you have provided is kept 
confidential. However we will like you to know that modern research methods can identify 
individuals from their blood samples. We do not intend to do such research with your samples. 
Researchers from the London School of Hygiene, UK and the Harvard School of Public Health, 
USA and ethics committees providing oversight may have access to your records.  
Voluntariness: You participation in this research is entirely of your own free will and you are 
free to withdraw at anytime during the course of the study without offering any reasons why. 
Withdrawal from this study will not affect your care in this hospital in anyway. 
 
Are there any benefits to taking part in the study? 
If you are one of those who have breast cancer, participating in this research will enable us to 
provide your doctor with information about your breast cancer type and this may be used to guide 
your treatment. 
The research may lead to identification of genes that may be of benefit to future cancer patients 
or their family members. In most instances, we do not intend to return the results of genetic tests 
because they require further study at this time except we find genetic information that is currently 
well understood and of clinical relevance to you or your family, you will be notified with 
appropriate counseling. 
Contact of next of kin: As part of this study, we request that you also give us permission to 
contact a specific next of kin and the person’s phone number in the event that we are unable to 
reach you for your 3 monthly telephone follow up. You should ensure that this person agrees to 
receive our phone calls to inquire only about matters related to this research. 
Future unspecified use research: A portion of the biopsy and blood samples obtained in the 
course of this study will be stored for future unspecified use research into how cancer develops in 
the human body and is passed from generations to generations. However we do not know the 
detailed nature of this research at this time.  
What happens to research participants and communities when the research is over: 
Participants will be informed of the outcome of the research through a news bulletin. For women 
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with breast cancer, the result of the laboratory tests identify types of breast cancer will be shared 
with your doctors and this will be used by your doctor in planning your treatment and advising 
you on the outcome of treatment.  
 
Statement of person obtaining informed consent: 
I have fully explained this research to ____________________________________ and have 
given sufficient information, including about risks and benefits, to make an informed decision. 
 
DATE: _____________________ SIGNATURE: _______________________________ 
 
NAME: ______________________________________________ 
 
 
Statement of person giving consent: 
I have read the description of the research or have had it explained in a language I understand. I 
have also talked it over with the doctor to my satisfaction. I understand that my participation is 
voluntary. I understand that I may freely stop being part of this study at any time. I have received 
a copy of this consent form and additional information sheet to keep for myself. 
 
I understand that my next of kin/ relative may also be contacted in the event that I cannot be 
reached on phone after several repeated phone calls and I have obtained permission of this person 
to be contacted. 
 
I hereby consent to take part in the study components marked “yes” and refuse to consent to 
participate in the components marked “no”.  
 
YES  NO  Study Component 
____ ____ ________________________ 
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[ ]    [ ]   Interview at start 
[ ]    [ ]   Phone call every 3 months 
[ ]    [ ]   Tumour tissue collection, storage and testing 
[ ]    [ ]   Access to hospital records 
[ ]    [ ]   Contact next of kin/relative 
 
Future unspecified use research 
[ ]     I do not wish to participate in future unspecified use research 
 [ ]     I do not wish to be re-contacted for permission before use  
[ ]     I wish to be re-contacted for permission before use 
 
DATE: ________________ SIGNATURE/THUMBPRINT: _________________________ 
NAME: _____________________________________________ 
 
WITNESS’ SIGNATURE (if thumbprint): ___________________________ 
WITNESS’ NAME (if thumprint): ______________________________________ 
 
Ethics approval: This research has been reviewed and approved by the National Health Research 
Ethics Committee and any inquiries can be directed at the Desk Officer, NHREC, Federal Ministry 
of Health, Abuja Nigeria Phone no: 08065479926.  
 
If you have any queries or complaints you can contact the Head of IHVN at 252 Herbert Macaulay 
Way, Abuja, Phone no: 08033047250  
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Detailed contact information including contact address, telephone, fax, e-mail and any other 
contact information of researcher(s),  
Dr. Clement Adebamowo 
Institute of Human Virology Nigeria 
Plot 252 Herbert Macaulay Way, Abuja 
+2348033520571 
 
PLEASE KEEP A COPY OF THE SIGNED INFORMED CONSENT.  
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APPENDIX 9: BOX PLOTS AND HISTOGRAMS FOR CONTINUOUS VARIABLES USED IN DELAY ANALYSES 
Figure 1: (a) Pre-contact (b) Post-contact in months by early vs late stage diagnosis in women with breast cancer 
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Figure 1c: Total delay in months by early vs late stage diagnosis in women with breast cancer 
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Figure 2: (a) Normal (time1) (b) Log-transformed (time1rlog) pre-contact delay time in months  
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Figure 3: (a) Normal (time3) (b) Log-transformed (time3rlog) post-contact delay time in months  
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Figure 4: (a) Normal (time2) (b) Log-transformed (time2rlog) total delay time in months  
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APPENDIX 10: ARTICLE PUBLISHED FROM THE PHD STUDY  
 
 
Articles
www.thelancet.com/lancetgh   Vol 4   December 2016 e923
Stage at diagnosis of breast cancer in sub-Saharan Africa: 
a systematic review and meta-analysis
Elima Jedy-Agba, Valerie McCormack, Clement Adebamowo, Isabel dos-Santos-Silva
Summary
Background The incidence of breast cancer in sub-Saharan Africa is relatively low, but as survival from the disease in the 
region is poor, mortality rates are as high as in high-income countries. Stage at diagnosis is a major contributing factor 
to poor survival from breast cancer. We aimed to do a systematic review and meta-analysis on stage at diagnosis of breast 
cancer in sub-Saharan Africa to examine trends over time, and investigate sources of variations across the region.
Methods We searched MEDLINE, Embase, Web of Knowledge, and Africa-Wide Information to identify studies on 
breast cancer stage at diagnosis in sub-Saharan African women published before Jan 1, 2014, and in any language. 
Random-eﬀ ects meta-analyses were done to investigate between-study heterogeneity in percentage of late-stage breast 
cancer (stage III/IV), and meta-regression analyses to identify potential sources of variation. Percentages of women 
with late-stage breast cancer at diagnosis in sub-Saharan Africa were compared with similar estimates for black and 
white women in the USA from the Surveillance, Epidemiology, and End Results database.
Findings 83 studies were included, which consisted of 26 788 women from 17 sub-Saharan African countries. There 
was wide between-study heterogeneity in the percentage of late-stage disease at diagnosis (median 74∙7%, 
range 30∙3–100%, I²=93∙3%, p<0∙0001). The percentage of patients with late-stage disease at diagnosis did not vary 
by region in black women, but was lower in non-black women from southern Africa than in black women in any 
region (absolute diﬀ erence [AD] from black women in western Africa [reference group] –18·1%, 95% CI –28·2 to –8·0), 
and higher for populations from mixed (urban and rural) settings rather than urban settings (13∙2%, 5∙7 to 20∙7, in 
analyses restricted to black women). The percentage of patients with late-stage disease at diagnosis in black Africans 
decreased over time (–10∙5%, –19∙3 to –1∙6; for 2000 or later vs 1980 or before), but it was still higher around 2010 
than it was in white and black women in the USA 40 years previously.
Interpretation Strategies for early diagnosis of breast cancer should be regarded as a major priority by cancer control 
programmes in sub-Saharan Africa.
Funding None.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND license.
Introduction
The incidence of breast cancer is highest in high-
income countries (HICs), but has been rising in 
low-income and middle-income countries (LMICs).1,2 
Survival rates for breast cancer are poorer in LMICs 
than in HICs and most deaths from breast cancer now 
occur in less developed parts of the world. In 2012, 
about 53% of all newly diagnosed cases of breast cancer, 
and about 58% of deaths, occurred in LMICs.3 Breast 
cancer incidence in LMICs is likely to increase further 
in forthcoming decades as a result of population ageing 
and increased adoption of the lifestyles of HICs.1,2
Breast cancer incidence in sub-Saharan Africa is among 
the lowest in the world. Estimated age-standardised 
rates in 2012 ranged from 27 cases per 100 000 women in 
middle Africa to 39 cases per 100 000 women in 
southern African regions. However, mortality due to 
cancer is as high as in high-incidence countries; estimated 
age-standardised rates in 2012 ranged from 15 deaths per 
100 000 women in middle Africa to 20 deaths per 
100 000 women in western Africa.3 These rates are higher 
than that of North America for the same year 
(age-standardised rate 14·8 cases per 100 000 women), 
which has a higher breast cancer incidence (age-
standardised rate 91·6 cases per 100 000 women).3
Stage at diagnosis is a major determinant of survival 
from breast cancer; early-stage disease is associated with a 
better prognosis than late-stage disease,4 a pattern present 
in sub-Saharan Africa.5–8 Earlier stage at diagnosis, 
combined with therapeutic advances, was a major 
contributor to the sharp reductions in breast cancer 
mortality rates in the past two decades in most HICs.4 
By contrast, most patients with breast cancer in 
sub-Saharan Africa present with late-stage disease, thought 
to be due to poor awareness, an absence of organised early 
detection programmes, and poor facilities for accurate and 
timely diagnosis and treatment.5,9–17 Variations in stage of 
breast cancer at diagnosis across sub-Saharan Africa and 
over time in some countries in sub-Saharan Africa have 
been previously reported in individual settings,5,7,9,13,18,19 but 
have not, to our knowledge, been examined systematically 
across sub-Saharan Africa.
Lancet Glob Health 2016; 
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In this study, we aimed to systematically review the 
published literature on stage at diagnosis of breast 
cancer in sub-Saharan Africa, examine trends over 
time, and investigate possible sources of between-study 
heterogeneity, which might help to identify appropriate 
approaches for stage-migration of this disease in 
the region.
Methods
Search strategy and selection criteria
For this systematic review and meta-analysis, we developed 
a study protocol (appendix p 1) based on the PRISMA 
guidelines (appendix p 4). We searched four databases 
(MEDLINE, Embase, Web of Knowledge, and Africa-Wide 
Information) to identify all studies published before 
Jan 1, 2014, which reported on stage at diagnosis of 
primary invasive breast cancer in women in sub-
Saharan Africa. The UN classiﬁ cation20 was used to deﬁ ne 
sub-Saharan African countries and to group them 
according to region (ie, southern, eastern, western, and 
middle Africa). We did an initial keyword search and 
subsequent searches based on Medical Subject 
Headings (MeSH) with various combinations of search 
terms “breast cancer*”, “breast neoplasm*”, “breast 
carcinoma*”, “breast sarcoma*”, “breast tumor*”, “breast 
tumour*”, or “breast malignanc*”, AND “stage”, 
“presentation”, “grade”, “clinical features”, or “clinical 
ﬁ ndings”, AND “Africa” (appendix p 7). No restrictions 
were imposed on the ethnicity or race of women, whether 
diagnoses were done in public or private settings, age at 
diagnosis, or language of the publication.
We identiﬁ ed and reviewed articles in a two-step process. 
The ﬁ rst step consisted of a title and abstract review to 
identify records that were deemed potentially eligible for 
inclusion. This review was done by one of three authors 
(EJ-A, Id-S-S, or VM) to exclude publications that were 
duplicates; that were from north Africa (ie, Algeria, Egypt, 
Libya, Morocco, Sudan, Tunisia, and Western Sahara20); 
that did not focus on breast cancer (eg, studies of “all 
cancers”); that did not include women with breast cancer 
(eg, surveys on awareness); that did not provide 
information on stage (eg, pathology series, papers about 
screening); or that focused exclusively on breast cancer in 
men. Articles that restricted inclusion to a particular stage 
(eg, metastatic breast cancer) were also excluded. Reviews 
and conference proceedings were not included, but their 
references were cross-checked for completeness. Studies 
that included both female and male patients with breast 
cancer were included, even if they did not provide enough 
information to allow the exclusion of male patients, 
because men typically represented less than 2% of all 
study participants. A random sample of 50% of the total 
abstracts was independently reviewed by one of the other 
two authors, which showed no disagreements on which 
papers to select for full-text review.
Quality assessment and data extraction
In the second step, all full-text articles retrieved were 
reviewed to conﬁ rm eligibility and, if eligible, data were 
extracted. EJ-A assessed all articles for eligibility and 
extracted the data, using an adapted version of a pre-tested 
data entry electronic form.21 All articles were independently 
reviewed by one of the other two reviewers (Id-S-S or VM). 
Data were extracted from each eligible paper on the 
numbers of patients who presented in stages I, II, III, and 
IV at diagnosis, or at early (I/II) and late (III/IV) stages if 
Research in context
Evidence before this study
We preliminarily searched MEDLINE with the terms “Breast 
Cancer” OR “Breast Carcinoma” AND “Stage” AND “Diagnosis” 
or “presentation” AND “Africa” OR “Sub-Saharan Africa”. No 
language restrictions were used. Previous studies have reported 
a wide variation in stage at diagnosis of breast cancer across 
sub-Saharan Africa, but none has examined trends in stage at 
diagnosis over time or investigated potential sources of 
variations across the region.
Added value of this study
We provide the most comprehensive synthesis to date of the 
available evidence on stage at diagnosis of breast cancer in 
sub-Saharan Africa. This review showed that most patients 
in sub-Saharan Africa were diagnosed at a late 
stage (stages III/IV). There was, however, a wide range of 
estimates across the region; the reasons for which were 
unclear. The percentage of women with late-stage disease at 
diagnosis was, as expected, higher in black women than 
non-black women; however, no clear diﬀ erences exist in 
black women by region or type of health facility, except that 
the percentage was lower in urban settings than in rural or 
urban areas. This review also highlights the paucity of 
published data on breast cancer stage from certain parts of the 
region (eg, from middle Africa).
Implications of all the available evidence
Although some improvements in stage at diagnosis of breast 
cancer in sub-Saharan Africa have occurred over the past few 
decades, very advanced disease is still prevalent at diagnosis in 
many settings. Nevertheless, within the region, public-sector 
settings exist with a much improved stage proﬁ le, indicating that 
stage migration is achievable in such settings—ie, in the absence 
of organised screening. To prevent avoidable deaths from this 
potentially good-prognosis cancer, breast cancer control 
measures require a strong emphasis on early diagnosis and 
treatment. Earlier diagnosis is dependent on the time window in 
which the patient has symptomatic disease; thus eﬀ orts to 
promote early presentation and faster referrals, diagnosis, and 
treatment need strengthening. 
For more on Africa-Wide 
Information see https://www.
ebscohost.com/academic/africa-
wide-information
See Online for appendix
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only this combined information was provided; country; 
study design; study population and type of clinical setting 
(eg, primary, secondary, or tertiary clinical facility; 
population-based cancer registry; public, private, or mixed 
patients); year of diagnosis; race; average age at time of 
diagnosis (mean or median; if only age categories were 
reported the mean age was estimated from the mid-point 
and the reported numbers in each category); and methods 
and classiﬁ cation used to ascertain stage. Time at 
diagnosis in the original papers was either the time at 
clinical or pathological diagnosis.
If a study provided numbers for each speciﬁ c American 
Joint Committee Cancer Tumour Node Metastases (TNM) 
category (eg, T2, N0, M0; appendix p 14), we used these to 
derive numbers in each one of the four stages. Whenever 
available, we extracted data on menopausal status, tumour 
characteristics (eg, histology, size, grade, receptor status), 
and time from ﬁ rst symptoms to diagnosis. Disagreements 
between extractors were discussed and a consensus 
reached. Most papers with missing information were 
from studies done several decades ago, hence no attempt 
was made to contact their authors because it was unlikely 
that the required information could still be retrieved. 
If there were several papers for the same study period, 
setting, and author, the paper with the most information 
on tumour stage was selected for inclusion.
The quality of the papers included in the review was 
assessed independently by two reviewers. An adapted 
version of the standardised quality assessment criteria 
developed by Eng and colleagues21 was used to assess the 
potential for selection and information bias as well as the 
availability of data on key variables (eg, age at diagnosis 
and year of diagnosis, tumour grade; details in the 
appendix; p 9). A quality score ranging from 0–28 (low to 
high quality) was given to each paper.
Data analysis
The primary outcome was percentage (p34) of breast cancer 
diagnosed at late stages (stages III/IV), deﬁ ned as p34=n34/n, 
where n34 is the number of women who presented at 
stages III or IV and n is the number of women with known 
stage information. The suite of metan and metaprop 
commands from Stata (version 13) were used to graphically 
display population-speciﬁ c late-stage percentages and to 
estimate pooled percentages using random eﬀ ect 
models. The metaprop command was speciﬁ cally designed 
to model binary data, thereby allowing for proportions 
near boundaries (ie, in this instance near 100% late-stage 
cancer). Between-population heterogeneity was assessed 
using I² statistic and the p value for heterogeneity 
(Cochrane’s Q statistic). To examine potential sources 
of heterogeneity, population-speciﬁ c estimates were 
stratiﬁ ed by relevant clinicoepidemiological variables, 
and meta-regression analyses were done to identify 
independent correlates of percentage of late-stage disease. 
Study-level determinants of late-stage disease are expressed 
as absolute diﬀ erences (AD) in the percentage of patients 
with late-stage disease (p34). Analyses were ﬁ rst done in all 
study populations (black and non-black African) and then 
in black African populations only. The latter analyses 
excluded non-black African populations, which were from 
South Africa, because of their known privileged access to 
health care. The potential for small study bias was assessed 
using funnel plots and the Egger test.22
To compare late-stage breast cancer in sub-Saharan 
Africa with corresponding ﬁ gures for white women and 
black women in the USA, relevant data were extracted 
from the Surveillance, Epidemiology, and End Results 
(SEER) database, which includes information on all cases 
of invasive primary breast cancer in women from nine US 
population-based cancer registries23 for two time periods: 
1973–2002 and 1998–2011. The SEER database provided 
numbers of in-situ, localised, regional, and distant 
(metastatic) breast cancer cases as well as numbers with 
unknown or missing stage. There were no age restrictions. 
The SEER summary staging classiﬁ cation was used to 
estimate the percentage of patients with regional or 
distant disease (proxy for stages III/IV) out of all patients 
with breast cancers of known stage.
Figure 1: Study selection
322 records identiﬁed
 from Africa-Wide 
 Information
675 abstracts screened (after removing duplicates)
456 records identiﬁed 
 from Web of 
 Science
183 records identiﬁed 
 from MEDLINE
284 records identiﬁed 
 from Embase
505 excluded
 7 non-human studies 
 111 not done in sub-Saharan Africa 
 152 not breast cancer studies 
 21 not done in women 
 46 conference abstracts 
 133 no information on stage or stage not mentioned in abstract 
 35 no stage distribution, only a particular stage given 
170 full-text articles assessed for eligibility
23 additional papers identiﬁed 
 through references 
101 excluded 
 8 meeting abstracts or PhD theses
 76 no information on stage 
 7 study population overlapped with another study 
 9 stage distribution was assumed or not original 
 1 attempts to retrieve paper unsuccessful 
83 studies eligible and included
9 excluded 
 1 study population overlapped with another study
 1 stage distribution excluded stage 4 patients (operable breast 
  cancer only)
 1 stage distribution unknown
 6 attempts to retrieve paper or abstracts unsuccessful
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Role of the funding source
There was no funding source for this study. EJ-A, VM, 
and Id-S-S had full access to all the data in the study and 
EJ-A and Id-S-S had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Our search retrieved 675 articles, of which 170 were 
considered as potentially relevant (ﬁ gure 1). The full text 
was retrieved for all of these articles except for six, which 
could not be traced through institutional libraries or 
direct contact with the authors (attempts to contact 
authors proved futile). The sample sizes of two of the 
untraceable studies24,25 were 47 and 120 according to 
Edmund and colleagues.26
The full-text review identiﬁ ed 83 eligible papers from 
17 sub-Saharan African countries consisting of late-stage 
disease estimates for 91 distinct study populations; ﬁ ve 
studies provided separate estimates for diﬀ erent subsets of 
participants (ie, for pregnant or lactating and non-pregnant 
or non-lactating women27 or diﬀ erent racial groups12,28–30). 
For three studies,31–33 we obtained estimates that diﬀ ered 
from those published because T3N1M0 tumours in the 
original articles were classiﬁ ed as stage II, but they should 
be stage III according to the 7th edition of the American 
Joint Committee on Cancer Breast Cancer Staging 
Manual.34 Four studies35–38 provided information on the 
tumour (T1–4) only and, for these, T3/T4 was regarded as a 
proxy for stages III/IV. The characteristics of the included 
studies are summarised in table 1; study-speciﬁ c details 
and references are given in the appendix (p 14). They 
comprised 26 788 patients with breast cancer, with sample 
sizes ranging from 12 to 2346 (median 141; appendix p 14). 
Stage information was available for 24 213 (90·4%) patients. 
36 studies (43%) were from Nigeria (8407 patients with 
cancer staging) and 16 studies (19%) were from 
South Africa (10 182 patients with cancer staging). 
35 studies (42%) were consecutive case series and the 
remaining were convenience case series (ie, patients seen 
in pathology or radiotherapy departments only or studies 
in which not all eligible patients who reported at the 
surgery or oncology clinics were included; table 1). The 
average age at diagnosis was less than 45 years in 34% of 
studies, between 45–49 years in 43% of studies, and 
50 years or older in 19% of studies. Age was not reported in 
only three studies (4%; table 1). The mean year of diagnosis 
ranged from 1960 to 2011, and was 2000 or later for 40% of 
the studies.
There was wide variation in the distribution of stage at 
diagnosis in sub-Saharan Africa. For example, in studies 
that provided stage IV-speciﬁ c estimates, the percentage of 
women diagnosed with stage IV breast cancer ranged from 
4%56 to 70%27 (ﬁ gure 2). Consequently, between-population 
heterogeneity was wide (I²=93·3%; p<0·0001) in the 
percentage of late-stage cancers (III/IV) (median 74·7%; 
range 30·3–100), with 59 (65%) of study populations 
yielding an estimate of greater than 70% (ﬁ gure 3).
Nine studies from western and eastern Africa were done 
exclusively in black women.5,37,38,42–47 The remaining 
58 studies did not report on race, but their populations 
were assumed to have the racial composition of their 
countries’ population and, hence, to consist pre dominantly 
(≥80%) of black women. Studies from South Africa 
included exclusively39–41 or predominantly (≥80%) black 
women;18 or predominantly (≥80%) non-black women (ie, 
white, Indian, or coloured women14,36,50–53); or provided 
separate estimates for black women and non-black 
women12,28–30 (appendix p 14).
Black women from South Africa presented much later 
than their non-black counterparts, but with marked 
Studies Study populations Patients with 
breast cancer
Patients with known 
breast cancer, n (%)
Total 83 91 26 788 24 213 (90·4%)
Race
Black† 75 76 18 805 16 669 (88·6%)
Non-black‡ 8 15 7983 7544 (94·5%)
Region or country
Western Africa 48 49
Nigeria 36 37 8623 8407 (97·5%)
Benin 2 2 204 204 (100%)
Ghana 5 5 1969 1191 (60·5%)
Mali 2 2 324 324 (100%)
Other§ 3 3 797 719 (90·2%)
Eastern or middle Africa 19 19
Tanzania 5 5 1310 1151 (87·7%)
Kenya 2 2 287 157 (54·7%)
Ethiopia 3 3 1267 841 (66·4%)
Madagascar 2 2 289 233 (80·6%)
Uganda 3 3 562 502 (89·3%)
Other¶ 4 4 445 302 (67·9%)
Southern Africa 16 23
South Africa 16 23 10 711 10 182 (95·1%)
Study design
Convenience case series 48 55 10 780 9788 (90·8%)
Consecutive case series 35 36 16 008 14 425 (90·1%)
Study population
Urban 27 34 15 571 14 208 (91·2%)
Mixed (rural and urban) 56 57 11 217 10 005 (89·2%)
Type of health facility
Tertiary, secondary, or 
primary||
9 12 1639 1503 (91·7%)
Tertiary 72 77 24 742 22 399 (90·5%)
Not reported in original 
study
2 2 407 311 (76·4%)
Age at diagnosis (years)**
<45 years 28 29 5475 4840 (88·4%)
≥45 to <50 years 36 37 7882 7218 (91·6%)
≥50 years 16 22 11 056 9841 (89·0%)
Not reported in original 
study
3 3 2375 2314 (97·4%)
(Table 1 continues on next page)
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between-population heterogeneity within each racial 
group (I²>97% for both groups; ﬁ gure 4). Four South 
African studies examined racial diﬀ erences (appendix 
p 11), which consistently showed a higher percentage of 
late-stage cancer in black Africans (range 74–91%) than 
white Africans (30–44%); the percentages of late-stage 
cancer in Indian and coloured women were intermediate, 
even when all the participants were diagnosed at the 
same health facility. However, these results were not 
adjusted for socioeconomic status because of a scarcity of 
information from the original publications.
Fully-adjusted meta-regression analysis (adjusting for 
region or race, study design, setting, facility type, age, 
and year of diagnosis) conﬁ rmed the diﬀ erence between 
racial groups; the percentage of late-stage cancers was 
18·1% lower (95% CI –28·2 to –8·0) for non-black women 
from South Africa than for black women in western Africa. 
By contrast, analysis restricted to black Africans revealed 
no diﬀ erence in late-stage cancer diagnosis between the 
three sub-Saharan African regions (table 2).
After adjustment for region or race, no diﬀ erences in 
late-stage disease were observed between consecutive or 
convenience case series, or by type of health facility 
(table 2). Studies done in mixed urban or rural populations 
had a higher percentage of women with late-stage disease 
than those done in urban populations, and this ﬁ nding 
remained signiﬁ cant in the fully adjusted model 
(AD 12·9%, 95% CI 5·5 to 20·3) and in the analysis 
restricted to black Africans (AD 13·2%, 5·7 to 20·7; 
table 2).
A smaller percentage of women aged 50 years or older 
had late-stage disease than those younger than 45 years 
(AD –13·2%, 95% CI –21·2 to –5·3), but most studies of 
older women consisted predominantly of non-black 
South Africans. Consequently, the age diﬀ erence 
attenuated markedly on adjustment for region and race, 
and disappeared in analyses restricted to black Africans 
(table 2). A slight improvement in stage at diagnosis was 
observed over time (appendix p 12). In the fully-adjusted 
meta-regression model, the percentage of women with 
late-stage disease was lower in black Africans diagnosed 
since 2000 compared with women diagnosed before 1980 
(AD –10·5%, 95% CI –19·3 to –1·6; table 2). In analyses 
restricted to black Africans, the percentage of women 
with late-stage cancer was lower in studies that did not 
report year of diagnosis than studies published 
before 1980, but this ﬁ nding was not statistically 
signiﬁ cant (table 2). Because the years of publication of 
these studies ranged from 2002 to 2011, it is likely that 
patients recruited into these studies would have been 
diagnosed in recent years.
The TNM or the Manchester staging classiﬁ cation 
(appendix p 14) were used in most studies, but this 
information was missing in 21 studies (table 1). No clear 
diﬀ erences in the percentage of late-stage disease were 
observed between studies that reported the staging 
classiﬁ cation used and studies that did not, or between 
studies done in facilities where there was access to imaging 
methods (eg, radiographs)—either routinely or in clinically 
suspicious cases—and studies done in settings without 
imaging facilities (table 2).
Few studies reported on tumour characteristics or 
duration of symptoms (appendix p 21). In studies of 
black African populations that reported on these 
characteristics, late-stage disease at diagnosis was 
positively associated with mean tumour size (Pearson 
correlation coeﬃ  cient r=0·63, p=0·004, based on data 
Studies Study populations Patients with 
breast cancer
Patients with known 
breast cancer stage, n (%)
(Continued from previous page)
Year of diagnosis††
Before 1980 11 16 3971 3782 (95·2%)
1980–1999 32 34 11 125 10 737 (96·5%)
2000 or after 33 33 8648 6733 (77·8%)
Not reported in original 
study
7 8 3044 2961 (97·3%)
Staging methods
Clinical and imaging 25 26 10 416 9516 (91·4%)
Clinical only 10 10 975 967 (99·2%)
Not reported in original 
study
48 55 15 397 13 730 (89·2%)
Staging classiﬁ cation
TNM 50 57 20 388 18 048 (88·5%)
Manchester 11 11 1436 1426 (99·3%)
Not reported in original 
study
22 23 4964 4739 (95·5%)
Study quality scores‡‡
≥23 (highest quality) 12 12 4067 3569 (87·8%)
22–20 26 27 6181 5721 (92·6%)
19–17 31 38 14 541 13 327 (91·7%)
<17 (lowest quality) 14 14 1999 1596 (79·8%)
Data are n or n (%). TNM=Tumour, Lymph Node, and Metastasis staging system. *Five studies provided separate estimates 
for diﬀ erent subsets of participants (ie, for pregnant or lactating and non-pregnant or non-lactating women27 or diﬀ erent 
ethnic groups12,28–30). †Includes seven southern African studies12,28–30,39–41 that reported estimates for black women only; 
one southern African study18 that presented only an overall (all ethnic groups combined) estimate, but reported that 
>80% of their study population was black; nine studies5,37,38,42–47 from western and eastern Africa that were done exclusively 
in black women, as well as the remaining 58 studies from these two regions that did not report on race, but were assumed 
to have been done in predominantly black women (ie, >80% black; see appendix p 14), which corresponded to 76 study 
population groups because one Nigerian study27 presented separate estimates for pregnant or lactating and non-pregnant 
or non-lactating women (appendix p 14). ‡Includes 15 southern African study population groups: four studies14,48–50 that 
did not report on race but were assumed to be predominantly non-black, four studies36,51–53 that present only overall 
estimates but reported an ethnically mixed population with ≤80% being black, and four multi-ethnic studies12,28–30 that 
together reported separate estimates for seven non-black population groups (appendix p 14). §Includes one study from 
Guinea (178 cases, 124 cases with known stage), one from Niger (146 cases, 146 cases with known stage), and one from 
Senegal (473 cases, 449 cases with known stage). ¶Includes one study from Rwanda (145 cases, seven cases with known 
stage), one from Zimbabwe (84 cases, 79 cases with known stage), one from Eritrea (82 cases, 82 cases with known 
stage), and one from Democratic Republic of the Congo (formerly known as Zaire; 134 cases, 134 cases with known stage). 
||All studies that recruited participants from secondary and primary health centres also included a tertiary centre. **Mean 
or median age at breast cancer diagnosis. If only age categories were reported, mean or median age was estimated from 
the mid-point and the reported number in each age category. The three studies in which age was not reported in the 
original category did not provide suﬃ  cient information to allow their allocation into one of the three age categories: 
Ajekigbe54 reported that 50·8% of the participants were aged <50 years; Amir and colleagues55 reported that 90% of the 
participants were aged <50 years; and Pegoraro and colleagues36 reported that 50% were between aged 45–64 years 
(appendix p 14). ††Middle year of the time interval during which patients were recruited. ‡‡Categories represent quartiles 
of the overall score distribution (appendix p 9).
Table 1: Study characteristics
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from 19 studies), but not with self-reported mean 
duration of symptoms (r=–0·14, p=0·42, 35 studies) or 
with percentages of tumours classiﬁ ed as invasive ductal 
carcinomas (r=0·09, p=0·50, 53 studies), oestrogen-
receptor positive (r=–0·03, p=0·91, 15 studies), or grade 3 
(r=0·21, p=0·26, 32 studies; appendix p 21).
The median study quality score was 19·5 
(IQR 17·5–21·5), with no evidence of regional or racial 
diﬀ erences. No variation in the percentage of women 
diagnosed with late-stage breast cancer was observed by 
study quality (table 2). The funnel plot (appendix p 13) 
and the value of the Egger’s test for small study bias 
(p=0·01) were diﬃ  cult to interpret because of the marked 
between-population heterogeneity.
The proportion of women with late-stage breast cancer 
at diagnosis declined markedly in the USA between 
1973 and 2011: from 50% to 27% in white women, and 
from 60% to 32% in black women23 (ﬁ gure 5). By contrast, 
most study-speciﬁ c estimates of late-stage disease in 
black sub-Saharan African women remained well above 
60% from the 1970s to 2011, albeit with some indication 
of a slight downward trend in some settings (ﬁ gure 5). 
Notably, the proportion of late-stage disease in black 
women in sub-Saharan Africa in the most recent study 
years (around 2010) was still higher than in black women 
from the USA 40 years previously. The proportion of 
women with late-stage disease in southern Africa 
remained unchanged for non-black Africans, but seemed 
to decline somewhat in black Africans. Remarkably, only 
two studies were done after 2000 in the southern African 
region. Both studies were done in South Africa: one in 
non-black Africans14 and one in black Africans.18 By 
contrast, the number of studies from eastern and 
western Africa published after 2000 was higher than in 
previous decades, although most had relatively small 
sample sizes.
Discussion
To our knowledge, this is the ﬁ rst systematic review of 
stage at diagnosis of breast cancer in sub-Saharan Africa. 
We compiled data from 83 studies consisting of 
24 213 patients with staged cancers. The ﬁ ndings 
highlight two main issues. First, our ﬁ ndings show the 
paucity of data on one of the most important clinical 
Figure 2: Study-speciﬁ c breast cancer stage at diagnosis
Study-speciﬁ c distribution of stages I, II, III, and IV cancers. Percentage of T3/T4 cancers was used as a proxy for percentage of stage III/IV cancers in four studies.35–38 Percentage with metastases (M1) 
was given in three studies24,35,37 and was used as percentage of stage IV. Race as deﬁ ned in table 1 and in the appendix (p 14). Study-speciﬁ c references given in the appendix (p 14). B=black. C=coloured. 
I=Indian. NPL=non-pregnant or non-lactating women. PL=pregnant or lactating women. W=white.
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Figure 3: Study-speciﬁ c 
breast cancer stage at 
diagnosis
Study-speciﬁ c percentage of 
late-stage disease (III/IV) 
ranked by increasing 
magnitude. Percentage of 
T3/T4 cancers was used as a 
proxy for percentage of 
stage III/IV cancers in four 
studies.35–38 Race as deﬁ ned in 
table 1 and in the appendix 
(p 14). Study-speciﬁ c 
references given in the 
appendix (p 14). B=black. 
C=coloured. DRC=Democratic 
Republic of the Congo. 
I=Indian. NPL=non-pregnant 
or non-lactating women. 
PL=pregnant or lactating 
women. W=white.
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Figure 4: Study-speciﬁ c 
percentage of late-stage 
breast cancer at diagnosis, by 
region of sub-Saharan Africa
B=black African. C=coloured. 
I=Indian. NPL=non-pregnant 
or non-lactating women. 
PL=pregnant or lactating 
women. W=white. Study-
speciﬁ c references given in the 
appendix (p 14). *Weights are 
from random eﬀ ects analyses.
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prognostic markers of breast cancer in this region. 
Speciﬁ cally, no published data from middle Africa were 
identiﬁ ed, and data from southern Africa were 
restricted to one country (South Africa), with only two 
studies done after 2000 (one in black Africans and 
another in non-black Africans). Furthermore, no study 
presented data from population-based cancer registries. 
Second, the ﬁ ndings show that most patients in 
sub-Saharan Africa (77% across all black study 
populations) were diagnosed at stages III/IV. Although 
this overall situation might seem grave, the presence 
of public-sector sub-Saharan Africa settings with 
improved stage proﬁ le needs to be highlighted because 
those settings reveal that progress in stage migration of 
breast cancer can be made within the public sector 
setting in which mammography is often unavailable. 
However, the reasons for the marked heterogeneity 
between populations, which is present even in analyses 
restricted to black Africans, are not entirely clear—no 
distinct patterns deﬁ ne the better settings. Late-stage 
breast cancer was, as expected, more frequent in 
black Africans than in non-black Africans; however, no 
clear diﬀ erences in the percentage of late-stage cancers 
at diagnosis by region or type of health facility were 
observed in black African women, except that the 
percentage of late-stage cancers at diagnosis was lower 
in urban settings. There was evidence of stage 
migration of breast cancer over time in black Africans 
diagnosed after 2000, consistent with the downward 
trend within studies in late-stage disease at diagnosis 
described by one of the studies in this review. 
McCormack and colleagues18 reported a decrease in the 
frequency of stage III/IV cancers in South Africa 
from 66% in 2006–07 to 46% in 2010–12.
We did not ﬁ nd a strong association between age at 
diagnosis and late-stage cancer at diagnosis in black 
African women. Most patients were aged 35–49 years at 
diagnosis (approximately 10–15 years younger than 
patients in developed countries).57 This ﬁ nding likely 
reﬂ ects the younger age structure of the sub-Saharan 
African population, consequent to higher fertility and 
shorter life expectancy, and the lower prevalence of 
risk factors in older generations than in young 
generations, rather than any inherent biological 
diﬀ erences in disease aggressiveness between black and 
white patients. Consistent with this interpretation is the 
fact that, at a study level, late-stage cancer at diagnosis 
was not correlated with tumour grade, which could 
indicate that late-stage cancer at diagnosis is not entirely 
a consequence of black African women having 
more biologically aggressive forms of disease—indeed 
a 2014 review21 suggests that oestrogen-receptor-
positive disease constitutes two-thirds of tumours in 
black women from sub-Saharan Africa. Late-stage disease 
was, however, positively correlated with mean tumour size 
(as expected given that tumour size is used to derive 
stage), consistent with delays in access to health care.
Increased breast cancer awareness and improvements 
in health care over time have been paralleled by decreases 
in tumour size and downstaging of breast cancer in other 
Figure 5: Trends in stage of breast cancer at diagnosis in sub-Saharan Africa in 1960–2011, and in the USA in 1973–2002 and 1988–2011
The US estimates represent percentage of patients with breast cancer with regional or distant disease (as a proxy for stages III/IV) out of all patients with known stage 
in the Surveillance Epidemiology End Results (SEER) database (see Methods); the SEER summary staging classiﬁ cation was used for both time periods: 1973–2002 
(based on 365 695 white women and 31 781 black women with breast cancer in the USA) and 1998–2011 (based on 780 137 white women and 96 526 black women 
with breast cancer in the USA). The discontinuity between the two time series was due to a change in staging classiﬁ cation. The sub-Saharan Africa estimates 
correspond to percentage of patients with stage III/IV breast cancer at diagnosis; the size of the point estimate symbols are proportional to the size of the study.
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LMICs.58,59 However, studies have reported low levels of 
breast cancer awareness in the general population and 
health-care professionals in sub-Saharan Africa.60,61 The 
poor awareness contributes to the high frequency of late-
stage cancer at diagnosis seen in sub-Saharan Africa.62,63 
Other barriers to access, such as distance to health-care 
facility, also play a role in this region.64
Most studies used the TNM or the Manchester staging 
classiﬁ cations, but only a quarter reported on the staging 
methods used. Of these, most studies relied on both 
clinical and imaging methods, but a few studies used 
clinical methods only. Although the clinical methods 
only approach leads to under-staging,65 most women in 
settings where imaging procedures are unavailable or 
unaﬀ ordable are likely to have presented at advanced 
stages when clinical methods might suﬃ  ce.66 This is 
consistent with our ﬁ nding of no diﬀ erences in late-stage 
disease depending on whether staging methods were 
reported and, if reported, by the type used.
There was no correlation, at a study level, between 
percentage of late-stage disease and average self-reported 
duration of symptoms (ie, time between onset of 
symptoms and diagnosis). The extent to which this 
ecological-level association reﬂ ects a similar absence of 
an association at an individual level is unclear. Women 
might not recognise symptoms because of poor breast 
cancer awareness,67,68 or they might not accurately 
remember the dates on which they ﬁ rst noticed 
symptoms. Nevertheless, the average duration of 
symptoms was between 8 months and 12 months in 
most studies (appendix p 21), indicating that for the most 
part advanced stage at diagnosis might be a result of 
delayed diagnosis. Hence, a large window exists in which 
delays to diagnosis can be shortened.
The frequency of late-stage disease at diagnosis in black 
women in sub-Saharan Africa was higher than in white 
and black women from the USA in 1970–2010, including 
during the pre-mammography screening era (screening 
in the USA began in 197669). This shows that, through 
more rapid diagnosis of palpable clinical disease, 
considerable improvements can be made before expensive 
systems for the detection of preclinical disease are 
warranted. In sub-Saharan Africa, where mammography 
is often unavailable or unaﬀ ordable, stage migration 
through breast cancer awareness and improved access to 
diagnostic facilities, not mammo graphic screening, is 
urgently required.
Major strengths of this review include the detailed and 
inclusive search strategy, which included non-English 
publications; the large sample size of more than 
24 000 women with breast cancer in the region; and the 
use of standard methods for study identiﬁ cation, and data 
extraction and synthesis. There were also limitations. The 
representativeness of the review might have been 
compromised by several factors. First, we included 
studies from only 17 of 49 sub-Saharan Africa countries, 
albeit together they represent 71% of the total population 
in the region, with most studies based on convenience 
samples of patients. Second, by deﬁ nition, the large 
numbers of patients with breast cancer in the region who 
never reach a health-care facility could not be included. 
Dickens and colleagues64 showed that distance to a tertiary 
care facility was a major determinant of access to 
diagnosis even within a relatively small geographical area 
(ie, Soweto in Johannesburg, South Africa). Because the 
patients included in this review are, by deﬁ nition, patients 
who were able to reach a health-care facility, predominantly 
tertiary centres, they might not be a representative sample 
of all patients with breast cancer in sub-Saharan Africa. 
Third, some participants might have been included in 
more than one study; to minimise this, whenever papers 
from the same institution and recruitment period were 
identiﬁ ed, we only included the paper that had the more 
comprehensive information on stage at diagnosis. Fourth, 
six potentially eligible papers could not be retrieved; the 
sample sizes for two of these papers are known to be 
small, and therefore their exclusion is not likely to have 
substantially aﬀ ected our ﬁ ndings. Finally, the absence of 
information on staging methods and procedures in many 
studies and the absence of standardisation in staging 
procedures between studies, and possibly even within 
studies, might have obscured some of the ﬁ ndings. 
Staging is aﬀ ected by neoadjuvant chemotherapy, but this 
treatment is not available in most sub-Saharan Africa 
settings.9 Neoadjuvant chemotherapy was mentioned in 
only two papers included in this review,14,70 and whether 
staging was ascertained before or after chemotherapy was 
not clear.
This review showed that the percentage of late-stage 
breast cancer at diagnosis in black populations from 
sub-Saharan Africa around 2010 was higher than in 
black and white populations in the USA 40 years 
previously. Cancer control strategies in the region 
should target early detection and diagnosis of 
symptomatic disease as one essential component of the 
strategy to improve survival from breast cancer. In most 
settings, symptom duration of 8–12 months shows that 
there is a considerable delay between symptom onset 
and diagnosis and thus a considerable time window 
exists in which to realistically achieve early detection 
and diagnosis. Population-level interventions for the 
stage migration of breast cancer have been shown to be 
successful in Tanzania71 and other LMICs, such as 
Malaysia.72 Several sub-Saharan Africa studies have 
shown improved survival rates in women diagnosed at 
earlier stages,6,19 which shows that early diagnosis 
coupled with timely and appropriate treatment can 
prevent deaths from this disease in this region.
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